# ESC Guidelines: CVD Diabetes (2023)

**Source**: `2023_CVD_Diabetes.pdf`
**Converted**: 2025-11-27 10:02
**Pages**: 98

---

## Table of Contents

- [2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes](#2023-esc-guidelines-for-the-management-of-cardiova) *(p. 1)*
  - [1. Preamble](#1-preamble) *(p. 8)*
  - [2. Introduction](#2-introduction) *(p. 8)*
    - [2.1. Central figure](#21-central-figure) *(p. 10)*
    - [2.2. What is new](#22-what-is-new) *(p. 11)*
  - [3. Diagnosis of diabetes](#3-diagnosis-of-diabetes) *(p. 15)*
    - [3.1. Laboratory criteria for diagnosing diabetes and pre-diabetes](#31-laboratory-criteria-for-diagnosing-diabetes-and) *(p. 15)*
      - [3.1.1. Fasting glucose](#311-fasting-glucose) *(p. 15)*
      - [3.1.2. Two-hour oral glucose tolerance test and random glucose](#312-two-hour-oral-glucose-tolerance-test-and-rando) *(p. 15)*
      - [3.1.3. Glycated haemoglobin](#313-glycated-haemoglobin) *(p. 16)*
    - [3.2. Classifying diabetes](#32-classifying-diabetes) *(p. 17)*
      - [3.2.1. Type 1 diabetes](#321-type-1-diabetes) *(p. 17)*
      - [3.2.2. Type 2 diabetes](#322-type-2-diabetes) *(p. 17)*
      - [3.2.3. Monogenic diabetes](#323-monogenic-diabetes) *(p. 17)*
      - [3.2.4. Secondary diabetes and stress hyperglycaemia](#324-secondary-diabetes-and-stress-hyperglycaemia) *(p. 17)*
      - [3.2.5. Gestational diabetes](#325-gestational-diabetes) *(p. 17)*
      - [3.2.6. Further sub-group classification of type 2 diabetes](#326-further-sub-group-classification-of-type-2-dia) *(p. 17)*
    - [3.3. Screening for diabetes](#33-screening-for-diabetes) *(p. 17)*
  - [4. Cardiovascular risk assessment in patients with type 2 diabetes](#4-cardiovascular-risk-assessment-in-patients-with-) *(p. 18)*
    - [4.1. Assessing cardiovascular risk in type 2 diabetes](#41-assessing-cardiovascular-risk-in-type-2-diabete) *(p. 18)*
      - [4.1.1. Cardiovascular risk categories in type 2 diabetes](#411-cardiovascular-risk-categories-in-type-2-diabe) *(p. 18)*
      - [4.1.2. SCORE2-Diabetes: estimating 10-year cardiovascular disease risk](#412-score2-diabetes:-estimating-10-year-cardiovasc) *(p. 18)*
  - [5. Cardiovascular risk reduction in patients with diabetes: targets and treatments](#5-cardiovascular-risk-reduction-in-patients-with-d) *(p. 19)*
    - [5.1. Lifestyle and diabetes](#51-lifestyle-and-diabetes) *(p. 19)*
      - [5.1.1. Weight reduction](#511-weight-reduction) *(p. 20)*
      - [5.1.2. Change in diet or nutrition](#512-change-in-diet-or-nutrition) *(p. 20)*
      - [5.1.3. Increasing physical activity and exercise](#513-increasing-physical-activity-and-exercise) *(p. 21)*
      - [5.1.4. Smoking cessation](#514-smoking-cessation) *(p. 21)*
    - [5.2. Glycaemic targets](#52-glycaemic-targets) *(p. 22)*
      - [5.2.1. Role of glycated haemoglobin](#521-role-of-glycated-haemoglobin) *(p. 22)*
      - [5.2.2. Additional glycaemic targets](#522-additional-glycaemic-targets) *(p. 22)*
      - [5.2.3. Glycaemic control following vascular events](#523-glycaemic-control-following-vascular-events) *(p. 22)*
    - [5.3. Atherosclerotic cardiovascular disease risk reduction by glucose-lowering medications in diabetes](#53-atherosclerotic-cardiovascular-disease-risk-red) *(p. 23)*
      - [5.3.1. Glucose-lowering medications with cardiovascular efficacy demonstrated in dedicated cardiovascular outcomes trials](#531-glucose-lowering-medications-with-cardiovascul) *(p. 23)*
        - [5.3.1.1. Sodium–glucose co-transporter-2 inhibitors](#5311-sodium–glucose-co-transporter-2-inhibitors) *(p. 23)*
        - [5.3.1.2. Glucagon-like peptide-1 receptor agonists](#5312-glucagon-like-peptide-1-receptor-agonists) *(p. 24)*
        - [5.3.1.3. Pioglitazone](#5313-pioglitazone) *(p. 26)*
      - [5.3.2. Glucose-lowering medications with cardiovascular safety but not incremental efficacy demonstrated in dedicated cardiovascular outcomes trials](#532-glucose-lowering-medications-with-cardiovascul) *(p. 26)*
        - [5.3.2.1. Dipeptidyl peptidase-4 inhibitors](#5321-dipeptidyl-peptidase-4-inhibitors) *(p. 26)*
        - [5.3.2.2. Lixisenatide and exenatide](#5322-lixisenatide-and-exenatide) *(p. 26)*
        - [5.3.2.3. Insulin](#5323-insulin) *(p. 26)*
        - [5.3.2.4. Glimepiride](#5324-glimepiride) *(p. 27)*
      - [5.3.3. Cardiovascular considerations of older glucose-lowering medications not tested in dedicated cardiovascular outcomes trials](#533-cardiovascular-considerations-of-older-glucose) *(p. 27)*
        - [5.3.3.1. Metformin](#5331-metformin) *(p. 27)*
        - [5.3.3.2. Sulphonylureas](#5332-sulphonylureas) *(p. 27)*
      - [5.3.4. Special considerations](#534-special-considerations) *(p. 27)*
        - [5.3.4.1. Hypoglycaemia and cardiovascular risk](#5341-hypoglycaemia-and-cardiovascular-risk) *(p. 27)*
        - [5.3.4.2. Effects on weight](#5342-effects-on-weight) *(p. 28)*
      - [5.3.5. Implications of results from cardiovascular outcomes trials of glucose-lowering medications](#535-implications-of-results-from-cardiovascular-ou) *(p. 28)*
    - [5.4. Blood pressure and diabetes](#54-blood-pressure-and-diabetes) *(p. 30)*
      - [5.4.1. Screening and diagnosis](#541-screening-and-diagnosis) *(p. 30)*
      - [5.4.2. Treatment targets](#542-treatment-targets) *(p. 30)*
      - [5.4.3. Management of hypertension](#543-management-of-hypertension) *(p. 31)*
        - [5.4.3.1. Effects of lifestyle intervention and weight loss](#5431-effects-of-lifestyle-intervention-and-weight-) *(p. 31)*
        - [5.4.3.2. Pharmacological treatments in patients with diabetes](#5432-pharmacological-treatments-in-patients-with-d) *(p. 32)*
        - [5.4.3.3. Blood pressure changes with glucose-lowering agents](#5433-blood-pressure-changes-with-glucose-lowering-) *(p. 32)*
      - [5.4.4. Sex-specific aspects](#544-sex-specific-aspects) *(p. 32)*
    - [5.5. Lipids and diabetes](#55-lipids-and-diabetes) *(p. 33)*
      - [5.5.1. Treatment targets](#551-treatment-targets) *(p. 33)*
      - [5.5.2. Lipid-lowering agents](#552-lipid-lowering-agents) *(p. 33)*
        - [5.5.2.1. Statins](#5521-statins) *(p. 33)*
        - [5.5.2.2. Ezetimibe](#5522-ezetimibe) *(p. 33)*
        - [5.5.2.3. Proprotein convertase subtilisin/kexin type 9 inhibitors](#5523-proprotein-convertase-subtilisin/kexin-type-9) *(p. 34)*
        - [5.5.2.4. Fibrates and other TG-lowering drugs](#5524-fibrates-and-other-tg-lowering-drugs) *(p. 34)*
      - [5.5.3. Novel cholesterol-lowering drugs](#553-novel-cholesterol-lowering-drugs) *(p. 34)*
        - [5.5.3.1. Inclisiran](#5531-inclisiran) *(p. 34)*
        - [5.5.3.2. Bempedoic acid](#5532-bempedoic-acid) *(p. 34)*
    - [5.6. Antithrombotic therapy and diabetes](#56-antithrombotic-therapy-and-diabetes) *(p. 35)*
      - [5.6.1. Patients without a history of symptomatic atherosclerotic cardiovascular disease or revascularization](#561-patients-without-a-history-of-symptomatic-athe) *(p. 35)*
      - [5.6.2. Patients with atherosclerotic cardiovascular disease and/or revascularization without an indication for long-term oral anticoagulation](#562-patients-with-atherosclerotic-cardiovascular-d) *(p. 36)*
        - [5.6.2.1. Chronic coronary syndromes](#5621-chronic-coronary-syndromes) *(p. 36)*
        - [5.6.2.2. Acute coronary syndrome](#5622-acute-coronary-syndrome) *(p. 37)*
          - [5.6.2.2.1. Peri-procedural management](#56221-peri-procedural-management) *(p. 37)*
          - [5.6.2.2.2. Post-procedural management](#56222-post-procedural-management) *(p. 37)*
          - [5.6.2.2.3. Prolonging DAPT post-ACS](#56223-prolonging-dapt-post-acs) *(p. 37)*
          - [5.6.2.2.4. Shortening or de-escalating DAPT post-ACS in diabetes](#56224-shortening-or-de-escalating-dapt-post-acs-in) *(p. 37)*
      - [5.6.3. Patients with atherosclerotic cardiovascular disease and/or revascularization requiring long-term oral anticoagulation](#563-patients-with-atherosclerotic-cardiovascular-d) *(p. 39)*
      - [5.6.4. Preventing gastrointestinal bleeding](#564-preventing-gastrointestinal-bleeding) *(p. 39)*
    - [5.7. Multifactorial approach to risk-factor management in diabetes](#57-multifactorial-approach-to-risk-factor-manageme) *(p. 40)*
  - [6. Management of coronary artery disease and diabetes](#6-management-of-coronary-artery-disease-and-diabet) *(p. 41)*
    - [6.1. Chronic coronary syndromes and diabetes](#61-chronic-coronary-syndromes-and-diabetes) *(p. 41)*
      - [6.1.1. Clinical presentation](#611-clinical-presentation) *(p. 41)*
      - [6.1.2. Screening and diagnosis](#612-screening-and-diagnosis) *(p. 41)*
      - [6.1.3. Management](#613-management) *(p. 42)*
        - [6.1.3.1. Pharmacotherapy](#6131-pharmacotherapy) *(p. 42)*
          - [6.1.3.1.1. Glucose-lowering medication](#61311-glucose-lowering-medication) *(p. 42)*
          - [6.1.3.1.2. Other medications](#61312-other-medications) *(p. 42)*
        - [6.1.3.2. Revascularization](#6132-revascularization) *(p. 42)*
    - [6.2. Acute coronary syndromes and diabetes](#62-acute-coronary-syndromes-and-diabetes) *(p. 42)*
      - [6.2.1. Clinical presentation and diagnosis](#621-clinical-presentation-and-diagnosis) *(p. 42)*
      - [6.2.2. Management](#622-management) *(p. 43)*
        - [6.2.2.1. Pharmacotherapy](#6221-pharmacotherapy) *(p. 43)*
        - [6.2.2.2. Glucose control in patients with acute coronary syndrome](#6222-glucose-control-in-patients-with-acute-corona) *(p. 43)*
        - [6.2.2.3. Reperfusion strategies in ST-elevation myocardial infarction](#6223-reperfusion-strategies-in-st-elevation-myocar) *(p. 43)*
        - [6.2.2.4. Optimal timing of invasive strategy in non-ST-elevation acute coronary syndrome](#6224-optimal-timing-of-invasive-strategy-in-non-st) *(p. 43)*
    - [6.3. Ischaemia with no obstructive coronary artery disease in diabetes](#63-ischaemia-with-no-obstructive-coronary-artery-d) *(p. 44)*
  - [7. Heart failure and diabetes](#7-heart-failure-and-diabetes) *(p. 44)*
    - [7.1. Definition and pathophysiology](#71-definition-and-pathophysiology) *(p. 44)*
    - [7.2. Epidemiology and prognosis](#72-epidemiology-and-prognosis) *(p. 44)*
    - [7.3. Screening and diagnosis](#73-screening-and-diagnosis) *(p. 45)*
    - [7.4. Treatment of heart failure in patients with diabetes](#74-treatment-of-heart-failure-in-patients-with-dia) *(p. 46)*
      - [7.4.1. Treatment of heart failure with reduced ejection fraction](#741-treatment-of-heart-failure-with-reduced-eject) *(p. 46)*
        - [7.4.1.1. Sodium–glucose co-transporter-2 inhibitors](#7411-sodium–glucose-co-transporter-2-inhibitors) *(p. 47)*
        - [7.4.1.2. Angiotensin receptor–neprilysin inhibitor and angiotensin-converting enzyme inhibitors](#7412-angiotensin-receptor–neprilysin-inhibitor-and) *(p. 47)*
        - [7.4.1.3. Mineralocorticoid receptor antagonists](#7413-mineralocorticoid-receptor-antagonists) *(p. 47)*
        - [7.4.1.4. Beta-blockers](#7414-beta-blockers) *(p. 47)*
        - [7.4.1.5. Angiotensin-II receptor blockers](#7415-angiotensin-ii-receptor-blockers) *(p. 47)*
        - [7.4.1.6. Ivabradine](#7416-ivabradine) *(p. 48)*
        - [7.4.1.7. Hydralazine and isosorbide dinitrate](#7417-hydralazine-and-isosorbide-dinitrate) *(p. 48)*
        - [7.4.1.8. Digoxin](#7418-digoxin) *(p. 48)*
        - [7.4.1.9. Diuretics](#7419-diuretics) *(p. 48)*
        - [7.4.1.10. Device therapy and surgery](#74110-device-therapy-and-surgery) *(p. 48)*
      - [7.4.2. Treatment of heart failure with mildly reduced ejection fraction](#742-treatment-of-heart-failure-with-mildly-reduced) *(p. 48)*
      - [7.4.3. Treatment of heart failure with preserved ejection fraction](#743-treatment-of-heart-failure-with-preserved-ejec) *(p. 49)*
    - [7.5. Safety profile of glucose-lowering agents in patients with heart failure and diabetes](#75-safety-profile-of-glucose-lowering-agents-in-pa) *(p. 49)*
      - [7.5.1. Sodium–glucose co-transporter-2 inhibitors](#751-sodium–glucose-co-transporter-2-inhibitors) *(p. 49)*
      - [7.5.2. Glucagon-like peptide-1 receptor agonists](#752-glucagon-like-peptide-1-receptor-agonists) *(p. 50)*
      - [7.5.3. Dipeptidyl peptidase-4 inhibitors](#753-dipeptidyl-peptidase-4-inhibitors) *(p. 51)*
      - [7.5.4. Insulin](#754-insulin) *(p. 51)*
      - [7.5.5. Metformin](#755-metformin) *(p. 51)*
      - [7.5.6. Sulphonylureas](#756-sulphonylureas) *(p. 51)*
      - [7.5.7. Thiazolidinediones](#757-thiazolidinediones) *(p. 51)*
      - [7.5.8. Special consideration: hypoglycaemia and risk of heart failure hospitalization](#758-special-consideration:-hypoglycaemia-and-risk-) *(p. 51)*
  - [8. Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden cardiac death and diabetes](#8-arrhythmias:-atrial-fibrillation,-ventricular-ar) *(p. 54)*
    - [8.1. Atrial fibrillation and diabetes](#81-atrial-fibrillation-and-diabetes) *(p. 54)*
      - [8.1.1. Epidemiology of atrial fibrillation and its association with diabetes](#811-epidemiology-of-atrial-fibrillation-and-its-as) *(p. 54)*
      - [8.1.2. Screening and managing atrial fibrillation in patients with diabetes](#812-screening-and-managing-atrial-fibrillation-in-) *(p. 54)*
      - [8.1.3. Preventing stroke in patients with atrial fibrillation and diabetes](#813-preventing-stroke-in-patients-with-atrial-fibr) *(p. 56)*
    - [8.2. Ventricular arrhythmias and risk of sudden cardiac death and diabetes](#82-ventricular-arrhythmias-and-risk-of-sudden-card) *(p. 56)*
  - [9. Chronic kidney disease and diabetes](#9-chronic-kidney-disease-and-diabetes) *(p. 57)*
    - [9.1. Chronic kidney disease definitions, staging, and screening](#91-chronic-kidney-disease-definitions,-staging,-an) *(p. 57)*
    - [9.2. Management of cardiovascular disease risk and kidney failure in patients with chronic kidney disease and diabetes](#92-management-of-cardiovascular-disease-risk-and-k) *(p. 58)*
    - [9.3. Blood pressure and glycaemic control in patients with diabetes and chronic kidney disease](#93-blood-pressure-and-glycaemic-control-in-patient) *(p. 61)*
    - [9.4. Roles for antithrombotic therapy and invasive strategies in managing atherosclerotic cardiovascular disease in patients with diabetes and chronic kidney disease](#94-roles-for-antithrombotic-therapy-and-invasive-s) *(p. 61)*
  - [10. Aortic and peripheral arterial diseases and diabetes](#10-aortic-and-peripheral-arterial-diseases-and-dia) *(p. 62)*
    - [10.1. The impact of diabetes on peripheral atherosclerosis](#101-the-impact-of-diabetes-on-peripheral-atheroscl) *(p. 62)*
      - [10.1.1. Diabetes and lower-extremity artery disease](#1011-diabetes-and-lower-extremity-artery-disease) *(p. 62)*
      - [10.1.2. Diabetes and carotid artery disease](#1012-diabetes-and-carotid-artery-disease) *(p. 64)*
    - [10.2. Diabetes and aortic aneurysm](#102-diabetes-and-aortic-aneurysm) *(p. 64)*
  - [11. Type 1 diabetes and cardiovascular disease](#11-type-1-diabetes-and-cardiovascular-disease) *(p. 65)*
    - [11.1. Cardiovascular risk assessment in type 1 diabetes](#111-cardiovascular-risk-assessment-in-type-1-diabe) *(p. 65)*
    - [11.2. Managing cardiovascular risk](#112-managing-cardiovascular-risk) *(p. 65)*
      - [11.2.1. Exercise and lifestyle](#1121-exercise-and-lifestyle) *(p. 66)*
      - [11.2.2. Lipid lowering](#1122-lipid-lowering) *(p. 66)*
      - [11.2.3. Blood pressure](#1123-blood-pressure) *(p. 66)*
      - [11.2.4. Antiplatelet therapy](#1124-antiplatelet-therapy) *(p. 66)*
    - [11.3. Glucose-lowering agents beyond insulin](#113-glucose-lowering-agents-beyond-insulin) *(p. 66)*
    - [11.4. Renal protection in type 1 diabetes](#114-renal-protection-in-type-1-diabetes) *(p. 66)*
  - [12. Person-centred care](#12-person-centred-care) *(p. 66)*
  - [13. Practical guidance](#13-practical-guidance) *(p. 68)*
  - [14. Key messages](#14-key-messages) *(p. 68)*
  - [15. Gaps in evidence](#15-gaps-in-evidence) *(p. 69)*
  - [16. Sex differences](#16-sex-differences) *(p. 70)*
  - [17. ‘What to do’ and ‘What not to do’ messages from the Guidelines](#17-‘what-to-do’-and-‘what-not-to-do’-messages-from) *(p. 71)*
  - [18. Quality indicators](#18-quality-indicators) *(p. 75)*
  - [19. Supplementary data](#19-supplementary-data) *(p. 75)*
  - [20. Data availability statement](#20-data-availability-statement) *(p. 75)*
  - [21. Author information](#21-author-information) *(p. 75)*
  - [Appendix](#appendix) *(p. 76)*
  - [Acknowledgements](#acknowledgements) *(p. 76)*

---

## Full Text


<!-- PAGE 1 -->

### Page 1

2023 ESC Guidelines for the management of 
cardiovascular disease in patients with diabetes
Developed by the task force on the management of cardiovascular 
disease in patients with diabetes of the European Society of 
Cardiology (ESC)
Authors/Task Force Members: Nikolaus Marx  *†, (Chairperson) (Germany), 
Massimo Federici  *†, (Chairperson) (Italy), Katharina Schütt  
‡, (Task Force 
Co-ordinator) (Germany), Dirk Müller-Wieland  
‡, (Task Force Co-ordinator) 
(Germany), Ramzi A. Ajjan  
(United Kingdom), Manuel J. Antunes  
(Portugal), 
Ruxandra M. Christodorescu (Romania), Carolyn Crawford (United Kingdom), 
Emanuele Di Angelantonio  
(United Kingdom/Italy), Björn Eliasson  
(Sweden), 
Christine Espinola-Klein (Germany), Laurent Fauchier (France), Martin Halle  
(Germany), William G. Herrington  
(United Kingdom), 
Alexandra Kautzky-Willer  
(Austria), Ekaterini Lambrinou  
(Cyprus), 
Maciej Lesiak  
(Poland), Maddalena Lettino  
(Italy), Darren K. McGuire  
(United States of America), Wilfried Mullens (Belgium), Bianca Rocca  
(Italy), 
Naveed Sattar  
(United Kingdom), and ESC Scientific Document Group
* Corresponding authors: Nikolaus Marx, Department of Internal Medicine I, Cardiology, RWTH Aachen University, Aachen, Germany. Tel: +49 241 80-89300, E-mail: nmarx@ukaachen.de; 
and Massimo Federici, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy, and Center for Atherosclerosis, Policlinico Tor Vergata, Rome, Italy. Tel: +39 06 
20902085, E-mail: federicm@uniroma2.it
† The two Chairpersons contributed equally to the document and are joint corresponding authors.
‡ The two Task Force Co-ordinators contributed equally to the document.
Author/Task Force Member affiliations are listed in author information.
ESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix.
ESC subspecialty communities having participated in the development of this document:
Associations: Association of Cardiovascular Nursing & Allied Professions (ACNAP), Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging 
(EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), 
and Heart Failure Association (HFA).
Councils: Council for Cardiology Practice, Council on Hypertension.
Working Groups: Aorta and Peripheral Vascular Diseases, Cardiovascular Pharmacotherapy, Cardiovascular Surgery, Thrombosis.
Patient Forum  
The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC 
Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford 
University Press, the publisher of the European Heart Journal, and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com).
Disclaimer. The ESC Guidelines represent the views of the ESC and were produced after careful consideration of the scientific and medical knowledge and the evidence available at the time 
of their publication. The ESC is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC Guidelines and any other official recommendations or 
guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the 
ESC Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies; 
however, the ESC Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each 
patient’s health condition and in consultation with that patient and, where appropriate and/or necessary, the patient’s caregiver. Nor do the ESC Guidelines exempt health professionals from 
taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient’s case 
in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional’s responsibility to verify the applicable rules and 
regulations relating to drugs and medical devices at the time of prescription.
© The European Society of Cardiology 2023. All rights reserved. For permissions please e-mail: journals.permissions@oup.com.
https://doi.org/10.1093/eurheartj/ehad192
ESC GUIDELINES


<!-- PAGE 2 -->

### Page 2

Document Reviewers: Eva Prescott, (Clinical Practice Guidelines Review Co-ordinator) (Denmark), 
Francesco Cosentino, (Clinical Practice Guidelines Review Co-ordinator) (Sweden), Magdy Abdelhamid (Egypt), 
Victor Aboyans (France), Sotiris Antoniou (United Kingdom), Riccardo Asteggiano (Italy), Iris Baumgartner 
(Switzerland), Sergio Buccheri (Sweden), Hector Bueno (Spain), Jelena Čelutkienė (Lithuania), Alaide Chieffo 
(Italy), Christina Christersson (Sweden), Andrew Coats (United Kingdom), Bernard Cosyns (Belgium), 
Martin Czerny (Germany), Christi Deaton (United Kingdom), Volkmar Falk (Germany), Brian A. Ference (United 
Kingdom), Gerasimos Filippatos (Greece), Miles Fisher (United Kingdom), Heikki Huikuri (Finland), Borja Ibanez 
(Spain), Tiny Jaarsma (Sweden), Stefan James (Sweden), Kamlesh Khunti (United Kingdom), Lars Køber 
(Denmark), Konstantinos C. Koskinas (Switzerland), Basil S. Lewis (Israel), Maja-Lisa Løchen (Norway), John 
William McEvoy (Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), 
Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Gianfranco Parati (Italy), Agnes A. Pasquet 
(Belgium), Carlo Patrono (Italy), Steffen E. Petersen (United Kingdom), Massimo Francesco Piepoli (Italy), 
Amina Rakisheva (Kazakhstan), Xavier Rossello (Spain), Peter Rossing (Denmark), Lars Rydén (Sweden), 
Eberhard Standl (Germany), Lale Tokgozoglu (Türkiye), Rhian M. Touyz (Canada/United Kingdom), 
Frank Visseren (Netherlands), Massimo Volpe (Italy), Christiaan Vrints (Belgium), and Adam Witkowski (Poland)
All experts involved in the development of these guidelines have submitted declarations of interest. These have 
been compiled in a report and simultaneously published in a supplementary document to the guidelines. The 
report is also available on the ESC website www.escardio.org/Guidelines
See the European Heart Journal online for supplementary documents that include background information and 
evidence tables.
Keywords 
Guidelines • Aortic and peripheral arterial diseases • Arrhythmias • Atrial fibrillation • Cardiovascular disease • 
Cardiovascular risk assessment • Chronic kidney disease • Coronary artery disease • Diabetes mellitus • Heart failure 
• Patient-centred care • Pharmacological treatment • Prevention • Risk factors
Table of contents
1. Preamble ................................................................................................................. 4050
2. Introduction .......................................................................................................... 4050
2.1. Central figure .............................................................................................. 4052
2.2. What is new ................................................................................................ 4053
3. Diagnosis of diabetes ......................................................................................... 4057
3.1. Laboratory criteria for diagnosing diabetes and pre-diabetes 4057
3.1.1. Fasting glucose .................................................................................... 4057
3.1.2. Two-hour oral glucose tolerance test and random 
glucose ................................................................................................................ 4057
3.1.3. Glycated haemoglobin ..................................................................... 4058
3.2. Classifying diabetes ................................................................................... 4059
3.2.1. Type 1 diabetes .................................................................................. 4059
3.2.2. Type 2 diabetes .................................................................................. 4059
3.2.3. Monogenic diabetes .......................................................................... 4059
3.2.4. Secondary diabetes and stress hyperglycaemia .................... 4059
3.2.5. Gestational diabetes ......................................................................... 4059
3.2.6. Further sub-group classification of type 2 diabetes ............ 4059
3.3. Screening for diabetes ............................................................................. 4059
4. Cardiovascular risk assessment in patients with type 2 diabetes .. 4060
4.1. Assessing cardiovascular risk in type 2 diabetes .......................... 4060
4.1.1. Cardiovascular risk categories in type 2 diabetes ................ 4060
4.1.2. SCORE2-Diabetes: estimating 10-year cardiovascular 
disease risk ........................................................................................................ 4060
5. Cardiovascular risk reduction in patients with diabetes: targets 
and treatments .......................................................................................................... 4061
5.1. Lifestyle and diabetes ............................................................................... 4061
5.1.1. Weight reduction .............................................................................. 4062
5.1.2. Change in diet or nutrition ........................................................... 4062
5.1.3. Increasing physical activity and exercise .................................. 4063
5.1.4. Smoking cessation ............................................................................. 4063
5.2. Glycaemic targets ...................................................................................... 4064
5.2.1. Role of glycated haemoglobin ...................................................... 4064
5.2.2. Additional glycaemic targets ......................................................... 4064
5.2.3. Glycaemic control following vascular events ......................... 4064
5.3. Atherosclerotic cardiovascular disease risk reduction by 
glucose-lowering medications in diabetes ............................................... 4065
5.3.1. Glucose-lowering medications with cardiovascular 
efficacy demonstrated in dedicated cardiovascular outcomes 
trials ..................................................................................................................... 4065
5.3.1.1. Sodium–glucose co-transporter-2 inhibitors ................ 4065
5.3.1.2. Glucagon-like peptide-1 receptor agonists .................... 4066
5.3.1.3. Pioglitazone .................................................................................. 4068
5.3.2. Glucose-lowering medications with cardiovascular safety 
but not incremental efficacy demonstrated in dedicated 
cardiovascular outcomes trials ................................................................. 4068
5.3.2.1. Dipeptidyl peptidase-4 inhibitors ....................................... 4068
5.3.2.2. Lixisenatide and exenatide .................................................... 4068
5.3.2.3. Insulin ............................................................................................. 4068
5.3.2.4. Glimepiride .................................................................................. 4069
5.3.3. Cardiovascular considerations of older glucose-lowering 
medications not tested in dedicated cardiovascular outcomes 
trials ..................................................................................................................... 4069


<!-- PAGE 3 -->

### Page 3

5.3.3.1. Metformin .................................................................................... 4069
5.3.3.2. Sulphonylureas ........................................................................... 4069
5.3.4. Special considerations ...................................................................... 4069
5.3.4.1. Hypoglycaemia and cardiovascular risk ........................... 4069
5.3.4.2. Effects on weight ....................................................................... 4070
5.3.5. Implications of results from cardiovascular outcomes 
trials of glucose-lowering medications .................................................. 4070
5.4. Blood pressure and diabetes ................................................................ 4072
5.4.1. Screening and diagnosis ................................................................... 4072
5.4.2. Treatment targets ............................................................................. 4072
5.4.3. Management of hypertension ....................................................... 4073
5.4.3.1. Effects of lifestyle intervention and weight loss ........... 4073
5.4.3.2. Pharmacological treatments in patients with diabetes 4074
5.4.3.3. Blood pressure changes with glucose-lowering agents 4074
5.4.4. Sex-specific aspects ........................................................................... 4074
5.5. Lipids and diabetes .................................................................................... 4075
5.5.1. Treatment targets ............................................................................. 4075
5.5.2. Lipid-lowering agents ....................................................................... 4075
5.5.2.1. Statins ............................................................................................. 4075
5.5.2.2. Ezetimibe ...................................................................................... 4075
5.5.2.3. Proprotein convertase subtilisin/kexin type 9 
inhibitors ....................................................................................................... 4076
5.5.2.4. Fibrates and other TG-lowering drugs ............................ 4076
5.5.3. Novel cholesterol-lowering drugs .............................................. 4076
5.5.3.1. Inclisiran ......................................................................................... 4076
5.5.3.2. Bempedoic acid .......................................................................... 4076
5.6. Antithrombotic therapy and diabetes .............................................. 4077
5.6.1. Patients without a history of symptomatic atherosclerotic 
cardiovascular disease or revascularization ........................................ 4077
5.6.2. Patients with atherosclerotic cardiovascular disease and/ 
or revascularization without an indication for long-term oral 
anticoagulation ................................................................................................ 4078
5.6.2.1. Chronic coronary syndromes .............................................. 4078
5.6.2.2. Acute coronary syndrome .................................................... 4079
5.6.2.2.1. Peri-procedural management ...................................... 4079
5.6.2.2.2. Post-procedural management ..................................... 4079
5.6.2.2.3. Prolonging DAPT post-ACS ........................................ 4079
5.6.2.2.4. Shortening or de-escalating DAPT post-ACS in 
diabetes .................................................................................................... 4079
5.6.3. Patients with atherosclerotic cardiovascular disease 
and/or revascularization requiring long-term  
oral anticoagulation ....................................................................................... 4081
5.6.4. Preventing gastrointestinal bleeding .......................................... 4081
5.7. Multifactorial approach to risk-factor management in diabetes 4082
6. Management of coronary artery disease and diabetes ....................... 4083
6.1. Chronic coronary syndromes and diabetes .................................. 4083
6.1.1. Clinical presentation ......................................................................... 4083
6.1.2. Screening and diagnosis ................................................................... 4083
6.1.3. Management ......................................................................................... 4084
6.1.3.1. Pharmacotherapy ...................................................................... 4084
6.1.3.1.1. Glucose-lowering medication ..................................... 4084
6.1.3.1.2. Other medications ........................................................... 4084
6.1.3.2. Revascularization ....................................................................... 4084
6.2. Acute coronary syndromes and diabetes ....................................... 4084
6.2.1. Clinical presentation and diagnosis ............................................ 4084
6.2.2. Management ......................................................................................... 4085
6.2.2.1. Pharmacotherapy ...................................................................... 4085
6.2.2.2. Glucose control in patients with acute coronary 
syndrome ...................................................................................................... 4085
6.2.2.3. Reperfusion strategies in ST-elevation myocardial 
infarction ....................................................................................................... 4085
6.2.2.4. Optimal timing of invasive strategy in non-ST- 
elevation acute coronary syndrome ................................................. 4085
6.3. Ischaemia with no obstructive coronary artery disease in 
diabetes .................................................................................................................. 4086
7. Heart failure and diabetes ............................................................................... 4086
7.1. Definition and pathophysiology .......................................................... 4086
7.2. Epidemiology and prognosis ................................................................. 4086
7.3. Screening and diagnosis .......................................................................... 4087
7.4. Treatment of heart failure in patients with diabetes ................. 4088
7.4.1. Treatment of heart failure with reduced  
ejection fraction .............................................................................................. 4088
7.4.1.1. Sodium–glucose co-transporter-2 inhibitors ................ 4089
7.4.1.2. Angiotensin receptor–neprilysin inhibitor and 
angiotensin-converting enzyme inhibitors ...................................... 4089
7.4.1.3. Mineralocorticoid receptor antagonists .......................... 4089
7.4.1.4. Beta-blockers .............................................................................. 4089
7.4.1.5. Angiotensin-II receptor blockers ........................................ 4089
7.4.1.6. Ivabradine ..................................................................................... 4090
7.4.1.7. Hydralazine and isosorbide dinitrate ................................ 4090
7.4.1.8. Digoxin .......................................................................................... 4090
7.4.1.9. Diuretics ........................................................................................ 4090
7.4.1.10. Device therapy and surgery ............................................... 4090
7.4.2. Treatment of heart failure with mildly reduced ejection 
fraction ............................................................................................................... 4090
7.4.3. Treatment of heart failure with preserved ejection 
fraction ............................................................................................................... 4091
7.5. Safety profile of glucose-lowering agents in patients with 
heart failure and diabetes ............................................................................... 4091
7.5.1. Sodium–glucose co-transporter-2 inhibitors ......................... 4091
7.5.2. Glucagon-like peptide-1 receptor agonists ............................ 4092
7.5.3. Dipeptidyl peptidase-4 inhibitors ................................................ 4093
7.5.4. Insulin ...................................................................................................... 4093
7.5.5. Metformin ............................................................................................. 4093
7.5.6. Sulphonylureas .................................................................................... 4093
7.5.7. Thiazolidinediones ............................................................................. 4093
7.5.8. Special consideration: hypoglycaemia and risk of heart 
failure hospitalization .................................................................................... 4093
8. Arrhythmias: atrial fibrillation, ventricular arrhythmias, and sudden 
cardiac death and diabetes ................................................................................... 4096
8.1. Atrial fibrillation and diabetes .............................................................. 4096
8.1.1. Epidemiology of atrial fibrillation and its association with 
diabetes .............................................................................................................. 4096
8.1.2. Screening and managing atrial fibrillation in patients with 
diabetes .............................................................................................................. 4096
8.1.3. Preventing stroke in patients with atrial fibrillation and 
diabetes .............................................................................................................. 4098
8.2. Ventricular arrhythmias and risk of sudden cardiac death and 
diabetes .................................................................................................................. 4098
9. Chronic kidney disease and diabetes ......................................................... 4099
9.1. Chronic kidney disease definitions, staging, and screening ...... 4099
9.2. Management of cardiovascular disease risk and kidney failure 
in patients with chronic kidney disease and diabetes ......................... 4100
9.3. Blood pressure and glycaemic control in patients with 
diabetes and chronic kidney disease .......................................................... 4103
9.4. Roles for antithrombotic therapy and invasive strategies in 
managing atherosclerotic cardiovascular disease in patients with 
diabetes and chronic kidney disease .......................................................... 4103
ESC Guidelines                                                                                                                                                                                          4045


<!-- PAGE 4 -->

### Page 4

10. Aortic and peripheral arterial diseases and diabetes ........................ 4104
10.1. The impact of diabetes on peripheral atherosclerosis ........... 4104
10.1.1. Diabetes and lower-extremity artery disease .................... 4104
10.1.2. Diabetes and carotid artery disease ....................................... 4106
10.2. Diabetes and aortic aneurysm .......................................................... 4106
11. Type 1 diabetes and cardiovascular disease ......................................... 4107
11.1. Cardiovascular risk assessment in type 1 diabetes .................. 4107
11.2. Managing cardiovascular risk .............................................................. 4107
11.2.1. Exercise and lifestyle ...................................................................... 4108
11.2.2. Lipid lowering ................................................................................... 4108
11.2.3. Blood pressure ................................................................................. 4108
11.2.4. Antiplatelet therapy ....................................................................... 4108
11.3. Glucose-lowering agents beyond insulin ...................................... 4108
11.4. Renal protection in type 1 diabetes ............................................... 4108
12. Person-centred care ....................................................................................... 4108
13. Practical guidance ............................................................................................. 4110
14. Key messages ..................................................................................................... 4110
15. Gaps in evidence ............................................................................................... 4111
16. Sex differences .................................................................................................. 4112
17. ‘What to do’ and ‘What not to do’ messages from the Guidelines 4113
18. Quality indicators ............................................................................................. 4117
19. Supplementary data ......................................................................................... 4117
20. Data availability statement ............................................................................ 4117
21. Author information ......................................................................................... 4117
22. Appendix .............................................................................................................. 4118
23. Acknowledgements ......................................................................................... 4118
Tables of Recommendations
Recommendation Table 1 — Recommendations for diagnosing 
diabetes ........................................................................................................................ 4060
Recommendation Table 2 — Recommendations for assessing 
cardiovascular risk in patients with type 2 diabetes ................................. 4061
Recommendation Table 3 — Recommendations for reducing 
weight in patients with type 2 diabetes with or without 
cardiovascular disease ............................................................................................ 4062
Recommendation Table 4 — Recommendations for nutrition in 
patients with type 2 diabetes with or without cardiovascular disease 4063
Recommendation Table 5 — Recommendations for physical 
activity/exercise in patients with type 2 diabetes with or without 
cardiovascular disease ............................................................................................ 4063
Recommendation Table 6 — Recommendations for smoking 
cessation in patients with type 2 diabetes with or without 
cardiovascular disease ............................................................................................ 4064
Recommendation Table 7 — Recommendations for glycaemic 
targets in patients with diabetes ........................................................................ 4064
Recommendation Table 8 — Recommendations for 
glucose-lowering treatment for patients with type 2 diabetes and 
atherosclerotic cardiovascular disease to reduce cardiovascular risk 4072
Recommendation Table 9 — Recommendation for 
glucose-lowering treatment for patients with type 2 diabetes 
without atherosclerotic cardiovascular disease or severe 
target-organ damage to reduce cardiovascular risk .................................. 4072
Recommendation Table 10 — Recommendations for blood 
pressure management in patients with diabetes ........................................ 4074
Recommendation Table 11 — Recommendations for the 
management of dyslipidaemia in patients with diabetes ......................... 4076
Recommendation Table 12 — Recommendations for patients with 
diabetes without a history of symptomatic atherosclerotic 
cardiovascular disease or revascularization ............................................................. 4077
Recommendation Table 13 — Recommendations for 
antithrombotic therapy in patients with diabetes and acute or 
chronic coronary syndrome without indications for long-term oral 
anticoagulation .......................................................................................................... 4080
Recommendation Table 14 — Recommendations for 
antithrombotic therapy in patients with diabetes and acute or 
chronic coronary syndrome and/or post-percutaneous coronary 
intervention requiring long-term oral anticoagulation ............................. 4081
Recommendation Table 15 — Recommendations for gastric 
protection in patients with diabetes taking antithrombotic drugs ..... 4081
Recommendation Table 16 — Recommendations for a 
multifactorial approach in patients with type 2 diabetes with and 
without cardiovascular disease ........................................................................... 4082
Recommendation Table 17 — Recommendations for 
revascularization in patients with diabetes ................................................... 4084
Recommendation Table 18 — Recommendations for glycaemic 
control in patients with diabetes and acute coronary syndrome ....... 4085
Recommendation Table 19 — Recommendations for heart failure 
screening and diagnosis in patients with diabetes ...................................... 4088
Recommendation Table 20 — Recommendations for heart failure 
treatments in patients with heart failure with reduced ejection 
fraction and diabetes .............................................................................................. 4090
Recommendation Table 21 — Recommendations for heart failure 
treatments in patients with diabetes and left ventricular ejection 
fraction over 40% .................................................................................................... 4091
Recommendation Table 22 — Recommendations for 
glucose-lowering medications in patients with type 2 diabetes with 
and without heart failure ...................................................................................... 4094
Recommendation Table 23 — Recommendations for atrial 
fibrillation in patients with diabetes ................................................................. 4098
Recommendation Table 24 — Recommendations for patients with 
chronic kidney disease and diabetes ................................................................ 4103
Recommendation Table 25 — Recommendations for peripheral 
arterial and aortic diseases in patients with diabetes ............................... 4106
Recommendation Table 26 — Recommendations for patients with 
type 1 diabetes .......................................................................................................... 4108
Recommendation Table 27 — Recommendations for 
person-centred care in diabetes ........................................................................ 4110
List of tables
Table 1 Classes of recommendations ............................................................. 4051
Table 2 Levels of evidence ................................................................................... 4051
Table 3 New recommendations ....................................................................... 4053
Table 4 Revised recommendations .................................................................. 4056
Table 5 Revised concepts 2023 Guidelines .................................................. 4057
Table 6 Biochemical diagnostic criteria for diabetes and pre-diabetes 
according to the World Health Organization and the American 
Diabetes Association .............................................................................................. 4058
Table 7 Cardiovascular risk categories in type 2 diabetes ..................... 4060
Table 8 Blood pressure measurement ........................................................... 4073
Table 9 Heart failure phenotypes according to ejection fraction 
distribution .................................................................................................................. 4086
Table 10 Risk factors for developing heart failure in patients with 
diabetes ........................................................................................................................ 4086
Table 11 KDIGO staging by glomerular filtration rate 
and urinary albumin-to-creatinine ratio categories with


<!-- PAGE 5 -->

### Page 5

colour chart for risk of initiation of maintenance kidney replacement 
therapy .......................................................................................................................... 4099
Table 12 ‘What to do’ and ‘What not to do’ ............................................. 4113
List of figures
Figure 1 Management of cardiovascular disease in patients with type 
2 diabetes: clinical approach and key recommendations ........................ 4052
Figure 2 Diagnosis of diabetes and pre-diabetes ........................................ 4058
Figure 3 Cardiovascular risk categories in patients with type 2 
diabetes ........................................................................................................................ 4061
Figure 4 Simple guide to glycaemic targets in patients with type 2 
diabetes and cardiovascular disease ................................................................. 4065
Figure 5 Meta-analysis of cardiovascular outcomes trial results of 
sodium–glucose co-transporter-2 inhibitors among patients with 
type 2 diabetes with or at high risk for atherosclerotic cardiovascular 
disease ........................................................................................................................... 4066
Figure 6 Meta-analysis of cardiovascular outcomes trials with 
glucagon-like peptide-1 receptor agonists (sensitivity analysis 
removing ELIXA). Risk of major adverse cardiovascular events and 
its components ......................................................................................................... 4067
Figure 7 Glucose-lowering treatment for patients with type 2 
diabetes to reduce cardiovascular risk based on the presence of 
atherosclerotic cardiovascular disease/severe target-organ damage 
and 10-year cardiovascular disease risk estimation via 
SCORE2-Diabetes ................................................................................................... 4070
Figure 8 Glucose-lowering treatment for patients with type 2 
diabetes and atherosclerotic cardiovascular disease to reduce 
cardiovascular risk .................................................................................................... 4071
Figure 9 Screening and diagnosis of hypertension in patients with 
diabetes ........................................................................................................................ 4073
Figure 10 Recommended low-density lipoprotein-cholesterol 
targets by cardiovascular risk categories in patients with type 2 
diabetes ........................................................................................................................ 4075
Figure 11 Mechanisms contributing to altered platelet activation and 
atherothrombosis in patients with diabetes ................................................. 4078
Figure 12 Recommendations for antiplatelet therapy in patients with 
diabetes with acute or chronic coronary syndrome undergoing 
percutaneous coronary intervention or coronary artery bypass 
grafting without indications for long-term oral anticoagulation .......... 4080
Figure 13 Assessment of lifestyle risk-factor components and 
stepwise lifestyle recommendations in patients with diabetes ............ 4083
Figure 14 Diagnostic algorithm for heart failure in patients with 
diabetes ........................................................................................................................ 4087
Figure 15 Absolute risk reduction with sodium–glucose 
co-transporter-2 inhibitors in relation to patient risk based on rate 
of heart failure-related endpoints in the placebo arm of the 
respective trials ......................................................................................................... 4092
Figure 16 Glucose-lowering treatment of patients with heart failure 
and type 2 diabetes ................................................................................................. 4095
Figure 17 Screening for atrial fibrillation in patients with diabetes .... 4097
Figure 18 Pharmacological management to reduce cardiovascular or 
kidney failure risk in patients with type 2 diabetes and chronic kidney 
disease ........................................................................................................................... 4101
Figure 19 Absolute benefits and harms of sodium–glucose 
co-transporter-2 inhibitors in patients with and without diabetes .... 4102
Figure 20 Screening for and managing lower-extremity artery 
disease in patients with diabetes ....................................................................... 4105
Figure 21 Person-centred care approach for patients with diabetes 
with or without cardiovascular disease .......................................................... 4109
Abbreviations and acronyms
2hPG
2 h plasma glucose
ABI
Ankle–brachial index
ABPM
Ambulatory blood pressure monitoring
ACCORD
Action to Control Cardiovascular Risk in 
Diabetes
ACE-I
Angiotensin-converting enzyme inhibitor
ACS
Acute coronary syndrome
ADA
American Diabetes Association
ADAPTABLE
Aspirin Dosing: A Patient-Centric Trial Assessing 
Benefits and Long-term
ADDITION
Anglo-Danish-Dutch Study of Intensive 
Treatment In People with Screen Detected 
Diabetes in Primary Care
ADJUNCT ONE
The Efficacy and Safety of Liraglutide as Adjunct 
Therapy to Insulin in the Treatment of Type 1 
Diabetes
ADVANCE
Action in Diabetes and Vascular Disease: 
Preterax and Diamicron MR Controlled 
Evaluation
AF
Atrial fibrillation
ARB
Angiotensin-II receptor blocker
ARNI
Angiotensin receptor–neprilysin inhibitor
ARR
Absolute risk reduction
ASA
Acetylsalicylic acid
ASCEND
A Study of Cardiovascular Events iN  
Diabetes
ASCVD
Atherosclerotic cardiovascular disease
ATTACK
Aspirin to Target Arterial Events in Chronic 
Kidney Disease b.i.d.
Twice a day b.p.m.
Beats per minute
BANTING
Evaluation of Evolocumab Efficacy in Diabetic 
Adults With Hypercholesterolemia/Mixed 
Dyslipidemia
BARC
Bleeding Academic Research Consortium
BARI 2D
Bypass Angioplasty Revascularization 
Investigation 2 Diabetes
BERSON
Safety and Efficacy of Evolocumab in 
Combination With Statin Therapy in Adults 
With Diabetes and Hyperlipidemia or Mixed 
Dyslipidemia
BMI
Body mass index
BNP
B-type natriuretic peptide
BP
Blood pressure
CABG
Coronary artery bypass graft
CAC
Coronary artery calcium
CAD
Coronary artery disease
CANVAS
Canagliflozin Cardiovascular Assessment  
Study
CARMELINA
Cardiovascular and Renal Microvascular 
Outcome Study With Linagliptin in Patients 
With Type 2 Diabetes Mellitus
CAROLINA
Cardiovascular Outcome Study of Linagliptin 
Versus Glimepiride in Patients With Type 2 
Diabetes
CCB
Calcium channel blocker
CCS
Chronic coronary syndrome
CGM
Continuous glucose monitoring
ESC Guidelines                                                                                                                                                                                          4047


<!-- PAGE 6 -->

### Page 6

CHA2DS2-VASc
Congestive heart failure, Hypertension, Age ≥75 
years (2 points), Diabetes mellitus, Stroke or 
transient ischaemic attack (2 points), Vascular 
disease, Age 65–74 years, Sex category (female)
CHAP
Chronic Hypertension and Pregnancy
CHD
Coronary heart disease
CI
Confidence interval
CKD
Chronic kidney disease
CKD-EPI
Chronic kidney disease epidemiology/CKD 
Epidemiology Collaboration
CKD-MBD
Chronic kidney disease–mineral bone disorder
CLEAR
Cholesterol Lowering via Bempedoic Acid, an 
ACL-Inhibiting Regimen
CLTI
Chronic limb-threatening ischaemia
COMPASS
Cardiovascular Outcomes for People Using 
Anticoagulation Strategies
CPG
Clinical Practice Guidelines
CREDENCE
Canagliflozin and Renal Events in Diabetes with 
Established Nephropathy Clinical Evaluation
CRT
Cardiac resynchronization therapy
CRT-D
Cardiac resynchronization therapy with an 
implantable defibrillator
CRT-P
Cardiac resynchronization therapy-pacemaker
CT
Computed tomography
CTA
Computed tomography angiography
CURRENT- 
OASIS
Clopidogrel Optimal Loading Dose Usage to 
Reduce Recurrent EveNTs/Optimal Antiplatelet 
Strategy for InterventionS
CV
Cardiovascular
CVD
Cardiovascular disease
CVOT
Cardiovascular outcomes trial
DAPA-CKD
Dapagliflozin and Prevention of Adverse 
Outcomes in Chronic Kidney Disease
DAPA-HF
Dapagliflozin and Prevention of Adverse 
Outcomes in Heart Failure
DAPT
Dual antiplatelet therapy
DAT
Dual antithrombotic therapy
DBP
Diastolic blood pressure
DCCT
Diabetes Control and Complications Trial
DD
Double diabetes
DECLARE-TIMI 
58
Dapagliflozin Effect on Cardiovascular Events 
−Thrombolysis In Myocardial Infarction 58
DELIVER
Dapagliflozin Evaluation to Improve the  Lives of 
Patients with Preserved Ejection Fraction Heart 
Failure
DES
Drug-eluting stent
DEVOTE
A Trial Comparing Cardiovascular Safety of 
Insulin Degludec vs Insulin Glargine in Patients 
With Type 2 Diabetes at High Risk of 
Cardiovascular Events
DIAL
Diabetes lifetime-perspective prediction
DIGAMI
Diabetes Mellitus Insulin-Glucose Infusion in 
Acute Myocardial Infarction
DiRECT
Diabetes Remission Clinical Trial
DPP-4
Dipeptidyl peptidase-4
EACTS
European Association for Cardio-Thoracic 
Surgery
EASD
European Association for the Study of Diabetes
ECG
Electrocardiogram
EDC
Pittsburgh Epidemiology of Diabetes 
Complications
EDIC
Epidemiology of Diabetes Interventions and 
Complications eGFR
Estimated glomerular filtration rate
ELIXA
Evaluation of Lixisenatide in Acute Coronary 
Syndrome
EMMY
Impact of EMpagliflozin on cardiac function and 
biomarkers of heart failure in patients with acute 
MYocardial infarction
EMPA-KIDNEY
The Study of Heart and Kidney Protection With 
Empagliflozin
EMPA-REG 
OUTCOME
Empagliflozin Cardiovascular Outcome Event 
Trial in Type 2 Diabetes Mellitus Patients
EMPA-RESPONSE- 
AHF
Empagliflozin on Clinical Outcomes in Patients 
With Acute Decompensated Heart Failure
EMPEROR- 
Preserved
EMPagliflozin outcomE tRial in Patients With 
chrOnic heaRt Failure With Preserved Ejection 
Fraction
EMPEROR- 
Reduced
Empagliflozin Outcome Trial in Patients with 
Chronic Heart Failure with Reduced Ejection 
Fraction
EMPULSE
A Study to Test the Effect of Empagliflozin in 
Patients Who Are in Hospital for Acute Heart 
Failure
EORP
EURObservational Research Programme
ER
Extended release
ESC
European Society of Cardiology
ESH
European Society of Hypertension
EXAMINE
Cardiovascular Outcomes Study of Alogliptin in 
Patients With Type 2 Diabetes and Acute 
Coronary Syndrome
EXSCEL
Exenatide Study of Cardiovascular Event 
Lowering
FIDELIO-DKD
Efficacy and Safety of Finerenone in Subjects 
With Type 2 Diabetes Mellitus and Diabetic 
Kidney Disease
FIGARO-DKD
Efficacy and Safety of Finerenone in Subjects 
With Type 2 Diabetes Mellitus and the Clinical 
Diagnosis of Diabetic Kidney Disease
FLOW
Effect of Semaglutide Versus Placebo on the 
Progression of Renal Impairment in Subjects 
With Type 2 Diabetes and Chronic Kidney 
Disease
FOURIER
Further Cardiovascular Outcomes Research 
with PCSK9 Inhibition in Subjects with Elevated 
Risk
FPG
Fasting plasma glucose
GDM
Gestational diabetes mellitus
GFR
Glomerular filtration rate
GLOBAL- 
LEADERS
A Clinical Study Comparing Two Forms of 
Antiplatelet Therapy After Stent  
Implantation
GLP-1 RA
Glucagon-like peptide-1 receptor agonist
GRACE
Global Registry of Acute Coronary Events
HARMONY 
Outcomes
Effect of Albiglutide, When Added to Standard 
Blood Glucose Lowering Therapies, on Major 
Cardiovascular Events in Subjects With Type 2 
Diabetes Mellitus
HAS-BLED
Hypertension, Abnormal renal/liver function, 
Stroke, Bleeding history or predisposition, Labile 
international normalized ratio, Elderly (>65 
years), Drugs/alcohol concomitantly


<!-- PAGE 7 -->

### Page 7

HbA1c
Glycated haemoglobin
HBPM
Home blood pressure monitoring
HCP
Healthcare professional
HDL-C
High-density lipoprotein-cholesterol
HF
Heart failure
HFmrEF
Heart failure with mildly reduced ejection 
fraction
HFpEF
Heart failure with preserved ejection fraction
HFrEF
Heart failure with reduced ejection fraction
HMOD
Hypertension-mediated organ damage
HR
Hazard ratio
ICD
Implantable cardioverter defibrillator
IFG
Impaired fasting glucose
IGT
Impaired glucose tolerance
IHD
Ischaemic heart disease
IMPROVE-IT
Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial
INR
International normalized ratio
IPD
Individual participant data
ISAR-REACT 5
Intracoronary Stenting and Antithrombotic 
Regimen: Rapid Early Action for Coronary 
Treatment
ISCHEMIA
International Study of Comparative Health 
Effectiveness with Medical and Invasive 
Approaches
ISCHEMIA-CKD
International Study of Comparative Health 
Effectiveness with Medical and Invasive 
Approaches–Chronic Kidney Disease
ISTH
International Society of Thrombosis and 
Haemostasis i.v.
Intravenous
J-DOIT3
Japan Diabetes Optimal Integrated Treatment 
Study for 3 Major Risk Factors of Cardiovascular 
Diseases
KDIGO
Kidney Disease: Improving Global Outcomes
KRT
Kidney replacement therapy
LDL-C
Low-density lipoprotein-cholesterol
LEAD
Lower-extremity artery disease
LEADER
Liraglutide Effect and Action in Diabetes: 
Evaluation of Cardiovascular Outcome Results
LIBERATES
Improving Glucose Control in Patients with 
Diabetes Following Myocardial Infarction: The 
Role of a Novel Glycaemia Monitoring Strategy
Look AHEAD
Action for Health in Diabetes
LV
Left ventricular
LVEF
Left ventricular ejection fraction
MACE
Major adverse cardiovascular events
MI
Myocardial infarction
MRA
Mineralocorticoid receptor antagonist
NNH
Number needed to harm
NNT
Number needed to treat
NO
Nitric oxide
NOAC
Non-Vitamin K Antagonist Oral Anticoagulant
NSTE-ACS
Non-ST-elevation acute coronary syndrome
NT-proBNP
N-terminal pro-B-type natriuretic peptide
NYHA
New York Heart Association o.d.
Once a day
OAC
Oral anticoagulant
OARS
Open-ended questions, Affirmation, Reflective 
listening, and Summarizing
ODYSSEY 
DM-DYSLIPIDE­
MIA
Efficacy and Safety of Alirocumab Versus Usual 
Care on Top of Maximally Tolerated Statin 
Therapy in Patients With Type 2 Diabetes and 
Mixed Dyslipidemia
ODYSSEY 
OUTCOMES
Evaluation of Cardiovascular Outcomes After an 
Acute Coronary Syndrome During Treatment 
With Alirocumab
OGTT
Oral glucose tolerance test
OMT
Optimal medical therapy
OR
Odds ratio
ORIGIN
Outcome Reduction With Initial Glargine 
Intervention
ORION
Inclisiran for Participants With Atherosclerotic 
Cardiovascular Disease and Elevated 
Low-density Lipoprotein Cholesterol
PA
Physical activity
PAD
Peripheral arterial diseases
PARAGON-HF
Efficacy and Safety of LCZ696 Compared to 
Valsartan, on Morbidity and Mortality in Heart 
Failure Patients With Preserved Ejection 
Fraction
PCI
Percutaneous coronary intervention
PCSK9
Proprotein convertase subtilisin/kexin type 9
PEGASUS-TIMI 
54
Prevention of Cardiovascular Events in Patients 
With Prior Heart Attack Using Ticagrelor 
Compared to Placebo on a Background of 
Aspirin
PIONEER 6
Trial Investigating the Cardiovascular Safety of 
Oral Semaglutide in Subjects With Type 2 
Diabetes
PROactive
PROspective pioglitAzone Clinical Trial In 
macroVascular Events
QI
Quality indicator
QTc
Correct QT interval
RAS
Renin–angiotensin system
RCT
Randomized controlled trial
REDUCE-IT
Reduction of Cardiovascular Events with 
Icosapent Ethyl–Intervention
REWIND
Researching Cardiovascular Events With a 
Weekly Incretin in Diabetes
ROS
Reactive oxygen species
RPG
Random plasma glucose
RR
Relative risk
SAPT
Single antiplatelet therapy
SAVOR-TIMI 53
Saxagliptin Assessment of Vascular Outcomes 
Recorded in Patients with Diabetes Mellitus 
−Thrombolysis In Myocardial Infarction 53
SBP
Systolic blood pressure s.c.
Subcutaneous
SCD
Sudden cardiac death
SCORED
Effect of Sotagliflozin on Cardiovascular and 
Renal Events in Participants With Type 2 
Diabetes and Moderate Renal Impairment Who 
Are at Cardiovascular Risk
SCORE2- 
Diabetes type 2 diabetes-specific 10-year CVD risk score
SCORE2-OP
SCORE2-older persons
SGLT2
Sodium–glucose co-transporter-2
SMART
Specific, Measurable, Achievable, Realistic, 
Timely
ESC Guidelines                                                                                                                                                                                          4049


<!-- PAGE 8 -->

### Page 8

SOLOIST-WHF
Effect of Sotagliflozin on Cardiovascular Events in 
Patients with Type 2 Diabetes Post Worsening 
Heart Failure
STEMI
ST-elevation myocardial infarction
STRONG-HF
Safety, Tolerability and Efficacy of Rapid 
Optimization, Helped by NT-proBNP testinG, of 
Heart Failure Therapies
SUSTAIN 6
Trial to Evaluate Cardiovascular and Other 
Long-term Outcomes With Semaglutide in 
Subjects With Type 2 Diabetes
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TAT
Triple antithrombotic therapy
TBI
Toe–brachial index
TcPO2
Transcutaneous oxygen pressure
TECOS
Trial Evaluating Cardiovascular Outcomes with 
Sitagliptin
TG
Triglyceride
THEMIS
Effect of Ticagrelor on Health Outcomes in 
Diabetes Mellitus Patients Intervention Study
TIMI
Thrombolysis in Myocardial Infarction
TOD
Target-organ damage
TRACK
Treatment of CVD with Low Dose Rivaroxaban 
in Advanced CKD
TRL
Triglyceride-rich lipoprotein
TROPICAL-ACS
Testing Responsiveness to Platelet Inhibition on 
Chronic Antiplatelet Treatment for Acute 
Coronary Syndromes
TSAT
Transferrin saturation
TZD
Thiazolidinedione
UACR
Urine albumin-to-creatinine ratio
UKPDS
United Kingdom Prospective Diabetes Study
VADT
Veterans Affairs Diabetes Trial
VALUE
Valsartan Antihypertensive Long-term Use 
Evaluation
VERTIS CV
Evaluation of Ertugliflozin Efficacy and Safety 
Cardiovascular Outcomes Trial
VKA
Vitamin K antagonist
WHO
World Health Organization
WIfI
Wound, Ischaemia, foot Infection
1. Preamble
Guidelines evaluate and summarize available evidence, with the aim of as­
sisting health professionals in proposing the best diagnostic or therapeut­
ic approach for an individual patient with a given condition. Guidelines are 
intended for use by health professionals and the European Society of 
Cardiology (ESC) makes its Guidelines freely available.
ESC Guidelines do not override the individual responsibility of health 
professionals to make appropriate and accurate decisions in consider­
ation of each patient’s health condition and in consultation with that pa­
tient or the patient’s caregiver where appropriate and/or necessary. It is 
also the health professional’s responsibility to verify the rules and reg­
ulations applicable in each country to drugs and devices at the time of 
prescription, and, where appropriate, to respect the ethical rules of 
their profession.
ESC Guidelines represent the official position of the ESC on a given 
topic and are regularly updated. ESC Policies and Procedures for 
formulating and issuing ESC Guidelines can be found on the ESC web­
site (https://www.escardio.org/Guidelines).
The Members of this Task Force were selected by the ESC to re­
present professionals involved with the medical care of patients with 
this pathology. The selection procedure aimed to include members 
from across the whole of the ESC region and from relevant ESC 
Subspecialty Communities. Consideration was given to diversity and in­
clusion, notably with respect to gender and country of origin. The Task 
Force performed a critical evaluation of diagnostic and therapeutic ap­
proaches, including assessment of the risk-benefit ratio. The strength of 
every recommendation and the level of evidence supporting them were 
weighed and scored according to pre-defined scales as outlined below. 
The Task Force followed ESC voting procedures, and all approved re­
commendations were subject to a vote and achieved at least 75% 
agreement among voting members.
The experts of the writing and reviewing panels provided declaration 
of interest forms for all relationships that might be perceived as real or 
potential sources of conflicts of interest. Their declarations of interest 
were reviewed according to the ESC declaration of interest rules and 
can be found on the ESC website (http://www.escardio.org/ 
Guidelines), and have been compiled in a report published in a supple­
mentary document with the guidelines. The Task Force received its en­
tire financial support from the ESC without any involvement from the 
healthcare industry.
The ESC Clinical Practice Guidelines (CPG) Committee supervises and 
co-ordinates the preparation of new guidelines and is responsible for the 
approval process. ESC Guidelines undergo extensive review by the CPG 
Committee and external experts, including members from across the 
whole of the ESC region and from relevant ESC Subspecialty 
Communities and National Cardiac Societies. After appropriate revisions, 
the guidelines are signed off by all the experts involved in the Task Force. 
The finalized document is signed off by the CPG Committee for publica­
tion in the European Heart Journal. The guidelines were developed after 
careful consideration of the scientific and medical knowledge and the evi­
dence available at the time of their writing. Tables of evidence summarizing 
the findings of studies informing development of the guidelines are in­
cluded. The ESC warns readers that the technical language may be misin­
terpreted and declines any responsibility in this respect.
Off-label use of medication may be presented in the current 
Guidelines if a sufficient level of evidence shows that it can be consid­
ered medically appropriate for a given condition. However, the final de­
cisions concerning an individual patient must be made by the 
responsible health professional giving special consideration to: 
• The specific situation of the patient. Unless otherwise provided for 
by national regulations, off-label use of medication should be limited 
to situations where it is in the patient’s interest with regard to the 
quality, safety, and efficacy of care, and only after the patient has 
been informed and has provided consent.
• Country-specific health regulations, indications by governmental 
drug regulatory agencies, and the ethical rules to which health profes­
sionals are subject, where applicable.
2. Introduction
Patients with diabetes are at increased risk of developing cardiovascular 
disease (CVD) with its manifestations of coronary artery disease (CAD), 
heart failure (HF), atrial fibrillation (AF), and stroke, as well as aortic and 
peripheral artery diseases. In addition, diabetes is a major risk factor for 
developing chronic kidney disease (CKD), which in itself is associated


<!-- PAGE 9 -->

### Page 9

with developing CVD. The combination of diabetes with these 
cardio-renal comorbidities enhances the risk not only for cardiovascular 
(CV) events but also for CV and all-cause mortality. The current 
European Society of Cardiology (ESC) Guidelines on the management 
of cardiovascular disease in patients with diabetes are designed to guide 
prevention and management of the manifestations of CVD in patients 
with diabetes based on data published until end of January 2023. Over 
the last decade, the results of various large cardiovascular outcome trials 
(CVOTs) in patients with diabetes at high CV risk with novel glucose- 
lowering agents, such as sodium–glucose co-transporter-2 (SGLT2) inhi­
bitors and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), but 
also novel non-steroidal mineralocorticoid receptor antagonists (MRAs), 
such as finerenone have substantially expanded available therapeutic op­
tions, leading to numerous evidence-based recommendations for the 
management of this patient population.
The current Guidelines—in contrast to the previous 2019 ESC 
Guidelines on diabetes, pre-diabetes, and cardiovascular diseases— 
only focus on CVD and diabetes and, given the lack of clear evidence, 
leave aside the aspect of pre-diabetes. In addition, this version of the 
Guidelines gives recommendations on stratifying CV risk, as well as 
on screening, diagnosis, and treatment of CVD in patients with dia­
betes. For all other aspects concerning the management of patients 
with diabetes, we refer to the recommendations from diabetes associa­
tions, e.g. the European Association for the Study of Diabetes (EASD) 
or the American Diabetes Association (ADA).1
These Guidelines offer evidence-based recommendations to manage 
CV risk in patients with diabetes and provide guidance for the treatment 
of atherosclerotic cardiovascular disease (ASCVD) in patients with dia­
betes. To individualize treatment strategies, the current Guidelines 
introduce a novel, dedicated, type 2 diabetes mellitus (T2DM)-specific, 
Table 1 Classes of recommendations
©ESC 2023
Classes of recommendations
Class I 
Evidence and/or general agreement that a given treatment or procedure is beneﬁcial, useful, eﬀective. 
Conﬂicting evidence and/or a divergence of opinion about the usefulness/ 
eﬃcacy of the given treatment or procedure. 
Is recommended or is indicated
Wording to use
Deﬁnition
Class III 
Evidence or general agreement that the given treatment or procedure is not useful/eﬀective, and in some cases may be harmful. 
Is not recommended
     Class IIb
Usefulness/eﬃcacy is less well established by evidence/opinion.
May be considered
 
   Class IIa
Weight of evidence/opinion is in favour of usefulness/eﬃcacy. 
Should be considered
Class II 
© ESC 2023
Table 2 Levels of evidence
Level of evidence A
Level of evidence B
Level of evidence C
Data derived from multiple randomized clinical trials or meta-analyses.
Data derived from a single randomized clinical trial or large non-randomized studies.
Consensus of opinion of the experts and/or small studies,
retrospective studies, registries.
©ESC 2023
© ESC 2023
ESC Guidelines                                                                                                                                                                                          4051


<!-- PAGE 10 -->

### Page 10

10-year CVD risk score (SCORE2-Diabetes) for patients with T2DM 
without ASCVD or severe target-organ damage (TOD). This score, 
which now extends the established SCORE2 prediction algorithm for 
T2DM, provides data on the 10-year risk of fatal and non-fatal CVD 
events (myocardial infarction [MI], stroke) based on individual patient 
characteristics. SCORE2-Diabetes serves as a guide for clinical decision- 
making in patients with T2DM at low, moderate, high, or very high risk, 
but without clinically overt ASCVD or severe TOD.
Given the high prevalence of undetected diabetes in patients with CVD, 
as well as the elevated risk and therapeutic consequences if both co­
morbidities co-exist, these Guidelines recommend systematic screening 
for diabetes in all patients with CVD. In addition, all patients with diabetes 
need to be evaluated for risk and presence of CVD and CKD. Based on 
evidence from large CVOTs, the current Guidelines provide clear recom­
mendations on how to treat patients with diabetes and clinical manifesta­
tions of cardiovascular-renal disease. As such, in patients with diabetes and 
ASCVD, treatment with GLP-1 RAs and/or SGLT2 inhibitors is 
recommended to reduce CV risk, independent of glucose control and in 
addition to standard of care, e.g. antiplatelet, anti-hypertensive, or 
lipid-lowering therapy. A special focus of these Guidelines is on managing 
HF in diabetes, a field that has been underestimated for years. Based on 
data from large CVOTs, it is recommended to treat patients with diabetes 
and chronic HF (independent of left ventricular ejection fraction [LVEF]) 
with SGLT2 inhibitors to reduce HF hospitalization. Finally, in patients 
with diabetes and CKD, it is recommended to treat with an SGLT2 inhibi­
tor and/or finerenone, since these agents reduce CV and kidney failure risk 
on top of standard of care (Figure 1).
Managing patients with diabetes and CVD requires an interdisciplin­
ary approach, which should involve healthcare clinicians from different 
disciplines and areas of expertise to support shared decision-making 
and implement a personalized treatment strategy to reduce each pa­
tient’s disease burden. Ultimately, our common goal in managing 
CVD in patients with diabetes is to improve patients’ prognosis and 
health-related quality of life.
Patient presentation
Cardiovascular disease
Type 2 diabetes mellitus
Evaluation
Diagnosis
Treatment
Type 2 diabetes mellitus?
(Class I)
GLP-1 RAa
(Class I)
SGLT2 inhibitorb
(Class I)
SGLT2 inhibitorc
(Class I)
Finerenone
(Class I)
SGLT2 inhibitord
(Class I)
CVD and type 2 diabetes mellitus
Type 2 diabetes mellitus and ASCVD
Type 2 diabetes mellitus and HF
All therapies are recommended independent of glucose control and in addition to standard of care
Type 2 diabetes mellitus and CKD
To reduce cardiovascular risk independent of glucose control
To reduce heart failure hospitalization in all patients with T2DM and HF
(HFpEF, HFmrEF, HFrEF)
To reduce cardiovascular and kidney failure risk
Cardiovascular disease?
(Class I)
Chronic kidney disease?
(Class I)
Confirmed
Confirmed
Confirmed
Figure 1 Management of cardiovascular disease in patients with type 2 diabetes: clinical approach and key recommendations. ASCVD, atherosclerotic 
cardiovascular disease; CKD, chronic kidney disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; 
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; s.c. subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. aGLP-1 RAs with proven cardiovascular benefit: lir­
aglutide, semaglutide s.c., dulaglutide, efpeglenatide. bSGLT2 inhibitors with proven cardiovascular benefit: empagliflozin, canagliflozin, dapagliflozin, sotagli­
flozin. cEmpagliflozin, dapagliflozin, sotagliflozin in HFrEF; empagliflozin, dapagliflozin in HFpEF and HFmrEF. dCanagliflozin, empagliflozin, dapagliflozin.
2.1. Central figure


<!-- PAGE 11 -->

### Page 11

2.2. What is new
Table 3 New recommendations
Recommendations
Classa
Levelb
Cardiovascular risk assessment in diabetes—Section 4
In patients with T2DM without symptomatic ASCVD 
or severe TOD, it is recommended to estimate 
10-year CVD risk via SCORE2-Diabetes.
I
B
Weight reduction in patients with diabetes—Section 5.1.1
It is recommended that individuals living with 
overweight or obesity aim to reduce weight and 
increase physical exercise to improve metabolic 
control and overall CVD risk profile.
I
A
Glucose-lowering medications with effects on weight 
loss (e.g. GLP-1 RAs) should be considered in 
patients with overweight or obesity to reduce 
weight.
IIa
B
Bariatric surgery should be considered for high and 
very high risk patients with BMI ≥35 kg/m2 (≥Class II) 
when repetitive and structured efforts of lifestyle 
changes combined with weight-reducing medications 
do not result in maintained weight loss.
IIa
B
Increasing physical activity and exercise in patients with 
diabetes—Section 5.1.3
It is recommended to adapt exercise interventions to 
T2DM-associated comorbidities, e.g. frailty, 
neuropathy, or retinopathy.
I
B
It is recommended to introduce structured exercise 
training in patients with T2DM and established CVD, 
e.g. CAD, HFpEF, HFmrEF, HFrEF, or AF to improve 
metabolic control, exercise capacity, and quality of 
life, and to reduce CV events.
I
B
The use of behavioural theory-based interventions, 
such as goal-setting, re-evaluation of goals, 
self-monitoring, and feedback, should be considered 
to promote physical activity behaviour.
IIa
B
It may be considered to use wearable activity 
trackers to increase physical activity behaviour.
IIb
B
Smoking cessation in patients with diabetes—Section 5.1.4
Nicotine replacement therapy, varenicline, and 
bupropion, as well as individual or telephone 
counselling, should be considered to improve 
smoking cessation success rate.
IIa
B
Glycaemic targets—Section 5.2
Tight glycaemic control should be considered for 
reducing CAD in the long term, preferably using 
agents with proven CV benefit.
IIa
B
Continued
Atherosclerotic cardiovascular disease risk reduction by 
glucose-lowering medications in diabetes—Section 5.3
It is recommended to prioritize the use of 
glucose-lowering agents with proven CV benefits 
followed by agents with proven CV safety over 
agents without proven CV benefit or proven CV 
safety.
I
C
If additional glucose control is needed, metformin 
should be considered in patients with T2DM and 
ASCVD.
IIa
C
If additional glucose control is needed, pioglitazone 
may be considered in patients with T2DM and 
ASCVD without HF.
IIb
B
Blood pressure and diabetes—Section 5.4
Regular BP measurements are recommended in all 
patients with diabetes to detect and treat 
hypertension to reduce CV risk.
I
A
Lipids and diabetes—Section 5.5
A PCSK9 inhibitor is recommended in patients at 
very high CV risk, with persistently high LDL-C levels 
above target despite treatment with a maximum 
tolerated statin dose, in combination with ezetimibe, 
or in patients with statin intolerance.
I
A
If a statin-based regimen is not tolerated at any 
dosage (even after re-challenge), a PCSK9 inhibitor 
added to ezetimibe should be considered.
IIa
B
If a statin-based regimen is not tolerated at any 
dosage (even after re-challenge), ezetimibe should be 
considered.
IIa
C
High-dose icosapent ethyl (2 g b.i.d.) may be 
considered in combination with a statin in patients 
with hypertriglyceridaemia.
IIb
B
Antithrombotic therapy in patients with diabetes—Section 5.6
Clopidogrel 75 mg o.d. following appropriate loading 
(e.g. 600 mg or at least 5 days already on 
maintenance therapy) is recommended in addition to 
ASA for 6 months following coronary stenting in 
patients with CCS, irrespective of stent type, unless a 
shorter duration is indicated due to the risk or 
occurrence of life-threatening bleeding.
I
A
In patients with diabetes and ACS treated with 
DAPT who are undergoing CABG and do not 
require long-term OAC therapy, resuming a P2Y12 
receptor inhibitor as soon as deemed safe after 
surgery and continuing it up to 12 months is 
recommended.
I
C
Adding very low-dose rivaroxaban to low-dose ASA 
for long-term prevention of serious vascular events 
should be considered in patients with diabetes and 
CCS or symptomatic PAD without high bleeding risk.
IIa
B
Continued
ESC Guidelines                                                                                                                                                                                          4053


<!-- PAGE 12 -->

### Page 12

In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation prolonging triple 
therapy with low-dose ASA, clopidogrel, and an 
OAC should be considered up to 1 month if the 
thrombotic risk outweighs the bleeding risk in the 
individual patient.
IIa
C
In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation prolonging triple 
therapy with low-dose ASA, clopidogrel, and an 
OAC up to 3 months may be considered if the 
thrombotic risk outweighs the bleeding risk in the 
individual patient.
IIb
C
When clopidogrel is used, omeprazole and 
esomeprazole are not recommended for gastric 
protection.
III
B
Multifactorial approach in patients with diabetes—Section 5.7
Identifying and treating risk factors and comorbidities 
early is recommended.
I
A
Multidisciplinary behavioural approaches that 
combine the knowledge and skills of different 
caregivers are recommended.
I
C
Principles of motivational interviewing should be 
considered to induce behavioural changes.
IIa
C
Telehealth may be considered to improve risk 
profile.
IIb
B
Management of coronary artery disease in patients with 
diabetes—Section 6
Myocardial revascularization in CCS is 
recommended when angina persists despite 
treatment with anti-anginal drugs or in patients with 
a documented large area of ischaemia (>10% LV).
I
A
Complete revascularization is recommended in 
patients with STEMI without cardiogenic shock and 
with multivessel CAD.
I
A
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.
I
B
Complete revascularization should be considered in 
patients with NSTE-ACS without cardiogenic shock 
and with multivessel CAD.
IIa
C
Glucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, 
while episodes of hypoglycaemia should be avoided.
IIa
C
Routine immediate revascularization of non-culprit 
lesions in patients with MI and multivessel disease 
presenting with cardiogenic shock is not 
recommended.
III
B
Continued
Heart failure and diabetes—Section 7
Evaluation for heart failure in diabetes
If HF is suspected, it is recommended to measure 
BNP/NT-proBNP.
I
B
Systematic survey for HF symptoms and/or signs of 
HF is recommended at each clinical encounter in all 
patients with diabetes.
I
C
Diagnostic tests in all patients with suspected heart failure
12-lead ECG is recommended.
I
C
Transthoracic echocardiography is recommended.
I
C
Chest radiography (X-ray) is recommended.
I
C
Routine blood tests for comorbidities are 
recommended, including full blood count, urea, 
creatinine and electrolytes, thyroid function, lipids, 
and iron status (ferritin and TSAT).
I
C
Pharmacological treatment indicated in patients with HFrEF 
(NYHA class II–IV) and diabetes
SGLT2 inhibitors (dapagliflozin, empagliflozin, or 
sotagliflozin) are recommended in all patients with 
HFrEF and T2DM to reduce the risk of HF 
hospitalization and CV death.
I
A
An intensive strategy of early initiation of 
evidence-based treatment (SGLT2 inhibitors, ARNI/ 
ACE-Is, beta-blockers, and MRAs), with rapid 
up-titration to trial-defined target doses starting 
before discharge and with frequent follow-up visits in 
the first 6 weeks following a HF hospitalization is 
recommended to reduce re-admissions or mortality.
I
B
Other treatments indicated in selected patients with HFrEF 
(NYHA class II–IV) and diabetes
Hydralazine and isosorbide dinitrate should be 
considered in self-identified Black patients with 
diabetes and LVEF ≤35% or with an LVEF <45% 
combined with a dilated LV in NYHA class III–IV 
despite treatment with an ACE-I (or ARNI), a 
beta-blocker, and an MRA, to reduce the risk of HF 
hospitalization and death.
IIa
B
Digoxin may be considered in patients with 
symptomatic HFrEF in sinus rhythm despite 
treatment with sacubitril/valsartan or an ACE-I, a 
beta-blocker, and an MRA, to reduce the risk of 
hospitalization.
IIb
B
Heart failure treatments in patients with diabetes and LVEF 
>40%
Empagliflozin or dapagliflozin are recommended in 
patients with T2DM and LVEF >40% (HFmrEF and 
HFpEF) to reduce the risk of HF hospitalization or 
CV death.
I
A
Continued


<!-- PAGE 13 -->

### Page 13

Special considerations for glucose-lowering medications in 
patients with T2DM with and without HF
It is recommended to switch glucose-lowering 
treatment from agents without proven CV benefit or 
proven safety to agents with proven CV benefit.
I
C
Atrial fibrillation and diabetes—Section 8.1
Opportunistic screening for AF by pulse taking or 
ECG is recommended in patients with diabetes <65 
years of age (particularly when other risk factors are 
present) because patients with diabetes exhibit a 
higher AF frequency at a younger age.
I
C
Systematic ECG screening should be considered to 
detect AF in patients aged ≥75 years, or those at high 
risk of stroke.
IIa
B
Chronic kidney disease and diabetes—Section 9
Intensive LDL-C lowering with statins or a statin/ 
ezetimibe combination is recommended.
I
A
A SGLT2 inhibitor (canagliflozin, empagliflozin, or 
dapagliflozin) is recommended in patients with 
T2DM and CKD with an eGFR ≥20 mL/min/1.73 m2 
to reduce the risk of CVD and kidney failure.
I
A
Finerenone is recommended in addition to an ACE-I 
or ARB in patients with T2DM and eGFR >60 mL/ 
min/1.73 m2 with a UACR ≥30 mg/mmol (≥300 mg/ 
g), or eGFR 25–60 mL/min/1.73 m2 and UACR 
≥3 mg/mmol (≥30 mg/g) to reduce CV events and 
kidney failure.
I
A
Low-dose ASA (75–100 mg o.d.) is recommended in 
patients with CKD and ASCVD.
I
A
Treatment with intensive medical or an initial invasive 
strategy is recommended in people with CKD, 
diabetes, and stable moderate or severe CAD, due to 
similar outcomes.
I
B
Kidney specialist advice may be considered for 
managing a raised serum phosphate, other evidence 
of CKD-MBD, and renal anaemia.
IIb
C
Combined use of an ARB with an ACE-I is not 
recommended.
III
B
Continued
Aortic and peripheral arterial diseases and diabetes—Section 10
In patients with diabetes and aortic aneurysm, it is 
recommended to implement the same diagnostic 
work-up and therapeutic strategies (medical, surgical, 
or endovascular) as in patients without diabetes.
I
C
Type 1 diabetes and cardiovascular disease—Section 11
In patients with T1DM, it is recommended that 
adjustment of glucose-lowering medication follows 
principles of patient self-management under the 
guidance of the diabetes healthcare multidisciplinary 
team.
I
C
Avoiding hypoglycaemic episodes is recommended, 
particularly in those with established CVD.
I
C
Statins should be considered for LDL-C lowering in 
adults older than 40 years with T1DM without a 
history of CVD to reduce CV risk.
IIa
B
Statins should be considered for use in adults 
younger than 40 years with T1DM and other risk 
factors of CVD or microvascular end-organ damage 
or 10-year CVD risk ≥10% to reduce CVD risk.
IIa
B
The use of the Scottish/Swedish risk prediction 
model may be considered to estimate 10-year CVD 
risk in patients with T1DM.
IIb
B
© ESC 2023
ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial 
fibrillation; ARB, angiotensin-II receptor blocker; ARNI, angiotensin receptor–neprilysin 
inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; b.i.d., 
twice a day; BMI, body mass index; BNP, B-type natriuretic peptide; BP, blood pressure; 
CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, chronic 
coronary syndrome; CKD-MBD, chronic kidney disease–mineral bone disorder; CV, 
cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; ECG, 
electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like 
peptide-1 receptor agonist; HF, heart failure; HFmrEF, heart failure with mildly reduced 
ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart 
failure with reduced ejection fraction; LDL-C, low-density lipoprotein-cholesterol; LV, 
left ventricular/ventricle; LVEF, left ventricular ejection fraction; MI, myocardial infarction; 
MRA, mineralocorticoid receptor antagonist; NSTE-ACS, non-ST-elevation acute 
coronary syndrome; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, 
New York Heart Association; OAC, oral anticoagulant; o.d., once daily; PAD, peripheral 
arterial disease; PCSK9, proprotein convertase subtilisin/kexin type 9; T1DM, type 1 
diabetes mellitus; T2DM, type 2 diabetes mellitus; TOD, target-organ damage; TSAT, 
transferrin saturation; SCORE2-Diabetes, type 2 diabetes-specific 10-year CVD risk 
score; SGLT2, sodium–glucose co-transporter-2; STEMI, ST-elevation myocardial 
infarction; UACR, urinary albumin-to-creatinine ratio. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4055


<!-- PAGE 14 -->

### Page 14

Table 4 Revised recommendations
2019
Classa
Levelb
2023
Classa
Levelb
Change in diet and nutrition in patients with diabetes—Section 5.1.2
A Mediterranean diet, rich in polyunsaturated 
and monounsaturated fats, should be 
considered to reduce CV events.
IIa
B
It is recommended to adopt a Mediterranean or plant-based diet 
with high unsaturated fat content to lower CV risk.
I
A
Atherosclerotic cardiovascular disease risk reduction by glucose-lowering medications in diabetes—Section 5.3
Empagliflozin, canagliflozin, or dapagliflozin 
are recommended in patients with T2DM and 
CVD, or at very high/high CV risk to reduce 
CV events.
I
A
SGLT2 inhibitors with proven CV benefit are recommended in 
patients with T2DM and ASCVD to reduce CV events, 
independent of baseline or target HbA1c and independent of 
concomitant glucose-lowering medication.
I
A
In patients with T2DM without ASCVD or severe TOD but with 
a calculated 10-year CVD risk ≥10%, treatment with an SGLT2 
inhibitor or GLP-1 RA may be considered to reduce CV risk.
IIb
C
Liraglutide, semaglutide, or dulaglutide are 
recommended in patients with T2DM and 
CVD, or at very high/high CV risk to reduce 
CV events.
I
A
GLP-1 RAs with proven CV benefit are recommended in patients 
with T2DM and ASCVD to reduce CV events, independent of 
baseline or target HbA1c and independent of concomitant 
glucose-lowering medication.
I
A
In patients with T2DM without ASCVD or severe TOD but with 
a calculated 10-year CVD risk ≥10%, treatment with an SGLT2 
inhibitor or GLP-1 RA may be considered to reduce CV risk.
IIb
C
Antithrombotic therapy in patients with diabetes—Section 5.6
When low-dose aspirin is used, proton pump 
inhibitors should be considered to prevent 
gastrointestinal bleeding.
IIa
A
When antithrombotic drugs are used in combination, proton 
pump inhibitors are recommended to prevent gastrointestinal 
bleeding.
I
A
When a single antiplatelet or anticoagulant drug is used, proton 
pump inhibitors should be considered to prevent gastrointestinal 
bleeding, considering the bleeding risk of the individual patient.
IIa
A
Multifactorial approach to risk-factor management in patients with diabetes—Section 5.7
A multifactorial approach to diabetes 
management with treatment targets should 
be considered in patients with diabetes and 
CVD.
IIa
B
A multifactorial approach to managing T2DM with treatment 
targets is recommended.
I
B
Heart failure and diabetes—Section 7
GLP-1 RAs (lixisenatide, liraglutide, 
semaglutide, exenatide, dulaglutide) have a 
neutral effect on the risk of HF hospitalization, 
and may be considered for diabetes treatment 
in patients with HF.
IIb
A
GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, 
dulaglutide, efpeglenatide) have a neutral effect on the risk of HF 
hospitalization, and should be considered for glucose-lowering 
treatment in patients with T2DM at risk of or with HF.
IIa
A
Insulin may be considered in patients with 
advanced, systolic HFrEF.
IIb
C
Basal insulins (glargine and degludec) have a neutral effect on the 
risk of HF hospitalization, and should be considered for 
glucose-lowering treatment in patients with T2DM at risk of or 
with HF.
IIa
B
Atrial fibrillation and diabetes—Section 8.1
Screening for AF by pulse palpation should be 
considered in patients aged >65 years with 
diabetes and confirmed by ECG, if any 
suspicion of AF, as AF in patients with diabetes 
increases morbidity and mortality.
IIa
C
Opportunistic screening for AF by pulse taking or ECG is 
recommended in patients ≥65 years of age.
I
B
Continued


<!-- PAGE 15 -->

### Page 15

### 3 Diagnosis of diabetes

Diabetes mellitus, a common metabolic condition, affected 537 million 
individuals worldwide in 2021 (10.5% prevalence), and this is expected 
to rise to 783 million cases by 2045 (12.2% prevalence).2
Diabetes is suspected in the presence of specific symptoms, includ­
ing polyuria, polydipsia, fatigue, blurred vision, weight loss, poor 
wound healing, and recurrent infections. However, the condition 
can be asymptomatic and is therefore undiagnosed in over 40% of 
adults worldwide (ranging from 24% to 75% across regions).3
Abnormal glucose metabolism has been divided into two clinical cat­
egories: diabetes and pre-diabetes, which are biochemical definitions 
(discussed below).
3.1. Laboratory criteria for diagnosing 
diabetes and pre-diabetes
Several biochemical tests are used to diagnose diabetes, including fast­
ing glucose, 2 h glucose (during the glucose tolerance test), random glu­
cose, and glycated haemoglobin (HbA1c).4–7
3.1.1. Fasting glucose
Fasting glucose levels ≥7.0 mmol/L (≥126 mg/dL) is diagnostic of dia­
betes, although two tests are usually recommended to diagnose in 
the absence of hyperglycaemic symptoms. In patients with typical symp­
toms, a single test is adequate, and it should be noted that fasting is de­
fined as no caloric intake for at least 8 h.
While international guidelines agree on the cut-off value for diagnos­
ing diabetes, they are divided on the criteria for diagnosing pre-diabetes. 
The World Health Organization (WHO) defines pre-diabetes as fasting 
glucose 
levels 
6.1–6.9 mmol/L 
(110–125 mg/dL) 
with 
levels 
<6.1 mmol/L (<110 mg/dL) regarded as normal.5 However, the ADA 
has more stringent criteria, with glucose levels 5.6–6.9 mmol/L (100– 
125 mg/dL) falling into the pre-diabetes range and only those with glu­
cose <5.6 mmol/L (<100 mg/dL) classified as having normal glucose 
metabolism.7,8
3.1.2. Two-hour oral glucose tolerance test and random 
glucose
Following an oral glucose load equivalent to 75 g glucose, 2 h glucose 
≥11.1 mmol/L (≥200 mg/dL) is diagnostic of diabetes. Two-hour glu­
cose 7.8–11.0 mmol/L (140–199 mg/dL) indicates impaired glucose tol­
erance, and the individual is diagnosed with pre-diabetes. However, an 
oral glucose tolerance test (OGTT) is not routinely performed, as it is 
time-consuming and inconvenient, and is therefore usually reserved for 
unclear cases. Of note, OGTT should be performed under resting con­
ditions, as exercise during the test can invalidate the results.
Chronic kidney disease and diabetes—Section 9
Treatment with the GLP-1 RAs liraglutide and 
semaglutide is associated with a lower risk of 
renal endpoints and should be considered for 
diabetes treatment if eGFR is >30 mL/min/ 
1.73 m2.
IIa
B
A GLP-1 RA is recommended at an eGFR >15 mL/min/1.73 m2 
to achieve adequate glycaemic control, due to low risk of 
hypoglycaemia and beneficial effects on weight, CV risk, and 
albuminuria.
I
A
© ESC 2023
AF, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular disease; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; ER, 
extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; SGLT2, sodium– 
glucose co-transporter-2; T2DM, type 2 diabetes mellitus; TOD, target-organ damage. 
aClass of recommendation. 
bLevel of evidence.
Table 5 Revised concepts 2023 Guidelines
Focus of the Guidelines is prevention and management of 
cardiovascular disease in diabetes
The aspect of pre-diabetes is no longer covered in the current 
Guidelines.
Cardiovascular risk assessment in diabetes
For patients without ASCVD or severe target-organ damage, a novel 
T2DM-specific risk score (SCORE2-Diabetes) is introduced.
CV risk categories in T2DM are now defined based on the presence of 
ASCVD or severe target-organ damage or the 10-year CVD risk using 
SCORE2-Diabetes.
Atherosclerotic cardiovascular risk reduction by 
glucose-lowering medications in diabetes
Based on various meta-analyses including data from CVOTs with SGLT2 
inhibitors and GLP-1 RAs, the current Guidelines give separate 
recommendations for patients with and without ASCVD/severe 
target-organ damage.
Special attention is given on the aspect of proven CV benefit and/or 
safety of glucose-lowering medications.
Heart failure and diabetes
Detailed recommendations are given on HF screening and diagnosis in 
patients with diabetes.
Based on data from outcome trials in patients with HF (HFrEF, HFmrEF, 
HFpEF) with and without diabetes, the current Guidelines provide 
recommendations for the treatment of HF in patients with diabetes 
across the whole spectrum of left ventricular ejection fraction.
Detailed recommendations are given for the use of glucose-lowering 
medications in patients with HF and diabetes.
Arrhythmias and diabetes
Given that patients with diabetes exhibit a higher AF frequency at a 
younger age, the concept of opportunistic screening for AF by pulse 
taking or ECG in patients with diabetes <65 years of age (particularly 
when other risk factors are associated) is introduced.
Chronic kidney disease and diabetes
A dedicated section on managing CV risk in patients with CKD and 
diabetes is introduced covering aspects of screening (including regular 
screening with eGFR and UACR) and treatment.
© ESC 2023
AF, atrial fibrillation; ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney 
disease; CV, cardiovascular; CVD, cardiovascular disease; CVOT, cardiovascular outcomes 
trial; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; GLP-1 RA, 
glucagon-like peptide-1 receptor agonist; HF, heart failure; HFmrEF, heart failure with 
mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; 
HFrEF, heart failure with reduced ejection fraction; SCORE2-Diabetes, type 2 
diabetes-specific 10-year CVD risk score; SGLT2, sodium–glucose co-transporter-2; 
T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine ratio.
ESC Guidelines                                                                                                                                                                                          4057


<!-- PAGE 16 -->

### Page 16

Following on, a random glucose ≥11.1 mmol/L (≥200 mg/dL) is also 
diagnostic of diabetes in the presence of symptoms. In the absence of 
symptoms, two random glucose levels ≥11.1 mmol/L (≥200 mg/dL) 
are required to diagnose diabetes. One-hour OGTT ≥8.6 mmol/L 
(≥155 mg/dL) has been suggested as a better predictor of diabetes 
than 2 h OGTT ≥11.1 mmol/L (≥200 mg/dL), and is associated with 
vascular complications and mortality.9 However, further validation is 
required before this new measure is widely adopted.
3.1.3. Glycated haemoglobin
Following high-quality epidemiological studies, it was suggested that 
HbA1c could be used to diagnose diabetes, and this was subsequently 
endorsed by international guidelines.10 It should be noted that epi­
demiological studies have relied on the adult population, though 
HbA1c is also used in younger individuals as a diagnostic test.11
Advantages of HbA1c include ease of measurement, limited 
within-individual variability, and the convenience of anytime testing 
without the need for fasting or a cumbersome OGTT.
However, HbA1c is not accurate in specific groups where the rela­
tionship between HbA1c and glucose levels is altered for any reason 
(Supplementary data online, Table S1).12,13 Moreover, in cases of short­
er diabetes duration, such as early type 1 diabetes mellitus (T1DM) or 
Diabetes ruled out (normal glucose metabolism)
Pre-diabetes (IGT)c
Diabetesb
Values indicative of diabetes or pre-diabetes
Fasting glucose ≥7.0 mmol/L (≥126 mg/dL), or
 HbA1c ≥48 mmol/mol (≥6.5%), or 
OGTT (2 h) glucosea ≥11.1 mmol/L (≥200 mg/dL)
Fasting glucose 5.6–6.9 mmol/L (100–125 mg/dL), or
 HbA1c 39–47 mmol/mol (5.7–6.4%), or 
OGTT (2 h) glucose 7.8–11.0 mmol/L (140–199 mg/dL)
Fasting glucose ≥5.6 mmol/L (≥100 mg/dL), or 
HbA1c ≥39 mmol/mol (≥5.7%), or 
OGTT (2 h) glucose ≥7.8 mmol/L (≥140 mg/dL)
N
Diagnosis of diabetes and pre-diabetes
Y
Figure 2 Diagnosis of diabetes and pre-diabetes. HbA1c, glycated haemoglobin; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test. aRule 
out stress hyperglycaemia (often manifests as elevated glucose and normal HbA1c). bIn the presence of symptoms, a single test is enough; in the absence of 
symptoms, two abnormal tests are required to make the diagnosis. cAmerican Diabetes Association criteria are used in this scheme for the diagnosis of 
pre-diabetes.
Table 6 Biochemical diagnostic criteria for diabetes 
and pre-diabetes according to the World Health 
Organization and the American Diabetes Association
Glycaemic marker
WHO criteria 
(2011, 2019)5,6
ADA criteria 
(2021)7
Diabetes
FPG
≥7.0 mmol/L (≥126 mg/dL)
2hPG (OGTT)
≥11.1 mmol/L (≥200 mg/dL)
HbA1c
≥6.5% (≥48 mmol/mol)
RPG
≥11.1 mmol/L (≥200 mg/dL)
Pre-diabetes
FPG
6.1–6.9 mmol/L 
(110–125 mg/dL)
5.6–6.9 mmol/L 
(100–125 mg/dL)
2hPG (OGTT)
7.8–11.0 mmol/L (140–199 mg/dL)
HbA1c
6.0–6.4% 
(42–47 mmol/mol)
5.7–6.4% 
(39–47 mmol/mol)
© ESC 2023
ADA, American Diabetes Association; 2hPG, 2 h plasma glucose; FPG, fasting plasma 
glucose; HbA1c, glycated haemoglobin; RPG, random plasma glucose; OGTT, oral 
glucose tolerance test; WHO, World Health Organization.


<!-- PAGE 17 -->

### Page 17

acute pancreatic damage, HbA1c can lead to false-negative results. 
Another practical limitation is the lack of test availability in some parts 
of the world due to financial constraints.
Guidelines agree that HbA1c ≥48 mmol/mol (≥6.5%) is diagnostic of 
diabetes, while the diagnosis of pre-diabetes uses two different cut-off 
values. The WHO criteria define pre-diabetes as HbA1c 42–47 mmol/ 
mol (6.0–6.4%), while the ADA recommends a wider range of 39– 
47 mmol/mol (5.7–6.4%).5,7 Notably, the combination of HbA1c and 
fasting glucose in the diabetes range is diagnostic of diabetes and a se­
cond test is not required, even if the individual is asymptomatic. 
However, if the two are discordant, the number in the diabetes range 
should be repeated or, preferably, an OGTT performed, which remains 
the gold standard for diagnosing diabetes in unclear cases. The criteria 
used for diagnosing diabetes and pre-diabetes are summarized in 
Table 6. It should be noted that data from 73 studies on 294 998 indi­
viduals without known diabetes suggest that HbA1c is as good as or 
better than fasting, random, or post-load glucose levels for predicting 
CV risk.14
A diagram for the diagnosis of diabetes is shown in Figure 2.
3.2. Classifying diabetes
After abnormal glucose metabolism is diagnosed, the next step is to as­
certain the type of diabetes in order to start the appropriate therapies 
(Supplementary data online, Table S2).
3.2.1. Type 1 diabetes
Type 1 diabetes constitutes 5–10% of individuals with diabetes and is 
secondary to destruction of pancreatic β-cells by an autoimmune pro­
cess, with subsequent insulin deficiency. Recent guidance on diagnosing 
T1DM has been published.13
Briefly, individuals aged <35 years presenting with diabetes should be 
suspected of having T1DM, although this condition can occur at any 
age. A short history of osmotic symptoms accompanied by weight 
loss and raised glucose levels in a younger individual is highly suggestive 
of T1DM. Antibody testing helps to confirm the diagnosis, although this 
can be negative in 5–10% of individuals with T1DM, while C-peptide 
helps to assess endogenous insulin production in unclear cases 
(Supplementary data online, Table S2).
Pancreatic β-cell function can partially recover after the diagnosis of 
T1DM, and this can last several years, often referred to as the ‘honey­
moon period’. However, if this persists beyond 5 years, an alternative 
type of diabetes needs to be considered.15 Of importance, the combin­
ation of T1DM with insulin resistance, which can be referred to as dou­
ble diabetes (DD), increases the risk of vascular complications, although 
the exact definition of DD is yet to be determined.16
3.2.2. Type 2 diabetes
Type 2 diabetes is the most common cause of diabetes (90% of the dia­
betes population) and is usually caused by insulin resistance coupled 
with ‘relative’ insulin deficiency, resulting in raised glucose levels. 
Individuals with T2DM can be asymptomatic and can be diagnosed after 
presenting with CV complications (Supplementary data online, 
Table S2). Therefore, it is mandatory to screen all patients with CVD 
for the presence of diabetes.
3.2.3. Monogenic diabetes
This comprises many mutations that cause glucose mishandling. A full 
description can be found elsewhere.17 Briefly, monogenic diabetes 
should be suspected in the presence of a strong family history of abnor­
mal glucose metabolism in an autosomal dominant manner (i.e. succes­
sive generations with diabetes at a young age).17
Patients diagnosed with diabetes before the age of 6 months and 
those not fitting the T1DM or T2DM profiles should be suspected of 
having monogenic diabetes.
3.2.4. Secondary diabetes and stress hyperglycaemia
Diabetes can occur secondary to various conditions and therapies 
(Supplementary data online, Table S2). Stress hyperglycaemia is not un­
common in hospitalized patients and can occur in individuals with acute 
coronary syndrome (ACS) or HF.18 Stress hyperglycaemia without dia­
betes is associated with adverse in-hospital outcomes, and should be 
suspected in those with raised glucose levels during admission and nor­
mal HbA1c.19 Such individuals are best investigated using OGTT a few 
weeks after discharge to rule out diabetes or impaired glucose toler­
ance. Some studies suggest performing OGTT before hospital dis­
charge but robust data supporting this approach are lacking.20,21
3.2.5. Gestational diabetes
Gestational diabetes mellitus (GDM) is defined as diabetes diagnosed 
in the second or third trimester of pregnancy that was not overt dia­
betes before gestation.7 While there is still no worldwide consensus 
regarding the best testing strategy, the ‘one-step’ 75 g OGTT, also 
recommended by the WHO, is the preferred test in many coun­
tries.22 In women with GDM, repeat testing is required in the post- 
partum period to rule out persistent abnormal glucose metabolism. 
Women with GDM will require lifelong annual diabetes screening gi­
ven the high risk of developing diabetes.23–25 Also, evidence suggests 
that women with a history of GDM are at increased CV risk, even 
with normal post-partum glucose levels. Given that GDM is an im­
portant precursor of future cardiometabolic complications, women 
with a history of GDM should regularly be screened not only for dia­
betes, but also for CV health.26–29
3.2.6. Further sub-group classification of type 2 
diabetes
For information regarding further sub-group classification of T2DM, 
see Supplementary data online, Section 1.1.1.
3.3. Screening for diabetes
Criteria for diabetes testing differ widely across regions, and a com­
prehensive global screening programme is yet to be developed. It is 
generally agreed, however, that individuals in high-risk groups (those 
living with overweight or obesity, or having markers of insulin resist­
ance, such as acanthosis nigricans or fatty liver disease) should be 
regularly screened, particularly after age 45 years. The ADA devel­
oped a relatively simple 7-point scoring system based on age, sex, 
weight, physical activity (PA), history of GDM, presence of hyperten­
sion, and family history of diabetes; it is advised that those scoring ≥5 
are screened for diabetes.7
The prevalence of diabetes is increased among patients with CVD, 
with 23–37% of patients with ACS and 10–47% of patients with HF di­
agnosed with diabetes. This results in worse clinical outcomes com­
pared with individuals with normal glucose metabolism.30–33
Therefore, individuals with ASCVD and/or HF and/or AF, particularly 
those admitted to hospital with an acute event, should be tested for dia­
betes; those with suspected stress hyperglycaemia (raised glucose levels 
ESC Guidelines                                                                                                                                                                                          4059


<!-- PAGE 18 -->

### Page 18

during admission with normal HbA1c) should undergo post-discharge 
glucose testing, preferably with OGTT, to rule out persistent abnormal 
glucose metabolism.
Although OGTT has been previously advocated for diabetes screen­
ing in individuals with CVD, practicalities and low reproducibility of the 
test limited widespread use.34,35 Importantly, evidence indicates that 
HbA1c, or fasting glucose, are stronger predictors of vascular complica­
tions than 2 h OGTT and it is therefore best to adopt these simple 
measures for general screening, particularly given their high reproduci­
bility.35–38
4. Cardiovascular risk assessment 
in patients with type 2 diabetes
Individuals with T2DM are at a two- to four-fold higher risk of develop­
ing CVD during their lifetime alongside its manifestations CAD, stroke, 
HF, and AF, as well as peripheral artery diseases (PAD).40,41 In addition, 
many patients with CVD have undiagnosed T2DM. Given that having 
diabetes and CVD, especially at a younger age, has a major impact on 
prognosis, it is of utmost importance to screen patients with CVD 
for diabetes and to assess CV risk in individuals with diabetes, and evalu­
ate them for CV and kidney disease.42
4.1. Assessing cardiovascular risk in type 2 
diabetes
When assessing CV risk in individuals with T2DM, it is important to 
consider medical and family history, symptoms, findings from examin­
ation, laboratory and other diagnostic test results, and the presence 
of ASCVD or severe TOD. There is not enough robust evidence to 
suggest that assessment of coronary artery calcium (CAC) or intima 
media thickness help reclassify CV risk in people with T2DM. Severe 
TOD is defined as: 
(i) Estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 
irrespective of albuminuria, or
(ii) eGFR 45–59 mL/min/1.73 m2 and microalbuminuria (urinary 
albumin-to-creatinine ratio [UACR] 30–300 mg/g; stage A2), or
(iii) Proteinuria (UACR >300 mg/g; stage A3), or
(iv) Presence of microvascular disease in at least three different sites 
(e.g. microalbuminuria (stage A2) plus retinopathy plus neur­
opathy; see Section 9.1 for CKD screening).43–45
4.1.1. Cardiovascular risk categories in type 2 
diabetes
Individuals with T2DM should be categorized into different CV risk 
groups based on the following criteria (Table 7):
4.1.2. SCORE2-Diabetes: estimating 10-year 
cardiovascular disease risk
In patients aged ≥40 years with T2DM without ASCVD or severe TOD, 
it is recommended to estimate 10-year CVD risk using the 
SCORE2-Diabetes algorithm (Figure 3). In these patients, risk factors 
for ASCVD should be evaluated on an individual basis. In the 2021 
ESC Guidelines on cardiovascular disease prevention in clinical practice, 
the ADVANCE (Action in Diabetes and Vascular disease: preterAx and 
diamicroN MR Controlled Evaluation) or DIAL (Diabetes lifetime- 
perspective prediction) models were suggested for estimating CVD 
risk among patients with diabetes.46–48 However, these models have 
some limitations for use in Europe, as they do not allow for substantial 
variations of risk across countries, meaning they may misestimate risk 
in these circumstances. Furthermore, these models have been developed 
from a narrow set of studies and have not been systematically ‘recali­
brated’ (i.e. statistically adapted) to contemporary CVD rates, meaning 
they are not ideal for use in contemporary European populations. To ad­
dress these limitations, the current Guidelines recommend use of the 
SCORE2-Diabetes model, which extends the regionally recalibrated 
European SCORE2 10-year risk model to enable use in individuals with 
T2DM aged 40–69 years without ASCVD or severe TOD, and to esti­
mate an individual’s 10-year risk of fatal and non-fatal CVD events (MI, 
stroke).49
SCORE2-Diabetes integrates information on conventional CVD risk 
factors (i.e. age, smoking status, systolic blood pressure [SBP], and total 
and high-density lipoprotein [HDL]-cholesterol) with diabetes-specific 
information (e.g. age at diabetes diagnosis, HbA1c, and eGFR).50 This 
model is calibrated to four clusters of countries (low, moderate, high, 
and very high CVD risk) using the similar methodology of the 
Recommendation Table 1 — Recommendations for 
diagnosing diabetes
Recommendations
Classa
Levelb
Screening for diabetes is recommended in all 
individuals with CVD,c using fasting glucose and/or 
HbA1c.5–7,36,37,39
I
A
It is recommended that the diagnosis of diabetes is 
based on HbA1c and/or fasting plasma glucose, or on 
an OGTT if still in doubt.d,5–8,10,11
I
B
© ESC 2023
CVD, cardiovascular disease; HbA1c, glycated haemoglobin; OGTT, oral glucose tolerance 
test. 
aClass of recommendation. 
bLevel of evidence. 
cCardiovascular disease includes atherosclerotic cardiovascular disease, atrial fibrillation, 
and heart failure. 
dStress hyperglycaemia should be suspected in the presence of high glucose levels and 
normal HbA1c (see text for details).
Table 7 Cardiovascular risk categories in type 2 
diabetes
Very high CV 
risk
Patients with T2DM with: 
• Clinically established ASCVD or
• Severe TOD or
• 10-year CVD risk ≥20% using SCORE2-Diabetes
High CV risk
Patients with T2DM not fulfilling the very high-risk 
criteria and a: 
• 10-year CVD risk 10 to <20% using 
SCORE2-Diabetes
Moderate CV 
risk
Patients with T2DM not fulfilling the very high-risk 
criteria and a: 
• 10-year CVD risk 5 to <10% using 
SCORE2-Diabetes
Low CV risk
Patients with T2DM not fulfilling the very high-risk 
criteria and a: 
• 10-year CVD risk <5% using SCORE2-Diabetes
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular 
disease; eGFR, estimated glomerular filtration rate; SCORE2-Diabetes, type 2 
diabetes-specific 10-year CVD risk score; T2DM, type 2 diabetes mellitus; TOD, 
target-organ damage; UACR, urinary albumin-to-creatinine ratio. 
Severe TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 45– 
59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria 
(UACR >300 mg/g; stage A3); or presence of microvascular disease in at least three 
different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neuropathy].43–45


<!-- PAGE 19 -->

### Page 19

SCORE2 and SCORE2-Older Persons (SCORE2-OP) algorithms 
(Supplementary data online, Section 2; Table S3).49,51
The ESC CVD Risk Calculation App includes SCORE2-Diabetes to 
facilitate risk estimation and communication between health profes­
sionals and individuals with T2DM (Supplementary data online, Tables 
S4–6).
Additional risk scores that attempt to estimate lifetime risk in indivi­
duals with diabetes (such as the DIAL2 [DIAbetes Lifetime] model, 
which is calibrated to different European countries) can also be used 
to aid treatment decisions.52 However, estimation of lifetime risk 
should be adapted as new methods become available in the future.
Thresholds for the different risk categories are shown in Table 7 and 
Figure 3. In general, no risk threshold is universally applicable, and the 
risk thresholds suggested in these Guidelines for use with 
SCORE2-Diabetes should be used to help guide clinicians and patients 
to prompt joint decision-making conversations for considering the in­
tensity of treatment and additional interventions to prevent ASCVD 
(such as lipid-lowering therapies [Section 5.5] or SGLT2 inhibitors 
and/or GLP-1 RAs [Section 5.3]). However, 10-year risk thresholds 
are for guidance only and other patient characteristics may lead to de­
cisions to treat or not treat irrespective of such thresholds.
5. Cardiovascular risk reduction in 
patients with diabetes: targets and 
treatments
5.1. Lifestyle and diabetes
Lifestyle changes are recommended as the basic measure for preventing 
and managing T2DM.48 Advice should be addressed by a multifactorial 
approach with patient-centred communication adapted to the health 
status and health literacy of the patient (Section 5.7). In T2DM, as inves­
tigated in the Action for Health in Diabetes trial (Look AHEAD; 5145 
T2DM patients, 59% female, mean age 58 years, mean body mass index 
[BMI] 36 kg/m2), lifestyle intervention by nutritional counselling, meal 
replacement, and exercise induced an average of 8.6% weight loss, 
which was associated with a significant reduction in HbA1c and BP.56
Effects on weight and risk-factor control diminished after 5 years in 
those with low adherence to the lifestyle programme.56 After 10 years, 
CV events (i.e. a composite endpoint of CV death, non-fatal MI, non- 
fatal stroke, and hospitalization for angina) were not different to usual 
Very high risk
High risk
Moderate risk
Low risk
Scoringb
SCORE2-Diabetes
Patient with ASCVD or severe TODa
Y
≥20%
10% to <20%
5% to <10%
<5%
N
Figure 3 Cardiovascular risk categories in patients with type 2 diabetes. ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease risk; 
eGFR, estimated glomerular filtration rate; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio. aSevere TOD defined as eGFR <45 mL/ 
min/1.73 m2 irrespective of albuminuria; or eGFR 45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR 
>300 mg/g; stage A3), or presence of microvascular disease in at least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neur­
opathy].43–45 bThe thresholds (10-year CVD risk) suggested are not definitive but rather designed to prompt joint decision-making conversations with pa­
tients about intensity of treatment, as well as additional interventions. SCORE2-Diabetes refers to patients aged ≥40 years.
Recommendation Table 2 — Recommendations for 
assessing cardiovascular risk in patients with type 2 
diabetes
Recommendations to assess cardiovascular 
risk in patients with diabetes
Classa
Levelb
It is recommended to screen patients with diabetes 
for the presence of severe TOD.c,43,44
I
A
It is recommended to assess medical history and the 
presence of symptoms suggestive of ASCVD in 
patients with diabetes.53–55
I
B
Continued
In patients with T2DM without symptomatic ASCVD 
or severe TOD,c it is recommended to estimate 
10-year CVD risk via SCORE2-Diabetes.d,50
I
B
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; eGFR, estimated glomerular filtration rate; 
SCORE2-Diabetes, type 2 diabetes-specific 10-year ASCVD risk score; T2DM, type 2 
diabetes mellitus; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio. 
aClass of recommendation. 
bLevel of evidence. 
cSevere TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 
45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or 
proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at 
least three different sites (e.g. microalbuminuria (stage A2) plus retinopathy plus 
neuropathy). 
dSCORE2-Diabetes refers to patients aged ≥40 years. In patients with T2DM without 
ASCVD and/or severe TOD, with age <40 years, risk factors for ASCVD should be 
evaluated on an individual basis.
ESC Guidelines                                                                                                                                                                                          4061


<!-- PAGE 20 -->

### Page 20

care.56 However, microvascular disease complications (i.e. develop­
ment of CKD) were significantly reduced (hazard ratio [HR] 0.69; 
95% confidence interval [CI], 0.55–0.87; P = 0.002) by lifestyle interven­
tion, an effect associated with improvements in CV risk factors.57
Additional analyses 16.7 years after the start of the study (9.6 years 
of intervention and then observation) revealed that participants who 
lost ≥10% of weight at 1 year of intervention had a 21% reduced risk 
of mortality (HR 0.79; 95% CI, 0.67–0.94; P = 0.007).58 The decline in 
body fat mass was significantly associated with a lower risk of HF 
with reduced ejection fraction (HFrEF) and HF with preserved ejection 
fraction (HFpEF), while a decline in waist circumference was only signifi­
cantly associated with a lower risk of HFpEF.59 In addition, baseline 
cardio-pulmonary fitness was associated with reduced risks of mortality 
and CV events during follow-up of 9.2 years.60
The DiRECT (Diabetes Remission Clinical Trial)—an open-label, 
cluster-randomized trial in patients with T2DM—assigned practices 
to provide either a weight-management programme including exercise 
(intervention group) or best-practice care by guidelines (control 
group). At 12 months, almost half of the participants in the intervention 
group achieved remission to a non-diabetic state and were off glucose- 
lowering drugs.61 Home-based exercise intervention in patients with 
CAD and T2DM (ARTEMIS study; Finnish randomized controlled trial 
[RCT]; n = 127; 2-year controlled, home-based exercise training vs. 
usual care), however, did not significantly improve CV risk factors des­
pite significant improvements in exercise capacity (P = 0.030).62
5.1.1. Weight reduction
In patients with obesity and T2DM, reducing weight is one of the cor­
nerstones of treatment.63 Weight loss of >5% improves glycaemic con­
trol, lipid levels, and BP in overweight and obese adults with T2DM.64,65
These effects can be achieved by improving energy balance and/or 
introducing obesity medications. Orlistat, naltrexone/bupropion, and 
phentermine/topiramate are each associated with achieving >5% 
weight loss at 52 weeks compared with placebo.66 However, glucose- 
lowering agents such as GLP-1 RAs, the dual agonist tirzepatide, and 
SGLT2 inhibitors also significantly reduce body weight.67,68 Adding ex­
ercise to a GLP-1 RA (liraglutide) had a greater effect on weight reduc­
tion and maintenance.69 Comparing the effects on weight reduction 
between GLP-1 RAs and SGLT2 inhibitors, the former seems to be su­
perior. Given the additional beneficial effects of GLP-1 RAs and SGLT2 
inhibitors on CV outcomes in T2DM (Section 5.3), these agents should 
be the preferred glucose-lowering medication in overweight and obese 
patients with CVD and T2DM, as obesity medications have, to date, not 
shown to reduce CV events.70–72
If weight is not managed effectively by lifestyle interventions and 
medication, bariatric surgery should be considered in patients with 
T2DM and a BMI ≥35 kg/m2 (≥Class II; WHO classification) to achieve 
long-term weight loss, reduce blood glucose, and improve CV risk fac­
tors. Data from the Swedish Obesity Subjects (SOS) study revealed 
that after 24-year follow-up, bariatric surgery was associated with a 
prolonged life expectancy compared with lifestyle and intensive medical 
management alone.73,74 The corresponding HR was 0.70 (95% CI, 
0.57–0.85) for CV death and 0.77 (95% CI, 0.61–0.96) for death 
from cancer.75,76 This evidence has been extended to patients with 
CVD and obesity, as a large case-control study (n = 2638) revealed 
that bariatric surgery was also associated with a lower incidence of ma­
jor adverse cardiovascular events (MACE) in those patients.77 Still, po­
tential adverse events after bariatric surgery should also be 
considered.78
5.1.2. Change in diet or nutrition
In general, patients with T2DM should follow nutritional recommenda­
tions that reduce body weight and improve metabolic control and out­
comes.48 A Mediterranean-style eating pattern improves glycaemic 
control, lipids, and BP.80,81 If this diet is supplemented with olive oil or 
nuts, as in the non-randomized PREvencion con Dieta MEDiterranea 
(PREDIMED) study in individuals at high CV risk (49% T2DM), the risk 
of ASCVD was reduced by 28–31%.82 Recent data from the Coronary 
Diet Intervention With Olive Oil and Cardiovascular Prevention 
(CORDIOPREV) study confirmed the benefit of a Mediterranean diet 
by showing that male patients with established CAD benefitted more 
from a Mediterranean diet than from a low-fat diet intervention after 
7 years of follow-up. A shift from a more animal-based to a plant-based 
food pattern may also reduce ASCVD risk.83–85
Data from studies on supplementation with n–3 fatty acids do not 
support recommending n–3 fatty acid supplements for secondary pre­
vention of CVD in T2DM.86,87
The consumption of sugars, 
sugar-sweetened soft drinks, and fruit juices should be avoided.88,89
Moreover, alcohol intake should generally be moderate, as any amount 
of alcohol uniformly increases BP and BMI.90–92 A high-protein diet 
(30% protein, 40% carbohydrates, and 30% fat) seems to be superior 
to a standard-protein diet (15% protein, 55% carbohydrates, and 
30% fat) in overweight and obese (mean weight 107.8 ± 20.8 kg) pa­
tients with HF; both diets were equal in reducing body weight (3.6 vs. 
2.9 kg, respectively) and waist circumference (1.9 vs. 1.3 cm, respective­
ly), but the high-protein diet resulted in greater reductions in CV risk 
factors, e.g. HbA1c, cholesterol, triglycerides, and BP.93
People with CVD and T2DM are encouraged to reduce sodium in­
take, as this may reduce systolic BP by, on average, 5.8 mmHg in hyper­
tensive patients and 1.9 mmHg in normotensive patients.94,95 In a 
meta-analysis, in hypertensive and normotensive people, reducing salt 
intake by 2.5 g/day resulted in a 20% relative reduction of ASCVD 
events.95 In addition, salt substitution with reduced sodium levels and 
increased potassium levels has been shown to reduce stroke, CVD, 
and overall mortality in patients with high CV risk.96
Recommendation Table 3 — Recommendations for 
reducing weight in patients with type 2 diabetes with 
or without cardiovascular disease
Recommendations
Classa
Levelb
It is recommended that individuals living with 
overweight or obesity aim to reduce weight and 
increase physical exercise to improve metabolic 
control and overall CVD risk profile.56,79
I
A
Glucose-lowering medications with effects on weight 
loss (e.g. GLP-1 RAs) should be considered in 
patients with overweight or obesity to reduce 
weight.67
IIa
B
Bariatric surgery should be considered for high and 
very high risk patients with BMI ≥35 kg/m2 (≥Class 
IIc) when repetitive and structured efforts of lifestyle 
changes combined with weight-reducing medications 
do not result in maintained weight loss.73–77
IIa
B
© ESC 2023
BMI, body mass index; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 
receptor agonist. 
aClass of recommendation. 
bLevel of evidence. 
cWorld Health Organization classification.


<!-- PAGE 21 -->

### Page 21

5.1.3. Increasing physical activity and exercise
Regular moderate to vigorous PA has favourable effects on metabolic 
control and CV risk factors in T2DM.97–100 Intervention programmes 
reduce HbA1c by 0.6% in patients with T2DM, with the combination 
of endurance and resistance exercise having the most beneficial ef­
fects.101 Moreover, compared with low total PA, high total PA is asso­
ciated with a lower CV mortality risk, as well as a reduction in all-cause 
mortality (all-cause mortality: HR 0.60 [95% CI, 0.49–0.73], comparing 
high vs. low total PA).97
Structured exercise intervention is also recommended in patients with 
T2DM with established CVD (e.g. CAD, AF, HFpEF; heart failure with 
mildly reduced ejection fraction [HFmrEF]; HFrEF).102–104 Interval endur­
ance exercise training of more vigorous intensity (e.g. interval walking, al­
ternating between moderate to vigorous intensities) has superior effects 
compared with moderate-intensity continuous walking regarding body 
weight, waist circumference, and glucose control.105 Before starting a 
structured exercise programme in patients with T2DM and established 
CVD, performing a maximal exercise stress test to assess CV pathologies 
should be considered. Moreover, assessment of aerobic and anaerobic 
thresholds by spiroergometry is particularly useful to provide an indivi­
dualized endurance exercise prescription including exercise inten­
sity.106–108 Optimal intensity is determined based on an individual’s 
maximum (peak) effort during spiroergometry, e.g. percentage of cardio­
respiratory fitness (% peak oxygen consumption), percentage of 
maximum (peak) heart rate (% HRmax), or perceived exertion rate ac­
cording to the Borg scale.107–109 Exercise prescription is recommended 
to be adapted to T2DM-associated comorbidities, e.g. CAD, HF, AF, dia­
betic peripheral neuropathy, or retinopathy, as well as age and 
frailty.104,107,108 Resistance exercise is recommended to be performed 
at least twice weekly (intensity of 60–80% of the individual’s 
one-repetition maximum). For older or deconditioned adults, less vol­
ume and lower intensities are recommended, particularly during the ini­
tiation phase of 3–6 weeks.106
Interventions are based on encouraging an increase in any PA, as 
even small amounts were shown to have beneficial effects; even an ex­
tra 1000 steps of walking per day is advantageous and may be a good 
starting point for many patients.98,100 Moreover, a gradual increase in 
activity level is recommended. Structured exercise should be addition­
ally introduced at the start or after first achievements to increase activ­
ity. Patients should perform ≥2 sessions per week of endurance 
exercise and/or resistance exercise training. PA accumulated in bouts 
of even <10 min is associated with favourable outcomes, including re­
duced mortality.110,111
Interventions shown to increase PA level or reduce sedentary behav­
iour include behaviour theory-based interventions, such as goal-setting, 
re-evaluation of goals, self-monitoring, and feedback.112,113 Using a 
wearable activity tracker (e.g. smartphones) may help increase PA.114
Most important is to encourage PA that people enjoy and/or can 
include in their daily routines, as such activities are more likely to be 
feasible and sustainable.
5.1.4. Smoking cessation
Smoking cessation is a key lifestyle intervention in patients with T2DM 
with or without CVD with evidence suggesting a 36% reduction in mor­
tality in CVD patients.118–120 If advice, encouragement, and motivation 
are insufficient, then drug therapies should be considered early, includ­
ing nicotine replacement therapy (chewing gum, transdermal nicotine 
patches, nasal spray, inhaler, sublingual tablets) followed by bupro­
pion.121 In patients with ASCVD, varenicline, bupropion, telephone 
therapy, and individual counselling all increase success rates.122
Electronic cigarettes (e-cigarettes) have been addressed as a potential 
smoking cessation aid to bridge transition from smoking to abstention, 
but—if used at all—should be limited for a short period of time. A con­
sensus regarding the efficacy and safety for this approach has yet to be 
reached.123,124 Overall, smoking cessation programmes have low effi­
cacy at 12 months; nonetheless, cessation measures should be repeti­
tively addressed for smoking abstention to succeed.125
Recommendation Table 5 — Recommendations for 
physical activity/exercise in patients with type 2 diabetes 
with or without cardiovascular disease
Recommendation
Classa
Levelb
It is recommended to increase any physical activity 
(e.g. 10 min daily walking) in all patients with T2DM 
with and without CVD. Optimal is a weekly activity 
of 150 min of moderate intensity or 75 min of 
vigorous endurance intensity.97,98
I
A
It is recommended to adapt exercise interventions to 
T2DM-associated comorbidities, e.g. frailty, 
neuropathy, or retinopathy.108,115
I
B
It is recommended to introduce structured exercise 
training in patients with T2DM and established CVD, 
e.g. CAD, HFpEF, HFmrEF, HFrEF, or AF to improve 
metabolic control, exercise capacity and quality of 
life, and to reduce CV events. 108,115,116
I
B
It is recommended to perform resistance exercise in 
addition to endurance exercise at least twice a 
week.115,117
I
B
The use of behavioural theory-based interventions, 
such as goal-setting, re-evaluation of goals, 
self-monitoring, and feedback, should be considered 
to promote physical activity behaviour.112,113
IIa
B
It should be considered to perform a maximally 
tolerated exercise stress test in patients with T2DM 
and established CVD before starting a structured 
exercise programme.
IIa
C
It may be considered to use wearable activity 
trackers to increase physical activity behaviour.114
IIb
B
© ESC 2023
AF, atrial fibrillation; CAD, coronary artery disease; CV, cardiovascular; CVD, 
cardiovascular disease; HFpEF, heart failure with preserved ejection fraction; HFmrEF, 
heart failure with mildly reduced ejection fraction; HFrEF, heart failure with reduced 
ejection fraction; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 4 — Recommendations for 
nutrition in patients with type 2 diabetes with or without 
cardiovascular disease
Recommendations
Classa
Levelb
It is recommended to adopt a Mediterranean or 
plant-based diet with high unsaturated fat content to 
lower cardiovascular risk.82,85
I
A
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4063


<!-- PAGE 22 -->

### Page 22

The assessment of lifestyle risk-factor components and stepwise life­
style recommendations in patients with CVD and diabetes is summar­
ized in more detail in Section 5.7.
5.2. Glycaemic targets
5.2.1. Role of glycated haemoglobin
Reducing HbA1c decreases microvascular complications, particularly 
when achieving near-normal levels (HbA1c <7%, <53 mmol/mol), 
but the effects on macrovascular disease are more complex.126–129
The DCCT (Diabetes Control and Complications Trial) in T1DM 
and the UKPDS (United Kindom Prospective Diabetes Study) in new­
ly diagnosed T2DM have shown that reducing HbA1c decreases long- 
term macrovascular events without having a significant effect in the 
medium term of 6.5–10.0 years.130–132 Other studies, such as 
ADVANCE (Action in Diabetes and Vascular Disease: Preterax and 
Diamicron MR Controlled Evaluation), ACCORD (Action to 
Control Cardiovascular Risk in Diabetes), and VADT (Veterans 
Affairs Diabetes Trial), including higher-risk T2DM cohorts, have simi­
larly failed to show an effect for intensive glycaemic control on short/ 
medium-term macrovascular risk (over 3.5–5.6 years). Meta-analyses 
of the UKPDS, ADVANCE, ACCORD, and VADT studies, including 
27 049 participants, have demonstrated that lowering HbA1c reduces 
MACE, driven by a reduction in MI (HF and stroke risk were unaffect­
ed), and decreases microvascular complications (renal and retinal but 
not neuropathy).133,134
Of interest, the ACCORD trial, with 35% of participants having a 
previous CV event, showed increased mortality (HR 1.22; 95% CI, 
1.01–1.46; P = 0.04) in the intensive glycaemic arm (HbA1c 6.5%, 
48 mmol/mol) compared with controls.129 Also, observational studies 
have shown a U-shaped relationship between HbA1c and clinical out­
come, suggesting that lower HbA1c is not always better.135,136
5.2.2. Additional glycaemic targets
Hypoglycaemia is associated with an increased risk of vascular events, 
explaining recent consensus advocating hypoglycaemic exposure at 
<1% (i.e. <15 min/day) in individuals at high CV risk.137,138 A causal re­
lationship between hypoglycaemia and adverse outcomes is not always 
clear as low glucose levels can be a marker of ill health.139,140
In addition to hypoglycaemia, glycaemic variability is emerging as a 
potential vascular risk factor, but studies are limited and more research 
in this area is warranted.
Post-prandial glucose has been suggested to independently 
predict vascular disease, even in individuals without a previous history 
of diabetes.141 However, manipulating prandial glucose levels failed to 
impact clinical outcome, and therefore, this remains an unresolved 
area.142,143
5.2.3. Glycaemic control following vascular events
Hyperglycaemia following ACS is associated with worse clinical out­
come.144 The DIGAMI 1 (Diabetes Mellitus Insulin-Glucose Infusion 
in Acute Myocardial Infarction) trial demonstrated reduced mortal­
ity with intensive glucose control post-ACS, but DIGAMI 2, which 
was underpowered, failed to confirm these findings.145,146
Unexpectedly, DIGAMI 2 showed a numerical increase in mortality 
in the intervention arm, particularly in insulin-treated patients, sug­
gesting an adverse role for hypoglycaemia in this population.147
Therefore, large-scale glycaemic studies are required, using continu­
ous glucose monitoring (CGM) to assess glucose levels, to establish 
whether optimizing glycaemia in patients with CVD and diabetes 
improves clinical outcome.
In summary, glucose control in individuals with diabetes at high CV 
risk is a complex area and current evidence indicates the need to ad­
dress multiple glycaemic measures, including personalizing HbA1c tar­
gets, minimizing hypoglycaemic exposure, and limiting glucose 
variability. Figure 4 provides a simple guide to glycaemic control in pa­
tients with T2DM and CVD.
Recommendation Table 6 — Recommendations for 
smoking cessation in patients with type 2 diabetes with 
or without cardiovascular disease
Recommendations
Classa
Levelb
It is recommended to stop smoking to reduce 
cardiovascular risk.118–120
I
A
Nicotine replacement therapy, varenicline, and 
bupropion, as well as individual or telephone 
counselling, should be considered to improve 
smoking cessation success rate.121
IIa
B
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
Recommendation Table 7 — Recommendations for 
glycaemic targets in patients with diabetes
Recommendations
Classa
Levelb
It is recommended to apply tight glycaemic control 
(HbA1c <7%) to reduce microvascular 
complications.126–128,133
I
A
It is recommended to avoid hypoglycaemia, 
particularly in patients with CVD.134–137,147
I
B
It is recommended to individualize HbA1c targets 
according to comorbidities, diabetes duration, and 
life expectancy.134,137
I
C
Tight glycaemic control should be considered for 
reducing CAD in the long term, preferably using 
agents with proven CV benefit.c,129–132
IIa
B
© ESC 2023
CAD, coronary artery disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like 
peptide-1 receptor agonist; HbA1c, glycated haemoglobin; s.c. subcutaneous; SGLT2, 
sodium–glucose co-transporter-2. 
aClass of recommendation. 
bLevel of evidence. 
cSGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, sotagliflozin) or GLP-1 RAs 
(liraglutide, semaglutide s.c., dulaglutide, efpeglenatide).


<!-- PAGE 23 -->

### Page 23

5.3. Atherosclerotic cardiovascular disease 
risk reduction by glucose-lowering 
medications in diabetes
T2DM is common among patients with ASCVD or at the highest risk of 
CVD. The converse is also true: ASCVD is common in patients with 
T2DM.148 Given these relationships, it is key to consider the presence 
of T2DM when deciding strategies to mitigate CV risk. It is imperative 
that the first step in this process is to screen all patients with CVD for 
T2DM. Many decisions are independent of glucose management, there­
fore, T2DM status can inform clinical decision-making for mitigating CV 
risk, as discussed for several other interventions in the current 
Guidelines.149 Capitalizing on the results of multiple dedicated CVOTs 
of glucose-lowering medications in patients with diabetes and ASCVD 
or at high CV risk, there is now a wealth of data to inform the preferential 
use of selected glucose-lowering medications to reduce CV risk, inde­
pendent of glucose management considerations. Glucose-lowering med­
ications can be prescribed with two parallel, mutually exclusive intentions: 
(i) to improve CV outcomes and safety; and (ii) to control glucose. On this 
basis, in the current Guidelines, we have separated prescribing recom­
mendations into those intended to improve CV outcomes and those in­
tended to control glucose. Underpinning these recommendations are 
results from the key CVOTs delineating the efficacy and safety of glucose- 
lowering therapies for treating T2DM and their effect on CV outcomes.
5.3.1. Glucose-lowering medications with 
cardiovascular efficacy demonstrated in dedicated 
cardiovascular outcomes trials
5.3.1.1. Sodium–glucose co-transporter-2 inhibitors
The results of six CVOTs with SGLT2 inhibitors and one trial of a dual 
SGLT1/2 inhibitor have been published, comprising the EMPA-REG 
OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in 
Type 2 Diabetes Mellitus Patients–Removing Excess Glucose) trial, 
the CANVAS (Canagliflozin Cardiovascular Assessment Study) pro­
gramme (two trials combined for analyses), the DECLARE-TIMI 58 
(Dapagliflozin Effect on Cardiovascular Events−Thrombolysis In 
Myocardial Infarction 58) trial, the CREDENCE (Canagliflozin and 
Renal Events in Diabetes with Established Nephropathy Clinical 
Evaluation) trial, the VERTIS CV (eValuation of ERTugliflozin 
effIcacy and Safety CardioVascular Outcomes) trial, and the 
SCORED (Effect of Sotagliflozin on Cardiovascular and Renal 
Events in Patients with Type 2 Diabetes and Moderate Renal 
Impairment Who Are at Cardiovascular Risk) trial (Supplementary 
data online, Table S7).71,150–154
A meta-analysis of the six SGLT2 inhibitor trials demonstrated a re­
duction in the primary ASCVD-based composite of time to first event 
of CV death, MI, or stroke (MACE). This was most apparent in patients 
with established ASCVD (Figure 5).155 Of note, neither dapagliflozin nor 
Short life expectancy
Longer life expectancy
Relax glycaemic targets
HbA1c <69 mmol/mol (<8.5%)a
Tighten glycaemic targets but AVOID hypoglycaemiab
HbA1c <53 mmol/mol (<7.0%)
Give priority to agents with
Proven CV benefitc
Low hypoglycaemic risk
Figure 4 Simple guide to glycaemic targets in patients with type 2 diabetes and cardiovascular disease. CV, cardiovascular; GLP-1 RA, glucagon-like 
peptide-1 receptor agonist; HbA1c, glycated haemoglobin, s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2. aAdjust target in the presence 
of hyperglycaemic symptoms (polyuria and polydipsia). bHypoglycaemia is usually a concern only in those on a sulphonylurea and/or insulin. cSGLT2 inhibitors 
(empagliflozin, canagliflozin, dapagliflozin, sotagliflozin) or GLP-1 RAs (liraglutide, semaglutide s.c., dulaglutide, efpeglenatide).
ESC Guidelines                                                                                                                                                                                          4065


<!-- PAGE 24 -->

### Page 24

ertugliflozin reduced the risk of MACE, but both reduced risk of HF 
hospitalization, with consistency across the class for HF benefits 
(Section 7). Based on these aggregate results, along with the GLP-1 
RAs (see below), SGLT2 inhibitors are a preferred glucose-lowering 
therapy for patients with T2DM with ASCVD, independent of glucose 
control considerations, and independent of background metformin use.
Results from the meta-analysis demonstrated no statistically signifi­
cant benefit for risk of MACE in the subsets of patients without 
ASCVD but with multiple ASCVD risk factors; yet the point estimate 
remains favourable in this subset, with no significant interaction by 
ASCVD status (P = 0.63; Figure 5). In patients with T2DM without 
ASCVD or severe TOD but with a calculated 10-year CVD risk 
≥10% in the SCORE2-Diabetes algorithm (Section 4.1), treatment 
with SGLT2 inhibitors and/or GLP-1 RAs may be considered to re­
duce CV risk, independent of glucose control considerations. This 
recommendation is a consensus within the Task Force based on the 
assumption that some level of predicted CVD risk appears to be 
equivalent to ‘severe TOD risk’, acknowledging it is a Level C recom­
mendation. Of note, it is in line with recommendations from EASD 
and ADA.1,156,157
5.3.1.2. Glucagon-like peptide-1 receptor agonists
Eight randomized, placebo-controlled CVOTs have examined the CV 
safety and efficacy of GLP-1 RAs in patients with T2DM with or at high 
risk of ASCVD. These trials comprise the ELIXA (Evaluation of 
0.25
0.5
1.0
2.0
0.25
0.5
1.0
2.0
Favours Treatment
Favours Placebo
Favours Treatment
Favours Placebo
Treatment
Rate/1000
patient-years
Placebo
37.4
26.9
22.6
38.7
40.0
43.9
31.5
24.2
48.7
40.3
Rate/1000
patient-years
Hazard ratio
(95% CI)
0.86 (0.74–0.99)
0.86 (0.75–0.97)
0.93 (0.84–1.03)
0.80 (0.67–0.95)
0.99 (0.88–1.12)
0.90 (0.85–0.95)
Pooled estimate
(Q statistic P = 0.27; I2 = 23.4%)
A
Treatment
Rate/1000
patient-years
Placebo
ASCVD
No ASCVD
37.4
34.1
36.8
55.6
40.0
43.9
41.3
41.0
65.0
40.3
Rate/1000
patient-years
Hazard ratio
(95% CI)
0.86 (0.74–0.99)
0.82 (0.72–0.95)
0.90 (0.79–1.02)
0.85 (0.69–1.06)
0.99 (0.88–1.12)
0.89 (0.84–0.95)
Pooled estimate
(Q statistic P = 0.34; I2 = 11.8%)
EMPA-REG OUTCOME
CANVAS Program
DECLARE-TIMI 58
CREDENCE
VERTIS CV
EMPA-REG OUTCOME
CANVAS Program
DECLARE-TIMI 58
CREDENCE
VERTIS CV
CANVAS Program
DECLARE-TIMI 58
CREDENCE
15.8
13.4
22.0
15.5
13.3
32.7
0.98 (0.74–1.30)
1.01 (0.66–1.20)
0.68 (0.49–0.94)
0.94 (0.83–1.07)
Pooled estimate
(Q statistic P = 0.10; I2 = 56.5%)
P interaction = 0.63
B
Figure 5 Meta-analysis of cardiovascular outcomes trial results of sodium–glucose co-transporter-2 inhibitors among patients with type 2 diabetes with or 
at high risk for atherosclerotic cardiovascular disease. (A) Overall major adverse cardiovascular events; (B) Major adverse cardiovascular events by athero­
sclerotic cardiovascular disease status. ASCVD, atherosclerotic cardiovascular disease; CI, confidence interval; Figure adapted from McGuire et al. 2021.This 
is an open access article distributed under the terms of the CC-BY-NC-ND License https://creativecommons.org/licenses/by-nc-nd/4.0/ 155


<!-- PAGE 25 -->

### Page 25

Lixisenatide in Acute Coronary Syndrome) trial, the LEADER (Liraglutide 
Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome 
Results) trial, the SUSTAIN 6 (Trial to Evaluate Cardiovascular and 
Other Long-term Outcomes With Semaglutide in Subjects With Type 
2 Diabetes) trial, the EXSCEL (Exenatide Study of Cardiovascular Event 
Lowering) trial, the HARMONY Outcomes (Effect of Albiglutide, 
When Added to Standard Blood Glucose Lowering Therapies, on 
Major Cardiovascular Events in Subjects With Type 2 Diabetes 
Mellitus) trial, the REWIND (Researching Cardiovascular Events With a 
Weekly Incretin in Diabetes) trial, the PIONEER 6 (Trial Investigating 
the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 
Diabetes) trial, and the AMPLITUDE-O (Effect of Efpeglenatide on 
Cardiovascular 
Outcomes) 
trial 
(Supplementary 
data 
online, 
Table S8).70,72,158–163
Five of the eight GLP-1 RAs tested demonstrated superior CV out­
comes on the primary composite of time to the first event of CV death, 
0.5
1
1.5
Favours GLP-1RA
Favours Placebo
GLP-1 receptor agonist n/N (%)
Placebo n/N (%)
Hazard ratio
(95% CI)
NNT
(95% CI)
0.87 (0.78–0.97)
0.74 (0.58–0.95)
0.91 (0.83–1.00)
0.78 (0.68–0.90)
0.88 (0.79–0.99)
Subtotal (I2 = 14.9%, P = 0.316)
0.79 (0.57–1.11)
0.73 (0.58–0.92)
0.85 (0.80–0.90)
61 (46–92)
P value
0.01
0.016
0.061
0.0006
0.026
0.17
0.0069
<0.0001
Three-point MACE
0.78 (0.66–0.93)
0.98 (0.65–1.48)
0.88 (0.76–1.02)
0.93 (0.73–1.19)
0.91 (0.78–1.06)
Subtotal (I2 = 12.4%, P = 0.335)
0.49 (0.27–0.92)
0.72 (0.50–1.03)
0.85 (0.78–0.93)
142 (97–305)
0.007
0.92
0.096
0.58
0.21
0.021
0.07
0.0005
Cardiovascular death
0.86 (0.73–1.00)
0.81 (0.57–1.16)
0.97 (0.85–1.10)
0.75 (0.61–0.90)
0.96 (0.79–1.15)
Subtotal (I2 = 16.2%, P = 0.306)
1.04 (0.66–1.66)
0.75 (0.54–1.05)
0.88 (0.81–0.96)
154 (97–463)
0.046
0.26
0.62
0.003
0.63
0.49
0.09
0.0048
Fatal or non-fatal myocardial infarction
0.86 (0.71–1.06)
0.65 (0.41–1.03)
0.85 (0.70–1.03)
0.86 (0.66–1.14)
0.76 (0.62–0.94)
Subtotal (I2 = 0.0%, P = 0.903)
Note:  Weights are from random effects analysis
LEADER
SUSTAIN-6
EXSCEL
Harmony Outcomes
REWIND
PIONEER 6
AMPLITUDE-O
LEADER
SUSTAIN-6
EXSCEL
Harmony Outcomes
REWIND
PIONEER 6
AMPLITUDE-O
LEADER
SUSTAIN-6
EXSCEL
Harmony Outcomes
REWIND
PIONEER 6
AMPLITUDE-O
LEADER
SUSTAIN-6
EXSCEL
Harmony Outcomes
REWIND
PIONEER 6
AMPLITUDE-O
0.76 (0.37–1.56)
0.74 (0.47–1.17)
0.81 (0.74–0.90) 171 (124–324)
0.16
0.066
0.095
0.30
0.010
0.43
0.19
<0.0001
Fatal or non-fatal stroke
TRIAL
608/
108/
839/
338/
594/
694/
146/
905/
428/
663/
61/
189/
76/
125/
219/
44/
340/
122/
317/
278/
46/
383/
130/
346/
15/
75/
30/
50/
292/
54/
483/
181/
223/
339/
67/
493/
240/
231/
37/
91/
35/
58/
173/
30/
187/
94/
158/
199/
46/
218/
108/
205/
13/
47/
17/
31/
4668
1648
7356
4731
4949
4672
1649
7396
4732
4952
1591
2717
1592
1359
4668
1648
7356
4731
4949
4672
1649
7396
4732
4952
1591
2717
1592
1359
4668
1648
7356
4731
4949
4672
1649
7396
4732
4952
1591
2717
1592
1359
4668
1648
7356
4731
4949
4672
1649
7396
4732
4952
1591
2717
1592
1359
(13%)
(7%)
(11%)
(7%)
(12%)
(15%)
(9%)
(12%)
(9%)
(13%)
(4%)
(7%)
(5%)
(9%)
(5%)
(3%)
(5%)
(3%)
(6%)
(6%)
(3%)
(5%)
(3%)
(7%)
(1%)
(3%)
(2%)
(4%)
(6%)
(3%)
(7%)
(4%)
(5%)
(7%)
(4%)
(7%)
(5%)
(5%)
(2%)
(3%)
(2%)
(4%)
(4%)
(2%)
(3%)
(2%)
(3%)
(4%)
(3%)
(3%)
(2%)
(4%)
(1%)
(2%)
(1%)
(2%)
Figure 6 Meta-analysis of cardiovascular outcomes trials with glucagon-like peptide-1 receptor agonists (sensitivity analysis removing ELIXA). Risk of major 
adverse cardiovascular events and its components. CI, confidence interval; GLP-1, glucagon-like peptide-1; MACE, major adverse cardiovascular outcomes; 
NNT, number needed to treat. Figure adapted from Sattar et al. 2021.Reprinted from the Lancet with permission from Elsevier.164
ESC Guidelines                                                                                                                                                                                          4067


<!-- PAGE 26 -->

### Page 26

MI, and stroke compared with placebo. A meta-analysis of seven of the 
eight completed GLP-1 RA trials, excluding the ELIXA trial results (due 
to a very short pharmacodynamic half-life [3 h] of once a day [o.d.] lix­
isenatide, and the very high-risk population post-ACS differentiating it 
from all others), showed that a pooled estimate for GLP-1 RA vs. pla­
cebo for the primary outcome was reduced by 15% (HR 0.85; 95% CI, 
0.80–0.90; Figure 6).164 Results from pooled analyses of the effects of 
GLP-1 RA vs. placebo on individual CV outcomes included CV death 
(HR 0.85; 95% CI, 0.78–0.93), MI (HR 0.88; 95% CI, 0.81–0.96), stroke 
(HR 0.81; 95% CI, 0.74–0.90), and hospitalization for HF (HR 0.88; 95% 
CI, 0.79–0.98). Notably, the point estimate in the seven trials was lower 
(HR = 0.85) in those with established ASCVD than in those without 
(HR = 0.94), with Pint = 0.068, suggesting but not conclusively proving 
that GLP-1 RAs may reduce risks more in those with established 
ASCVD. As absolute risks are greater in those with established CV dis­
ease, the absolute benefits are also expected to be greater.
Based on these aggregate results, along with the SGLT2 inhibitors (see 
above) GLP-1 RAs are a preferred glucose-lowering therapy for patients 
with T2DM and ASCVD, independent of glucose control considera­
tions, and independent of background metformin use. In patients with 
T2DM without ASCVD or severe TOD, but with a calculated 10-year 
CVD risk ≥10% in the SCORE2-Diabetes algorithm (Section 4), treat­
ment with GLP-1 RAs and/or SGLT2 inhibitors may be considered to re­
duce CV risk, independent of glucose control considerations. This 
recommendation is a consensus within the Task Force based on the as­
sumption that some level of predicted CVD risk appears to be equivalent 
to ‘severe TOD risk’, acknowledging it is a Level C recommendation. Of 
note, it is in line with recommendations from EASD and ADA.1,156,157
5.3.1.3. Pioglitazone
The PROactive (Prospective Pioglitazone 
Clinical Trial in 
Macrovascular Events) randomized CVOT assessed the CV effects 
of the thiazolidinedione (TZD) pioglitazone vs. placebo, independent 
of glucose control, in patients with T2DM and ASCVD. It failed to 
achieve statistical significance for its primary composite outcome of 
all-cause death, MI, stroke, unstable angina, coronary or peripheral re­
vascularization, and amputation (HR 0.90; 95% CI, 0.80–1.02).165
However, for the principal secondary outcome evaluating the gold- 
standard, three-point composite outcome of CV death, MI, and 
stroke, there was a nominally significant 16% relative risk (RR) reduc­
tion (HR 0.84; 95% CI, 0.72–0.98).165
Results from subsequent meta-analyses and observational studies 
have supported the suggested efficacy of pioglitazone in persons with 
ASCVD.166–169 Notably, the magnitude of the estimated treatment 
benefit with pioglitazone across these studies aligns with contemporary 
meta-analyses estimates of the effects of SGLT2 inhibitors and GLP-1 
RAs on the same composite MACE outcome.155,164
TZDs enhance fluid retention and the risk of peripheral oedema, es­
pecially with concomitant insulin use and in the context of kidney dys­
function. In addition, TZDs increase the risk of HF, with the incremental 
risk of HF with pioglitazone at an estimated 0.4% annualized, absolute 
increase.170 HF associated with TZDs appears to be attributable to ex­
panded plasma volume, with no evidence of myocardial toxicity.171
TZDs induce weight gain due to adipose tissue expansion, but with 
weight redistributed predominantly to less metabolically active adipose 
tissue; weight gain may be the greatest concern of patients and clinicians 
with the TZD class. Based on the data and net benefit-risk assessment, 
it is reasonable to consider using pioglitazone to mitigate ASCVD risk in 
patients with T2DM and prevalent ASCVD.
5.3.2. Glucose-lowering medications with 
cardiovascular safety but not incremental efficacy 
demonstrated in dedicated cardiovascular outcomes 
trials
5.3.2.1. Dipeptidyl peptidase-4 inhibitors
Five randomized CV safety trials in populations with T2DM with or at 
high risk of ASCVD have assessed the CV effects of dipeptidyl 
peptidase-4 (DPP-4) inhibitors (Supplementary data online, Table S9): 
saxagliptin, alogliptin, sitagliptin, and linagliptin each vs. placebo, and li­
nagliptin vs. glimepiride.172–175 All four of the placebo-controlled trials 
demonstrated statistical non-inferiority but not superiority for the 
DPP-4 inhibitors in the primary MACE endpoint. In the SAVOR-TIMI 
53 (Saxagliptin Assessment of Vascular Outcomes Recorded in 
Patients with Diabetes Mellitus—Thrombolysis in Myocardial 
Infarction 53) trial, saxagliptin statistically significantly increased the 
risk of hospitalization for HF vs. placebo.176 Numerically, more HF 
events occurred with alogliptin vs. placebo in the EXAMINE 
(Cardiovascular Outcomes Study of Alogliptin in Patients With Type 
2 Diabetes and Acute Coronary Syndrome) trial, though this difference 
was not nominally significant.177
These observations led to the development and regulatory filing of 
prospective HF analysis plans for the TECOS (Trial Evaluating 
Cardiovascular Outcomes with Sitagliptin) and CARMELINA 
(Cardiovascular and Renal Microvascular Outcome Study With 
Linagliptin in Patients With Type 2 Diabetes Mellitus) trials, each of 
which revealed no increased risk of HF with either sitagliptin or linaglip­
tin compared with placebo.178,179 In the CAROLINA (Cardiovascular 
Outcome Study of Linagliptin Versus Glimepiride in Patients With 
Type 2 Diabetes) trial, linagliptin was compared with the active com­
parator glimepiride, demonstrating no difference in any assessed CV 
or kidney outcome, though noting a higher risk of hypoglycaemia 
with glimepiride.180
5.3.2.2. Lixisenatide and exenatide
Of the eight GLP-1 RAs evaluated in CVOTs, two have demonstrated 
safety but not incremental efficacy. In the ELIXA trial, lixisenatide 10 or 
20 μg o.d. was non-inferior to placebo, but did not significantly affect a 
four-point MACE (three-point MACE plus hospitalization for unstable 
angina) in patients with T2DM post-ACS.158 In the EXSCEL trial of pa­
tients with T2DM in whom 73% had experienced a previous CV event, 
exenatide extended-release 2 mg once weekly showed non-inferiority 
but not superiority to placebo for the primary outcome of CV death, 
MI, and stroke.159
5.3.2.3. Insulin
Two basal insulins have been formally evaluated in dedicated CVOTs. In 
the ORIGIN (Outcome Reduction With Initial Glargine Intervention) 
trial, 12 537 patients (mean age 63.5 years) at high CVD risk with im­
paired fasting glucose (IFG), impaired glucose tolerance (IGT), or 
T2DM were randomized to insulin glargine titrated to a fasting blood 
glucose level of ≤5.3 mmol/L (≤95 mg/dL) or standard care.86 After a 
median follow-up of 6.2 years, the incidence of CV outcomes did not 
differ between the two groups.


<!-- PAGE 27 -->

### Page 27

The DEVOTE (A Trial Comparing Cardiovascular Safety of Insulin 
Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes 
at High Risk of Cardiovascular Events) trial, a randomized, double-blind 
comparison of the ultra-long-acting, o.d. insulin degludec vs. insulin glar­
gine U100, enrolled 7637 patients with T2DM with ASCVD or at high 
CV risk.181 Over a median follow-up of 1.8 years, there was no signifi­
cant difference in the primary composite of CV death, non-fatal MI, or 
non-fatal stroke between groups. A significantly lower frequency of 
hypoglycaemia was observed in the degludec arm compared with the 
glargine arm.181
5.3.2.4. Glimepiride
Based on the findings of statistical non-inferiority of linagliptin vs. pla­
cebo in CARMELINA coupled with the non-inferiority of linagliptin 
vs. glimepiride demonstrated in CAROLINA, one might conclude 
that glimepiride is most likely not different from placebo with regards 
to CV safety.180 Thus, the long-lasting uncertainty about the CV safety 
of sulphonylureas may no longer be clinically relevant for glimeperide, at 
least in patients with a shorter duration of diabetes like those enrolled 
in the CAROLINA trial (median duration of T2DM ∼6 years).182
5.3.3. Cardiovascular considerations of older 
glucose-lowering medications not tested in dedicated 
cardiovascular outcomes trials
5.3.3.1. Metformin
Despite its long history as the recommended first-line treatment of 
hyperglycaemia for patients with T2DM, there have been no dedicated 
randomized trials to rigorously assess the CV safety or efficacy of met­
formin. Randomized trials that have reported CV outcomes with met­
formin are most-commonly limited by small sample sizes and few CV 
events for analysis, yielding low statistical power and substantially un­
certain statistical precision of the estimates.
The largest randomized trial with the most encouraging CV results 
for metformin was a nested randomized trial of 753 patients in the 
UKPDS who were overweight or obese at trial entry, comparing con­
ventional glucose targets with a policy of intensive glucose lowering 
with metformin.183 In overweight and obese patients with newly diag­
nosed T2DM without previous CVD, metformin reduced MI by 39%, 
coronary death by 50%, and stroke by 41% over a median period of 
10.7 years. However, with only 39 MIs and 16 coronary deaths in the 
metformin arm of the UKPDS, the precision of these efficacy estimates 
is largely uncertain. Initial randomization to metformin in the UKPDS 
was also associated with a lower incidence of MI and longer survival 
during an additional 8–10 years of passive follow-up.132
In meta-analyses of 13 randomized clinical trials evaluating the CV ef­
fects of metformin vs. placebo or active control, including the data from 
the UKPDS, none of the differences in assessed CV outcomes was stat­
istically significant.184 The pooled HRs (95% CIs) were: all-cause mortal­
ity 0.96 (0.84–1.09); CV death 0.97 (0.80–1.16); MI 0.89 (0.75–1.06); 
stroke 1.04 (0.73–1.48); and peripheral vascular disease 0.81 (0.50– 
1.31). While failing to demonstrate CV efficacy, the upper confidence 
limits of each of the outcomes analysed provide reassurance on the 
CV safety of metformin.
Given the inconclusive results regarding the CV effects of metformin 
outlined above, metformin should not be a prerequisite for considering 
SGLT2 inhibitor or GLP-1 RA treatment for CV benefits. However, most 
patients in CVOTs with SGLT2 inhibitors or GLP-1 RAs were treated 
with metformin. Therefore, in patients already prescribed metformin, 
SGLT2 inhibitors and/or GLP-1 RAs should be added, independent of 
the need for additional glucose control. In patients with T2DM and 
ASCVD not treated with metformin, an SGLT2 inhibitor and/or GLP-1 
RA should be given first line, and metformin should be considered for 
those who thereafter warrant additional glucose control. This Class IIa 
recommendation for metformin is based on the weight of opinion rather 
than the weight of evidence; results from meta-analyses of observational 
studies suggest associations with better CV outcome, but this is not sup­
ported by results from meta-analyses restricted to randomized trials in 
patients with T2DM and ASCVD, where no statistically significant effect 
of metformin has been observed for any major CV outcome.184,185
In patients without ASCVD or severe TOD at low or moderate CV 
risk, treatment with metformin should be considered based on the 
metformin data from the randomized sub-group with overweight or 
obesity from the UKPDS.183 For patients without ASCVD or severe 
TOD at high or very CV high risk, treatment with metformin may be 
considered based on expert consensus of the Task Force.
5.3.3.2. Sulphonylureas
Excepting glimepiride, which was assessed for CV safety and efficacy 
head-to-head against linagliptin in the CAROLINA trial, and gliclazide- 
modified release, which was compared with usual care (that could 
have included treatment with a sulphonylurea other than gliclazide) in 
the ADVANCE trial, dedicated CV safety assessments have not been 
conducted for the other sulphonylureas.132,173,174,184 In the UKPDS, 
which enrolled patients with newly diagnosed T2DM, the sulphonylur­
eas chlorpropamide and glibenclamide (also known as glyburide) did 
not have statistically significant effects on CV outcomes, but important­
ly, no concerning signal of CV risk was observed.127 Likewise, in the 
ADVANCE trial evaluating more intensive glucose control vs. usual tar­
gets, patients randomized to the more intensive arm were randomized 
to treatment with gliclazide-modified release.128 While the gliclazide- 
based more intensive control strategy did not significantly improve 
CV outcomes, there were no major CV safety concerns observed. 
The relative CV safety of gliclazide and glimepiride is somewhat sup­
ported by results of contemporary real-world data analyses.186
5.3.4. Special considerations
5.3.4.1. Hypoglycaemia and cardiovascular risk
Results from numerous studies have demonstrated associations between 
hypoglycaemia and CV events, with substantial uncertainty about whether 
these relationships are causal or simply associations. Results from rando­
mized trials challenge a causal relationship between hypoglycaemia and ad­
verse CV outcomes. For example, insulin degludec compared with 
glargine in the DEVOTE trial reduced the risk of hypoglycaemia, yet this 
did not translate into any difference in CV risk.181 Likewise, in the 
CAROLINA randomized trial, while glimepiride was associated with sig­
nificantly more hypoglycaemia than the DPP-4 inhibitor linagliptin, 
MACE did not differ between the two randomized groups.180 The results 
of these two trials challenge, to some degree, the premise that avoiding 
hypoglycaemia may improve CV risk. In analyses of data from the 
TECOS randomized trial, which compared sitagliptin with placebo, hypo­
glycaemia events were independently associated with subsequent CV 
events, but importantly, the converse was also true.139 A non-fatal CV 
event was independently associated with subsequent hypoglycaemia. 
Similar results were confirmed in other trials.140,187,188
ESC Guidelines                                                                                                                                                                                          4069


<!-- PAGE 28 -->

### Page 28

Therefore, the data suggest that the relationship between hypogly­
caemia events and risk of CV events (and vice versa) is most likely 
one of association rather than causation, each risk marking vulnerability 
and frailty of high CV risk patients. Still, in certain patients, hypogly­
caemia may directly contribute to CV risk. In addition, avoiding hypogly­
caemia remains important given the unpleasant patient experience and, 
for severe events, life-threatening nature if third-party assistance is not 
available.
5.3.4.2. Effects on weight
The choice of glucose-lowering therapy is often influenced by effects on 
weight, when weight loss or avoiding weight gain is a priority. The insu­
lins, sulphonylureas, and pioglitazone all cause weight gain; metformin, 
acarbose, and the DPP-4 inhibitors are weight neutral or may result 
in small amounts of weight loss; and the SGLT2 inhibitors and GLP-1 
RAs are associated with clinically meaningful weight loss, with weight 
effects of GLP-1 RAs being more pronounced than that of SGLT2 
inhibitors.
5.3.5. Implications of results from cardiovascular 
outcomes trials of glucose-lowering medications
Beginning with the EMPA-REG OUTCOME trial results in 2015, an ever- 
increasing body of evidence has accumulated from many CVOTs of 
glucose-lowering medications for patients with T2DM that indicate CV 
benefits from using selected SGLT2 inhibitors and GLP-1 RAs in patients 
with ASCVD. The combined results obtained from CVOTs using GLP-1 
RAs and SGLT2 inhibitors support the primacy of their recommendation 
for all patients with T2DM with prevalent ASCVD, with such considera­
tions made independently of decisions about glycaemic management 
(Figures 7 and 8). Just as T2DM informs prescription of statins, antithrom­
botic therapy, angiotensin-converting enzyme inhibitors (ACE-Is)/ 
angiotensin-II receptor blockers (ARBs), and other CV risk-mitigating 
therapies independent of glycaemic considerations, the same should 
now apply to prescribing SGLT2 inhibitors and/or GLP-1 RAs.
The mechanisms of CV benefits of the novel glucose-lowering 
medications with proven efficacy remain incompletely understood. 
For the GLP-1 RAs, CV efficacy is driven by reduced risk of 
Risk assessment for patients with type 2 diabetes based on the presence of
ASCVD/severe TOD and 10-year CVD risk estimation via SCORE2-Diabetes
Me tfo rm in
SG
LT
2 i nhi bit or
GL
P1 R
A
(C
la ss
 I)
Me tf or mi n
(C
la ss
 II
a 
)
No
 A
SC
V
D 
or
 s ev er e 
T
O
D
SC
O
RE
2Di ab et es
 <
1
0
%
No
 A
SC
V
D 
or
 s ev er e T
O
D
SC
O
RE
2Di ab et es
 
10
%
Lo w 
ris k
M
od er at e 
ris k
Hi gh
 ri sk
Ve ry
 h ig h 
ris k
A
S
C
V
D
(C
las s II
b) 
SG
LT
2 
in hi bi to rb
  
G
LP
-1
 R
Aa
Figure 7 Glucose-lowering treatment for patients with type 2 diabetes to reduce cardiovascular risk based on the presence of atherosclerotic cardiovas­
cular disease/severe target-organ damage and 10-year cardiovascular disease risk estimation via SCORE2-Diabetes. ASCVD, atherosclerotic cardiovascular 
disease; CVD, cardiovascular disease; GLP-1 RA, glucagon-like peptide-1 receptor agonist; s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2; 
T2DM, type 2 diabetes mellitus; TOD, target-organ damage. Risk categorization is based on the presence of ASCVD/severe TOD and 10-year CVD risk 
estimation via SCORE2-Diabetes. For patients with ASCVD, only the Class I recommendation is shown. Treatment recommendations for patients with 
T2DM and severe TOD are described in Section 9. Severe TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 45–59 mL/ 
min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease 
in at least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus neuropathy]. aGLP-1 RAs with proven CV benefit: liraglutide, semaglu­
tide s.c., dulaglutide, efpeglenatide. bSGLT2 inhibitors with proven CV benefit: empagliflozin, canagliflozin, dapagliflozin, sotagliflozin.


<!-- PAGE 29 -->

### Page 29

To reduce CV risk independent of glucose controla
GLP-1 RAb
(Class I)
SGLT2 inhibitorc
(Class I)
Independent of HbA1c
Independent of concomitant glucose-lowering medication
For additional glucose control
Metformin
(Class IIa)
Pioglitazoned
(Class IIb)
Glucose-lowering agents with suggested CV benefit
Glucose-lowering agents with proven CV safety
DPP-4 inhibitors (sitagliptin, alogliptin, linagliptin)e
Other GLP-1 RAs (lixisenatide, exenatide ER, oral semaglutide)
Ertugliflozinf
Glucose-lowering agents without CV safety evaluation
E.g. short-acting insulins
E.g. other sulfonylureas
Sulfonylureas (glimepiride or gliclazide)
Insulin glargine or insulin degludec
Figure 8 Glucose-lowering treatment for patients with type 2 diabetes and atherosclerotic cardiovascular disease to reduce cardiovascular risk. ASCVD, 
atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration 
rate; ER, extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; MACE, major adverse cardiovascular events; 
s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. aIn patients with ASCVD and T2DM, it is recommended to 
treat with a GLP-1 RA and an SGLT2 inhibitor with proven benefit to reduce CV risk, independent of HbA1c and concomitant glucose-lowering medications. 
If additional glucose control is needed, treatment with metformin should be considered and treatment with pioglitazone may be considered. bGLP-1 RAs with 
proven CV benefit: liraglutide, semaglutide s.c., dulaglutide, efpeglenatide. cSGLT2 inhibitors with proven CV benefit: empagliflozin, canagliflozin, dapagliflozin, 
sotagliflozin. dPioglitazone should not be used in patients with heart failure; the use in CKD requires caution as intravascular volume expansion and heart 
failure are common at reduced eGFR. eDPP-4 inhibitors should not be used in patients on GLP-1 RAs. fErtugliflozin in the VERTIS CV trial showed safety 
with respect to three-point MACE but no benefit.
ESC Guidelines                                                                                                                                                                                          4071


<!-- PAGE 30 -->

### Page 30

ASCVD-related events.164 While empagliflozin and canagliflozin im­
proved the composite of CV death, MI, and stroke, all of the 
SGLT2 inhibitors reduce HF-related endpoints (Section 7) and pro­
gression of kidney disease (Section 9).155,190 Thus, SGLT2 inhibitors 
are recommended to reduce HF hospitalization in patients with 
T2DM with or at risk of HF, or who have CKD. In patients with newly 
diagnosed T2DM without CVD or other major CV risk factors who 
are at low or moderate CV risk, factors other than mitigating CV and 
kidney risk may play a greater role in selecting glucose-lowering med­
ications, such as affordability, accessibility, side effects, weight bene­
fits, tolerability, and ease of use.
5.4. Blood pressure and diabetes
In the most recent ESC/EURObservational Research Programme 
(EORP) EUROASPIRE surveys, history of hypertension was present 
in 80% of men and 87% of women with known diabetes and in 74% 
of men and 81% of women with newly diagnosed diabetes with a his­
tory of coronary heart disease (CHD).191
5.4.1. Screening and diagnosis
Regular BP measurements under standardized conditions are manda­
tory in all patients with diabetes (Figure 9; Table 8). Hypertension 
should be confirmed in both arms using multiple readings, including 
measurements on separate days.48,157 In patients with CVD and values 
>180/110 mmHg, it could be reasonable to diagnose hypertension at a 
single visit.192 Details on BP measurements are comprehensively sum­
marized in the 2018 ESC/European Society of Hypertension (ESH) 
Guidelines for the management of arterial hypertension and in the 
Supplementary data online, Section 2.6.1.193
5.4.2. Treatment targets
Randomized controlled trials have shown the benefit (reduction of 
stroke, coronary events, and kidney disease) of lowering SBP to 
Recommendation Table 8 — Recommendations for 
glucose-lowering treatment for patients with type 2 
diabetes and atherosclerotic cardiovascular disease to 
reduce cardiovascular risk
Recommendations
Classa
Levelb
It is recommended to prioritize the use of 
glucose-lowering agents with proven CV benefitsc,d 
followed by agents with proven CV safetye over agents 
without proven CV benefit or proven CV safety.
I
C
Sodium–glucose co-transporter-2 inhibitors
SGLT2 inhibitors with proven CV benefitc are 
recommended in patients with T2DM and ASCVD 
to reduce CV events, independent of baseline or 
target HbA1c and independent of concomitant 
glucose-lowering medication.71,150–152,155,189
I
A
Glucagon-like peptide-1 receptor agonists
GLP-1 RAs with proven CV benefitd are 
recommended in patients with T2DM and ASCVD 
to reduce CV events, independent of baseline or 
target HbA1c and independent of concomitant 
glucose-lowering medication.70,72,161,163,164
I
A
Other glucose-lowering medications to reduce cardiovascular 
risk
If additional glucose control is needed, metformin 
should be considered in patients with T2DM and 
ASCVD.
IIa
C
If additional glucose control is needed, pioglitazone 
may be considered in patients with T2DM and 
ASCVD without HF.165
IIb
B
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular 
disease; DPP-4, dipeptidyl peptidase-4; GLP-1 RA, glucagon-like peptide-1 receptor 
agonist; HbA1c, glycated haemoglobin; HF, heart failure; s.c., subcutaneous; SGLT2, 
sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cEmpagliflozin, canagliflozin, dapagliflozin, sotagliflozin. 
dLiraglutide, semaglutide s.c., dulaglutide, efpeglenatide. 
eMetformin, pioglitazone, DPP-4 inhibitor (sitagliptin, alogliptin, linagliptin), glimepiride, 
gliclazide, insulin glargine, insulin degludec, ertugliflozin, lixisenatide, exenatide (extended 
release), oral semaglutide.
Recommendation Table 9 — Recommendation for 
glucose-lowering treatment for patients with type 2 dia­
betes without atherosclerotic cardiovascular disease or 
severe target-organ damage to reduce cardiovascular 
risk
Recommendations
Classa
Levelb
In patients with T2DM without ASCVD or severe 
TODc at low or moderate risk, treatment with 
metformin should be considered to reduce CV risk.183
IIa
C
Continued
In patients with T2DM without ASCVD or severe 
TODc at high or very high risk, treatment with 
metformin may be considered to reduce CV risk.
IIb
C
In patients with T2DM without ASCVD or severe 
TODc but with a calculated 10-year CVD riskd 
≥10%, treatment with a SGLT2 inhibitor or GLP-1 
RA may be considered to reduce CV risk.155,164
IIb
C
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; CVD, cardiovascular 
disease; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 
receptor agonist; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes 
mellitus; TOD, target-organ damage; UACR, urinary albumin-to-creatinine ratio. 
aClass of recommendation. 
bLevel of evidence. 
cSevere TOD defined as eGFR <45 mL/min/1.73 m2 irrespective of albuminuria; or eGFR 
45–59 mL/min/1.73 m2 and microalbuminuria (UACR 30–300 mg/g; stage A2); or 
proteinuria (UACR >300 mg/g; stage A3); or presence of microvascular disease in at 
least three different sites [e.g. microalbuminuria (stage A2) plus retinopathy plus 
neuropathy]. 
dUsing SCORE2-Diabetes.


<!-- PAGE 31 -->

### Page 31

<140 mmHg and diastolic blood pressure (DBP) to <90 mmHg in pa­
tients with diabetes. However, the optimal BP target in patients with 
diabetes is still a matter of debate. The UKPDS post-trial, 10-year 
follow-up study reported no benefits persisting from the earlier period 
of tight BP control with respect to macrovascular events, death, and 
microvascular complications, while initial between-group BP differ­
ences were no longer maintained.132 RCTs evaluating the benefits 
and risks of more intense compared with standard hypertension treat­
ment strategies in patients with diabetes are summarized in 
Supplementary data online, Table S10.
In a meta-analysis of RCTs involving patients with diabetes or pre- 
diabetes, an SBP reduction to ≤135 mmHg compared with a less intensive 
control reduced the RR of all-cause mortality by 10% (odds ratio [OR] 0.90; 
95% CI, 0.83–0.98), whereas more intensive BP control (≤130 mmHg) was 
associated with a greater reduction in stroke but did not reduce other 
events.194,195 Similarly, anti-hypertensive treatment significantly reduced 
mortality in people with T2DM, CAD, HF, and stroke, with an achieved 
mean SBP of 138 mmHg, whereas only stroke was reduced significantly, 
with a mean SBP of 122 mmHg compared with higher BP values.196
Thus, reducing SBP to <130 mmHg may benefit patients with a particularly 
high risk of a cerebrovascular event, such as those with a history of 
stroke.193,194,196–200 However, SBP >140 mmHg or <120 mmHg were re­
lated to higher risk of adverse renal outcomes in patients with diabetes 
when compared with those without diabetes and with high CV risk.199–202
The 2018 ESC/ESH Guidelines for the management of arterial hyper­
tension recommend that in all patients with diabetes, office BP should 
be targeted to an SBP of 130 mmHg, and lower if tolerated but not 
<120 mmHg; DBP should be lowered to <80 mmHg but not 
<70 mmHg.193 In older patients (age ≥65 years), the SBP target range 
should be 130–140 mmHg if tolerated.193 However, more recent data 
challenge these recommendations for all patients with diabetes, and 
highlight a potential need for more individualized target levels.157,203,204
The 2021 ESC Prevention Guideline recommends office SBP treat­
ment target ranges of 120–130 mmHg in patients with diabetes, with 
lower SBP acceptable if tolerated until the age of 69 years.48 In patients 
aged ≥70 years, SBP values <140 mmHg, down to 130 mmHg if toler­
ated are recommended. DBP treatment target <80 mmHg is recom­
mended for all treated patients.
5.4.3. Management of hypertension
5.4.3.1. Effects of lifestyle intervention and weight loss
Diets rich in vegetables, fruits, and low-fat dairy products, such as the 
Mediterranean diets and Dietary Approaches to Stop Hypertension-style 
eating patterns (including reducing sodium to <100 mmol/day and increas­
ing potassium intake), improve BP control.205–207
Patient with increased BP
High normal BP
SBP 130–139 mmHg and/or DBP 85–89 mmHg
Hypertension
BP ≥140/90 mmHg
Out of office BP
measurement
(ABPM or HBPM)
Repeated visits for office BP measurements
Consider masked hypertension
To confirm diagnosis
Out of office BP
measurement
(ABPM or HBPM)
OR
Figure 9 Screening and diagnosis of hypertension in patients with diabetes. ABPM, ambulatory blood pressure monitoring; BP, blood pressure; DBP, dia­
stolic blood pressure; HBPM, home blood pressure monitoring; SBP, systolic blood pressure. Figure adapted from Williams et al. 2018.193
Table 8 Blood pressure measurement
BP measurements at the initial and every follow-up visit (at every routine 
clinical visit).
Patients should be seated comfortably in a quiet environment for 5 min 
before beginning BP measurements. 
Three BP measurements should be recorded, 1–2 min apart, and 
additional measurements if the first two readings differ by >10 mmHg. 
BP is recorded as the average of the last two BP readings.
Measure BP 1 min and 3 min after standing from a seated position in all 
patients on initial visit to exclude orthostatic hypotension; lying and 
standing BP measurements should also be considered in subsequent 
visits.
Out-of-office BP measurement with ambulatory and/or home BP 
monitoring should be implemented when feasible. 
Masked hypertension should be considered in patients with normal and 
high-normal office BP but with HMOD or at high cardiovascular risk.193
© ESC 2023
BP, blood pressure; HMOD, hypertension-mediated organ damage.
ESC Guidelines                                                                                                                                                                                          4073


<!-- PAGE 32 -->

### Page 32

Long-term exercise training intervention modestly but significantly 
reduces SBP (by −7 mmHg) and DBP (by −5 mmHg). Ideally, an exer­
cise prescription aimed at lowering BP in individuals with normal BP 
or hypertension would include a mix of predominantly aerobic exercise 
training supplemented with dynamic resistance exercise training.208
A marked improvement in CV risk factors (hypertension, dyslipidae­
mia, diabetes), associated with marked weight loss, was observed after 
bariatric surgery.209 In the Look AHEAD trial, those who lost 5 to 
<10% of body weight had increased odds of achieving a 5 mmHg de­
crease in SBP and DBP compared with those who lost >10% or 
<5%.210 The frequency of CV complications appears to be modulated 
by ethnicity or racial identity.193,211,212
5.4.3.2. Pharmacological treatments in patients with diabetes
If office SBP is ≥140 mmHg and/or DBP is ≥90 mmHg, drug therapy is 
necessary in combination with non-pharmacological treatment. It is re­
commended to start with a combination therapy.48 All available 
BP-lowering drugs can be used, but evidence strongly supports using a 
renin–angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in 
patients with evidence of end-organ damage (albuminuria and left ven­
tricular [LV] hypertrophy).213–216 However, in a recent meta-analysis, 
RAS inhibitors were not superior to other classes of anti-hypertensive 
drugs for reducing total or CV mortality and renal events.217
Controlling BP often requires multiple drug therapy with an RAS inhibi­
tor and a calcium channel blocker (CCB) or diuretic, while the combination 
of an ACE-I with an ARB is not recommended.218 Consider beta-blockers 
at any treatment step when specifically indicated, e.g. HF, angina, post-MI, 
AF, or younger women with or planning pregnancy.193 A combination of 
two or more drugs at fixed doses in a single pill should be considered to 
improve adherence and to achieve earlier control of BP.48,219
In apparent resistant (including MRA-resistant) hypertension in pa­
tients with HFpEF (61% diabetes; post-hoc analysis of PARAGON-HF 
[Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity 
and Mortality in Heart Failure Patients With Preserved Ejection 
Fraction] trial) sacubitril/valsartan helped to better control BP com­
pared with valsartan.220
5.4.3.3. Blood pressure changes with glucose-lowering agents
Trials testing GLP-1 RAs have shown a BP decrease with these drugs, 
partly due to weight loss. A sustained decrease in BP was observed 
with semaglutide therapy (SBP dose dependent: −1.3 to −2.6 mmHg) 
with a slight increase in heart rate (+2 to 2.5 beats per minute 
[b.p.m.]).72 Similar effects were seen in other studies of GLP-1 RAs 
and derived from meta-analysis.161,221,222
SGLT2 inhibitors induced a larger BP decrease than did GLP-1 RAs 
without changing heart rate.223–225 A recent meta-analysis including seven 
RCTs demonstrated that SGLT2 inhibitors were associated with an aver­
age reduction of 3.6/1.7 mmHg (systolic/diastolic) in 24 h ambulatory BP, 
which is comparable with efficacy of low-dose hydrochlorothiazide.224–226
5.4.4. Sex-specific aspects
In general, the diagnosis and treatment of hypertension is comparable 
between sexes, except for women of child-bearing potential or during 
pregnancy, when some drugs, such as RAS blockers, can have adverse 
effects on the foetus, especially in early gestation.227 The possible effect 
of oral contraceptives on BP should also be considered.48 There is 
some evidence from RCTs that BP targets during pregnancy should 
range from 110 to 135 mmHg for SBP and 80 to 85 mmHg for 
DBP.228 This is also supported by the recent CHAP (Chronic 
Hypertension and Pregnancy) study of mild chronic hypertension in 
pregnancy, where 16% of the pregnant women had diabetes.229 The 
strategy targeting a BP of <140/90 mmHg was related with better preg­
ancy outcomes without an increase in the number of Small for 
Gestational Age babies.
Women usually show greater differences in BP and higher propor­
tions of hypertension than men already at diagnosis of T2DM com­
pared with women and men without T2DM, and worse BP control 
thereafter.191,230 Moreover sex-specific, hypertension-mediated organ 
damage was evidenced with a very high risk of HFpEF in women, espe­
cially in the presence of diabetes.231
Recommendation Table 10 — Recommendations for 
blood pressure management in patients with diabetes
Recommendations
Classa
Levelb
Screening for hypertension
Regular BP measurementsc are recommended in all 
patients with diabetes to detect and treat 
hypertension to reduce CV risk.193,232,233
I
A
Treatment targets
Anti-hypertensive drug treatment is recommended 
for people with diabetes when office BP is ≥140/ 
90 mmHg.196,202,234,235
I
A
It is recommended to treat hypertension in patients 
with diabetes in an individualized manner. The BP goal 
is to target SBP to 130 mmHg and <130 mmHg if 
tolerated, but not <120 mmHg. In older people (age 
>65 years), it is recommended to target SBP to 130– 
139 mmHg.196,236–238
I
A
An on-treatment SBP target of <130 mmHg may be 
considered in patients with diabetes at particularly 
high risk of a cerebrovascular event to further reduce 
their risk of stroke.194–198,239,240
IIb
B
Treatment and evaluation
Lifestyle changes (weight loss if overweight, physical 
activity, alcohol restriction, sodium restriction, 
increased consumption of vegetables, using low-fat 
dairy products) are recommended in patients with 
diabetes and hypertension.205–207,210
I
A
It is recommended to initiate treatment with a 
combination of a RAS inhibitor and a CCB or 
thiazide/thiazide-like diuretic.196,213–216,218,241
I
A
Home BP self-monitoring should be considered in 
patients with diabetes on anti-hypertensive treatments 
to check that BP is appropriately controlled.242
IIa
B
24 h ambulatory blood pressure monitoring should 
be considered to assess abnormal 24 h BP patterns, 
including nocturnal hypertension and reduced or 
reversed nocturnal BP dipping, and to adjust 
anti-hypertensive treatment.243
IIa
B
© ESC 2023
BP, blood pressure; CCB, calcium channel blocker; CKD, chronic kidney disease; CV, 
cardiovascular; CVD, cardiovascular disease; RAS, renin–angiotensin system; SBP, systolic 
blood pressure. 
aClass of recommendation. 
bLevel of evidence. 
cIdeally at every encounter.


<!-- PAGE 33 -->

### Page 33

5.5. Lipids and diabetes
A cluster of lipid and apolipoprotein abnormalities accompanies dia­
betes. The core components are moderately elevated plasma triglycer­
ide (TG), TG-rich lipoprotein (TRL), and TRL cholesterol levels, 
normal-to-mildly 
elevated 
low-density 
lipoprotein-cholesterol 
(LDL-C), and low high-density lipoprotein-cholesterol (HDL-C). 
Other features comprise structure and function of lipoproteins, e.g. 
small dense LDL and HDL particles. The same abnormalities are also 
reported in patients with T1DM, whose long-lasting exposure to dysli­
pidaemia might induce atherosclerosis as early as in adolescence. In 
T1DM, high LDL-C values are seen in patients with uncontrolled gly­
caemia, while high levels of HDL-C might be pro-inflammatory and 
therefore atherogenic instead of protective.244 In well-controlled 
T1DM, HDL-C levels tend to be normal (or even slightly elevated), 
as are serum TGs.245
5.5.1. Treatment targets
Epidemiological studies have shown that high levels of LDL-C and 
non-HDL-C and low levels of HDL-C are associated with an increased 
risk of CV events and mortality in patients with and without diabetes.246
Conversely, RCTs with lipid-lowering agents in patients at risk of CV 
events (including patients with T2DM) have demonstrated a log-linear 
proportional reduction of CV events and mortality for each 1 mmol re­
duction of LDL-C.247 LDL-C is the primary target of lipid-lowering 
therapies. A secondary goal of non-HDL-C should also be considered 
in patients with diabetes and combined dyslipidaemias, although there 
are limited data from interventional trials. Treatment targets differ 
among patients with diabetes based on their CV risk (Section 4; 
Figure 10).48 Due to the lack of evidence, no clear recommendations 
can be given for patients with T2DM at low CV risk.
5.5.2. Lipid-lowering agents
5.5.2.1. Statins
Statins remain the first-line therapy to reduce LDL-C levels in patients 
with diabetes and dyslipidaemia, due to their efficacy in preventing CV 
events and reducing CV mortality with no evidence for sex 
differences.248,249
High-intensity statins (rosuvastatin and atorvastatin) are indicated in 
patients with diabetes at high or very high CV risk, as they lower LDL-C 
by 40–63% and significantly reduce the incidence of major cerebral and 
coronary complications.250 This beneficial effect outweighs the poten­
tial diabetogenic effect of these drugs, estimated as a 9% increased risk 
of incident diabetes, especially in older patients and in patients already 
at risk of developing diabetes.251,252 Similar benefits were seen in both 
T1DM and T2DM.253–255
Statins are safe and generally well tolerated. Subjective adverse events 
(such as fatigue, myalgias, and nervous system symptoms) are more fre­
quent than objective adverse events due to the nocebo effect, with wo­
men experiencing adverse events more frequently than men.256 In most 
cases of myopathy or rhabdomyolysis, there are drug interactions with a 
higher-than-standard dose of statin or combination with gemfibrozil.200
Evidence indicates that 70–90% of patients who report statin intolerance 
are able to take a statin when re-challenged.257
5.5.2.2. Ezetimibe
Lowering of LDL-C can be further intensified by adding ezetimibe to a 
statin, which reduces cholesterol absorption from the ileum.258 The 
IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy 
International Trial) trial showed significantly reduced MACE (compos­
ite of CV death, non-fatal MI, unstable angina requiring re- 
hospitalization, 
coronary 
revascularization 
≥30 
days 
after 
Very high risk
High risk
Moderate risk
LDL-C <1.4 mmol/L
(<55 mg/dL)
(Class I)
LDL-C <1.8 mmol/L
(<70 mg/dL)
(Class I)
LDL-C <2.6 mmol/L
(<100 mg/dL)
(Class I)
CV risk categorization in patients with T2DM based on ASCVD, severe TOD, or SCORE2-Diabetes
Figure 10 Recommended low-density lipoprotein-cholesterol targets by cardiovascular risk categories in patients with type 2 diabetes. ASCVD, athero­
sclerotic cardiovascular disease; CV, cardiovascular; LDL-C, low-density lipoprotein-cholesterol; TOD, target-organ damage; T2DM, type 2 diabetes mellitus.
ESC Guidelines                                                                                                                                                                                          4075


<!-- PAGE 34 -->

### Page 34

randomization, or non-fatal stroke; HR 0.94; 95% CI, 0.89–0.99) in pa­
tients post-ACS receiving simvastatin plus ezetimibe, with a stronger 
benefit in the sub-group of patients with diabetes (HR 0.85; 95% CI, 
0.78–0.94; P <0.001).259,260 The combination of ezetimibe with a statin 
is therefore recommended in patients with diabetes and a recent ACS, 
especially when an LDL-C target <1.4 mmol/L (55 mg/dL) is required 
and not achieved with a statin alone. Young adults with T1DM have in­
creased cholesterol absorption, as shown in a recent study, suggesting 
greater efficacy of ezetimibe in this population, which remains to be as­
sessed with dedicated RCTs.261
5.5.2.3. Proprotein convertase subtilisin/kexin type 9 inhibitors
The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors 
evolocumab and alirocumab are monoclonal antibodies that strongly 
reduce plasma LDL-C, targeting the protein involved in regulating the 
LDL receptor on the hepatocyte.262 Administered alongside high- 
intensity statin therapy (with or without ezetimibe), PCSK9 inhibitors 
significantly reduced MACE in the sub-groups of patients with diabetes 
with ASCVD enrolled in the FOURIER (Further Cardiovascular 
Outcomes Research with PCSK9 Inhibition in Subjects with Elevated 
Risk) trial and in the ODYSSEY OUTCOMES (Evaluation of 
Cardiovascular Outcomes After an Acute Coronary Syndrome 
During Treatment With Alirocumab) trial, respectively.263,264 In par­
ticular, evolocumab showed a 17% RR reduction of a composite pri­
mary endpoint of CV death, MI, stroke, hospitalization for unstable 
angina, or coronary revascularization in patients with diabetes included 
in the FOURIER trial (HR 0.83; 95% CI, 0.75–0.93; P = 0.0008).263
Compared with placebo, evolocumab also significantly reduced other 
atherogenic lipids (i.e. TGs, non-HDL-C, apolipoprotein B-containing 
particles) in patients with diabetes and mixed dyslipidaemia enrolled 
in the BANTING (Evaluation of Evolocumab Efficacy in Diabetic 
Adults 
With 
Hypercholesterolemia/Mixed 
Dyslipidemia) 
and 
BERSON (Safety and Efficacy of Evolocumab in Combination With 
Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed 
Dyslipidemia) studies.265,266
Alirocumab significantly reduced the rate of a composite of CV 
death, MI, stroke, or hospitalization for unstable angina in the sub-group 
of patients with ACS with T2DM (n = 5444) of the ODYSSEY 
OUTCOMES trial.267 Alirocumab on top of the maximum tolerated 
statin dose was also more effective than ezetimibe, fenofibrate, or 
non-lipid-lowering therapy in reducing non-HDL-C and other athero­
genic lipids in patients with diabetes enrolled in the ODYSSEY 
DM-DYSLIPIDEMIA (Efficacy and Safety of Alirocumab Versus Usual 
Care on Top of Maximally Tolerated Statin Therapy in Patients With 
Type 2 Diabetes and Mixed Dyslipidemia) trial.268
A meta-analysis by Khan et al. did not show a significant association be­
tween PCSK9 inhibitors and new-onset diabetes (HR 1.00; 95% CI, 0.93– 
1.07; P = 0.96; I2 = 0%), while confirming a modest risk of incident diabetes 
with statins only (HR 1.10; 95% CI, 1.05–1.15; P < 0.001; I2 = 0%).269
5.5.2.4. Fibrates and other TG-lowering drugs
Potential use of fibrates to reduce TG levels is quite limited, due to the 
risk of myopathy if given with statins and the little benefit demonstrated 
in RCTs, aside from sub-group analysis including subjects with very high 
TG levels.200,270,271 Pemafibrate is a new selective peroxisome 
proliferator-activated receptor-α 
modulator with a superior 
benefit-risk balance compared with conventional fibrates.272 A phase 
3 trial determining the efficacy of pemafibrate in preventing MACE in 
patients with diabetes has been terminated early for futility.273
If TGs remain elevated even with a statin-based regimen, icosapent 
ethyl, a stable ester of eicosapentaenoic acid, might be preferred 
over other omega–3 fatty acids at the dose of 2 g twice a day (b.i.d.), 
due to its favourable impact on CV outcomes reported in the 
REDUCE-IT (Reduction of Cardiovascular Events with Icosapent 
Ethyl—Intervention Trial) trial, where benefit was consistent in patients 
with (58%) and without diabetes (Pint = 0.29).274 This benefit remained 
significant even considering a slight increase of LDL-C and high- 
sensitivity C-reactive protein due to the effect of mineral oil in the pla­
cebo arm.275,276
5.5.3. Novel cholesterol-lowering drugs
5.5.3.1. Inclisiran
Inclisiran inhibits hepatic synthesis of PCSK9 with a long-lasting effect.277
Patients on statins with high LDL-C levels and ASCVD or at least one 
ASCVD risk equivalent were included in the two phase 3 trials 
ORION-10 and ORION-11 (Inclisiran for Participants With 
Atherosclerotic Cardiovascular Disease and Elevated Low-density 
Lipoprotein Cholesterol), and obtained a further 50% reduction of 
LDL-C with inclisiran.278 This benefit was consistent in patients with dia­
betes in both trials, and CV outcome endpoints are currently being tested 
in a phase 3 trial enrolling patients with ASCVD (ORION-4 trial).279
5.5.3.2. Bempedoic acid
Bempedoic acid is a pro-drug that reduces cholesterol synthesis by in­
hibiting adenosine triphosphate (ATP) citrate lyase, with very limited 
musculoskeletal-related side effects.280 In the CLEAR (Cholesterol 
Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen) Harmony 
trial, adding bempedoic acid to statins significantly reduced LDL-C le­
vels (–16.5%) in patients with ASCVD or familial hypercholesterol­
aemia, with consistent results in the sub-group of patients with 
diabetes (–19.1%).267 Bempedoic acid did not induce new-onset dia­
betes or worsen diabetes as shown by a subsequent meta-analysis.281
High CV risk patients who were unable or unwilling to take statins 
have been included in the CLEAR Outcomes study and randomized 
to bempedoic acid or placebo. Among the 6992 patients assigned to 
the active arm of the study 45% had T2DM. Bempedoic acid was asso­
ciated with a significantly lower incidence of the four-component com­
posite primary endpoint of CV death, non-fatal MI, non-fatal stroke, or 
coronary revascularization and a higher incidence of some adverse 
events (gout and cholelithiasis) at the 40.6 month follow-up. Of note, 
the data were only released just before finalising these Guidelines and 
could thus not be included.282
Recommendation Table 11 — Recommendations for 
the management of dyslipidaemia in patients with 
diabetes
Recommendations
Classa
Levelb
Lipid targets
In patients with T2DM at moderate CV risk, an 
LDL-C target of <2.6 mmol/L (<100 mg/dL) is 
recommended.248,249
I
A
In patients with T2DM at high CV risk, an LDL-C 
target of <1.8 mmol/L (<70 mg/dL) and LDL-C 
reduction of at least 50% is recommended.248,249
I
A
Continued


<!-- PAGE 35 -->

### Page 35

5.6. Antithrombotic therapy and diabetes
Several mechanisms contribute to platelet activation and coagulation in 
diabetes (Figure 11). The pharmacology of different antithrombotic 
agents can be found in the Supplementary data online, Section 2.7 and 
Figures S1–5.
5.6.1. Patients without a history of symptomatic 
atherosclerotic cardiovascular disease or 
revascularization
The largest meta-analysis on 95 000 individual participant data (IPD) of 
patients at average CV risk (0.57% MACE/year) from six RCTs, included 
3818 (4%) patients with diabetes. In the whole cohort, low-dose acetyl­
salicylic acid (ASA) significantly reduced MACE vs. control (absolute risk 
reduction [ARR] 0.06%/year; P = 0.0001), while increasing major extra­
cranial bleed (0.10% vs. 0.07%/year; absolute risk increase 0.03%/year; 
P < 0.0001; Supplementary data online, Table S11).291 A similar 
proportional benefit-risk profile was also observed in the diabetes sub- 
group (Supplementary data online, Table S11).
The ASCEND (A Study of Cardiovascular Events iN Diabetes) trial 
was the largest, adequately powered, placebo-controlled RCT testing 
low-dose ASA in patients with T1DM or T2DM (n = 15 480) with no 
evident CVD.292 Over 7.4 years, ASA significantly reduced serious vas­
cular events vs. placebo (8.5% vs. 9.6%, respectively; RR 0.88; 95% CI, 
0.79–0.90; P = 0.01; number needed to treat [NNT] 91; 
Supplementary data online, Table S11), with a relative benefit similar 
to the previous meta-analysis.291
Bleeding Academic Research 
Consortium (BARC) type 3–5 bleeding (Supplementary data online, 
Figure S6) occurred in 4.1% vs. 3.2% of patients in the ASA and placebo 
arms, respectively (RR 1.29; 95% CI, 1.09–1.52; P = 0.003; number 
needed to harm [NNH] 111). ASA-associated major bleeding excess 
was largely gastrointestinal, without differences in fatal, intracranial, 
and ocular bleeding. The NNT/NNH ratio was 0.8. The pre-specified 
sub-group analysis based on vascular risk score at baseline was consist­
ent with the overall population (Supplementary data online, Figure S7).
The benefit of ASA in the ASCEND trial was observed on top of sta­
tins (75% of patients) and/or anti-hypertensive (∼60% of patients) 
drugs.292 Consistently, a recent IPD meta-analysis of 18 162 patients 
with multiple CV risk factors and no previous ASCVD (risk 1.7%/ 
year) showed a significant benefit of low-dose ASA, incremental to 
lipid- and BP-lowering drugs. This was also observed in a diabetes sub- 
group (Supplementary data online, Table S11).293
A 9.2-year follow-up analysis of the ASCEND trial excluded harm of 
ASA on incident dementia, with a trend towards a reduction (HR 0.89; 
95% CI, 0.75–1.06) confirmed by a meta-analysis of three large primary 
prevention RCTs (HR 0.92; 95% CI, 0.84–1.01; P = 0.09).294
Large, observational, prospective data suggest CAC as a non-invasive 
biomarker to identify asymptomatic patients at the highest risk of 
ASCVD or revascularization, with or without diabetes, who may largely 
benefit from ASA.295 Ongoing trials are testing the relevance of CAC 
score and related thresholds in improving primary prevention, including 
in asymptomatic patients with diabetes.296–298
In summary, in patients with diabetes and no history of symptomatic 
ASCVD or revascularization, ASA (75–100 mg o.d.) may be considered 
to prevent the first severe vascular event. However, in patients with 
diabetes with asymptomatic ASCVD (including documented CAD con­
firmed by imaging) and a higher CV risk, the net benefit of platelet in­
hibition by ASA may be higher and thus, therapy needs to be 
individualized.
In patients with T2DM at very high CV risk, an LDL-C 
target of <1.4 mmol/L (<55 mg/dL) and LDL-C 
reduction of at least 50% is recommended.248,249
I
B
In patients with T2DM, a secondary goal of a 
non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in 
very high CV risk patients and <2.6 mmol/L 
(<100 mg/dL) in high CV risk patients is 
recommended.283–285
I
B
Lipid-lowering treatment
Statins are recommended as the first-choice 
LDL-C-lowering treatment in patients with diabetes 
and above-target LDL-C levels. Administration of 
statins is defined based on the CV risk profile of the 
patients and the recommended LDL-C (or 
non-HDL-C) target levels.247–249
I
A
A PCSK9 inhibitor is recommended in patients at 
very high CV risk, with persistently high LDL-C levels 
above target despite treatment with a maximum 
tolerated statin dose, in combination with ezetimibe, 
or in patients with statin intolerance.267,286
I
A
If the target LDL-C is not reached with statins, 
combination therapy with ezetimibe is 
recommended.259,260
I
B
If a statin-based regimen is not tolerated at any 
dosage (even after re-challenge), a PCSK9 inhibitor 
added to ezetimibe should be considered.287,288
IIa
B
If a statin-based regimen is not tolerated at any 
dosage (even after re-challenge), ezetimibe should be 
considered.259,260
IIa
C
High-dose icosapent ethyl (2 g b.i.d.) may be 
considered in combination with a statin in patients 
with hypertriglyceridaemiac.274
IIb
B
© ESC 2023
b.i.d., twice a day; CV, cardiovascular; HDL-C, high-density lipoprotein-cholesterol; LDL-C, 
low-density lipoprotein-cholesterol; PCSK9, proprotein convertase subtilisin/kexin type 9; 
T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cHypertriglyceridaemia: triglycerides 150–499 mg/dL, according to the inclusion of the 
REDUCE-IT trial.
Recommendation Table 12 — Recommendations for 
patients with diabetes without a history of symptomatic 
atherosclerotic cardiovascular disease or revascularization
Recommendation
Classa
Levelb
In adults with T2DM without a history of 
symptomatic ASCVD or revascularization, ASA (75– 
100 mg o.d.) may be considered to prevent the first 
severe vascular event, in the absence of clear 
contraindications.c,292,293
IIb
A
© ESC 2023
ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; o.d., once daily; 
T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cHigh risk of bleeding due to gastrointestinal haemorrhage or peptic ulcer within the 
previous 6 months, active hepatic disease (such as cirrhosis, active hepatitis), or history 
of ASA allergy.
ESC Guidelines                                                                                                                                                                                          4077


<!-- PAGE 36 -->

### Page 36

5.6.2. Patients with atherosclerotic cardiovascular 
disease and/or revascularization without an 
indication for long-term oral anticoagulation
5.6.2.1. Chronic coronary syndromes
Patients with diabetes and documented significant CAD or with prior 
revascularization are at very high CV risk, and low-dose ASA (75– 
100 mg o.d.) is recommended, although ad hoc RCTs are lacking.48,299
Both the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial 
Assessing Benefits and Long-term) and CURRENT-OASIS 7 
(Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent 
EveNTs/Optimal Antiplatelet Strategy for InterventionS) trials showed 
comparable efficacy of a lower dose (75–100 mg o.d.) and a three- to 
four-fold higher (300–325 mg o.d.) ASA dose in both chronic coronary 
syndrome (CCS) and ACS.300,301
Clopidogrel provides an alternative in ASA-intolerant patients or can 
be combined with low-dose ASA (clopidogrel 75 mg o.d. and ASA 75– 
100 mg o.d.) as dual antiplatelet therapy (DAPT) in patients with CCS 
undergoing percutaneous coronary intervention (PCI).
The THEMIS (Effect of Ticagrelor on Health Outcomes in Diabetes 
Mellitus Patients Intervention Study) trial tested the efficacy and safety of 
adding the P2Y12 inhibitor ticagrelor (60 mg b.i.d.) or placebo to ASA 
(75–150 mg o.d.) in 19 220 patients with diabetes and a history of PCI or 
coronary artery bypass graft (CABG), or a documented stenosis (≥50%) 
in at least one coronary artery, and no previous MI or stroke 
Hyperglycaemia, insulin resistance or deficiency, metabolic imbalances
Atherothrombosis
Hypertension
Smoking
Obesity
Dyslipidaemia
Fibrin network
Activated platelets
Thrombin generation
Inflammation
ROS
Platelet turnover
Non-enzymatic protein glycation modifying function
Pro-coagulant and hypofibrinotic milieu
Endothelial dysfunction
NO synthesis
Figure 11 Mechanisms contributing to altered platelet activation and atherothrombosis in patients with diabetes. ↑, increase; ↓, decrease; NO, nitric oxide; 
ROS, reactive oxygen species.289,290 The figure depicts the major determinants contributing to platelet activation leading to atherothrombosis in patients 
with diabetes. An inflammatory environment, metabolic changes, endothelial dysfunction and altered platelet turnover result in a platelet population char­
acterized by enhanced activation, increased thrombin generation, and suppression of the fibrinolytic system. Thrombin release by platelets and de novo gen­
eration through activation of the coagulation pathway further amplify platelet activation and result in fibrin network formation, thus playing a pivotal role in 
the increased risk of thrombosis in individuals with diabetes.


<!-- PAGE 37 -->

### Page 37

(Supplementary data online, Table S11).302 Over a median 3.3 years of 
follow-up, the primary efficacy outcome of CV death, MI, or stroke showed 
a marginal 10% RR reduction by ticagrelor vs. placebo, while both 
Thrombolysis in Myocardial Infarction (TIMI) major and intracranial bleed­
ing were significantly increased. The pre-specified sub-groups of CABG or 
previous PCI showed a benefit-risk profile consistent with the entire 
trial.302,303 The NNT/NNH ratio was 1.5. Thus, an unfavourable 
benefit-risk profile is associated with adding ticagrelor to ASA in this setting.
The COMPASS (Cardiovascular Outcomes for People Using 
Anticoagulation Strategies) trial enrolled 27 395 patients with stable 
ASCVD (previous MI, symptomatic CAD, and/or PAD). Low-dose 
ASA combined with very low-dose rivaroxaban (2.5 mg b.i.d.) was su­
perior to ASA and placebo in preventing MACE (4.1% vs. 5.4%, respect­
ively; HR 0.76; 95% CI, 0.66–0.86; P < 0.001; NNT 77).304 International 
Society on Thrombosis and Haemostasis-defined major bleeding, but 
not fatal or intracranial bleeding, was increased (1.9% vs. 3.1%, respect­
ively; HR 1.70; 95% CI, 1.40–2.05; P < 0.001; NNH 83), with an NNT/ 
NNH ratio of 0.9 (Supplementary data online, Figure S7). The propor­
tional benefit-risk profile of the diabetes sub-group (38% of all patients) 
was similar to the overall population. Based on these data, adding very 
low-dose rivaroxaban to low-dose ASA for long-term prevention of 
serious vascular events should be considered in patients with diabetes 
and CCS or symptomatic PAD without high bleeding risk.304,305 Data 
are available up to 47 months of ASA plus very low-dose rivaroxaban 
exposure; beyond this time, continuation should be determined on 
an individual basis and with regular evaluation of thrombotic vs. bleeding 
risks.
5.6.2.2. Acute coronary syndrome
5.6.2.2.1. Peri-procedural management. Peri-procedural management 
of patients with ACS or undergoing PCI, which may include glycoprotein 
IIb/IIIa inhibitors, cangrelor, heparins, or bivalirudin, is detailed in the 2018 
ESC/European Association for Cardio-Thoracic Surgery (EACTS) 
Guidelines on myocardial revascularization.299,306–308
5.6.2.2.2. Post-procedural management. In patients with ACS 
undergoing PCI, 12 months’ DAPT with low-dose ASA and prasugrel 
or ticagrelor was superior to DAPT with clopidogrel in the diabetes 
sub-group of the respective RCTs, with a benefit-risk profile similar 
to the overall trial populations (Supplementary data online, Tables 
S12–13).309–312 With the limitations of a subgroup analysis, patients 
with diabetes on DAPT with low-dose ASA and prasugrel tended to 
have a more favourable benefit-risk profile.312 The open-label 
ISAR-REACT 5 (Intracoronary Stenting and Antithrombotic Regimen: 
Rapid Early Action for Coronary Treatment) trial randomized 4018 pa­
tients with ACS to prasugrel or ticagrelor added to ASA.313 Prasugrel 
was superior to ticagrelor in reducing MACE without increasing major 
bleeding, with similar effects in the sub-group of patients with diabetes 
(n = 892; 22%; Supplementary data online, Table S12).313
Thus, DAPT, i.e. low-dose ASA with prasugrel or ticagrelor are pre­
ferred to DAPT with clopidogrel in patients with diabetes and ACS 
(Supplementary data online, Table S12),309–312 unless the patient is 
deemed at very high bleeding risk. Of note, patients with T2DM 
have a reduced generation of the active metabolite of clopidogrel 
compared with patients without diabetes (Supplementary data 
online, Section 2.7).323,324 Notably, previous intracranial bleeding con­
traindicates patients to both prasugrel and ticagrelor.
In patients with diabetes and ACS who do not undergo cardiac revas­
cularization, DAPT with ASA (75–100 mg o.d.) and a P2Y12 receptor 
inhibitor, preferably ticagrelor over clopidogrel, is recommended for 
12 months.314,315
5.6.2.2.3. Prolonging DAPT post-ACS. The GLOBAL-LEADERS 
(A Clinical Study Comparing Two Forms of Antiplatelet Therapy 
After Stent Implantation) trial failed to show superior efficacy or safety 
of 24 months of ticagrelor monotherapy post-ACS vs. the standard 
12-month DAPT followed by 12-month low-dose ASA monotherapy 
in the overall and diabetes (25% of all patients) cohorts.316
The PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in 
Patients With Prior Heart Attack Using Ticagrelor Compared to 
Placebo on a Background of Aspirin) trial compared prolonged ticagre­
lor therapy (60 or 90 mg b.i.d.) with placebo added to low-dose ASA in 
patients with an MI 1–3 years before study entry and additional CV risk 
factors.317 Reduced-dose ticagrelor (60 mg) decreased MACE com­
pared with placebo (7.77% vs. 9.04%, respectively; HR 0.84; 95% CI, 
0.74–0.95; P = 0.004; NNT 79), with no heterogeneity with respect 
to the diabetes sub-group, whereas it significantly increased TIMI major 
bleeding (2.3% vs. 1.06%, respectively; HR 2.32; 95% CI, 1.68–3.21; 
NNH 81), dyspnoea, serious adverse events, and drug discontinuation 
rates.317 Based on these data, DAPT prolonged beyond 12 months 
should be considered up to 3 years in patients with diabetes who 
have tolerated DAPT without major bleeding.63,317,318 The median 
follow-up across all trials on prolonging full-dose DAPT was 18 months 
(interquartile range 12–24 months), with a maximum DAPT exposure 
no longer than 36 months.318 No sufficient safety and efficacy data are 
available for DAPT with reduced-dose ticagrelor beyond 3 years, espe­
cially considering the significant TIMI major bleeding increase of the as­
sociation (Supplementary data online, Figure S6).317,319
5.6.2.2.4. Shortening or de-escalating DAPT post-ACS in diabetes.
No evidence supports shortening or de-escalating DAPT post-ACS specif­
ically in patients with diabetes, since RCTs on shorter DAPT duration fol­
lowed by ASA or a P2Y12 inhibitor monotherapy are relatively small, often 
with non-inferiority design for efficacy, relatively low power, and wide non- 
inferiority margins. In addition, these RCTs had primary endpoints combin­
ing minor bleeding with traditional efficacy outcomes, efficacy outcomes 
including not only MACE, and diabetes sub-groups that contain few pa­
tients and events, especially on the major hard endpoints 
(Supplementary data online, Table S13).320,321 Moreover, large, superiority 
RCTs have failed to show a higher efficacy of routine platelet-function test­
ing in guiding antiplatelet therapy post-PCI.322,322a Of note, the 
TROPICAL-ACS (Testing Responsiveness to Platelet Inhibition on 
Chronic Antiplatelet Treatment For Acute Coronary Syndromes) trial ‘de- 
escalating’ P2Y12 inhibition from prasugrel to clopidogrel after 2 weeks of 
DAPT based on platelet function testing showed an upper HR limit for 
MACE of 1.93 in the diabetes sub-group (HR 1.17; 95% CI, 0.71–1.93). 
Moreover, CV death was significantly increased in sub-groups with dia­
betes vs. without diabetes in the ‘de-escalating’ arm (HR 2.42; 95% CI, 
0.61–9.67; Pint = 0.04), thus suggesting harm from de-escalation compared 
with standard recommended DAPT.321 In addition, patients with diabetes 
form less of the clopidogrel active metabolite resulting in less platelet inhib­
ition (Supplementary data online, Section 2.7).323,324
Thus, shortening or de-escalating DAPT below 12 months is not recom­
mended in patients with diabetes in the 12 months post-ACS. Current evi­
dence does not support platelet function testing to adjust DAPT.
Figure 12 summarizes recommendations in patients with diabetes 
and ACS or CCS undergoing PCI or CABG.
ESC Guidelines                                                                                                                                                                                          4079


<!-- PAGE 38 -->

### Page 38

Low dose ASA
(Class I)
Revascularization (PCI, CABG) for ACS and CCS in patients with diabetes and no indication for anticoagulation
DAPT
Low dose ASA and prasugrel or ticagrelor
(Class I)
DAPT
Low dose ASA and prasugrel or ticagrelor
(Class 1)
DAPT
Low dose ASA
and clopidogrel
(Class I)
Low dose
ASA
(Class I)
Low dose
ASA
(Class I)
Low dose
ASA
(Class I)
Low dose 
ASA
(Class I)
DAPT
based on bleeding risk
(Class Ila)
PCI
CABG
ACS
PCI
CABG
CCS
0 months
6 months
12 months
24 months
36 months
Time
Figure 12 Recommendations for antiplatelet therapy in patients with diabetes with acute or chronic coronary syndrome undergoing percutaneous cor­
onary intervention or coronary artery bypass grafting without indications for long-term oral anticoagulation. ACS, acute coronary syndrome; ASA, acetyl­
salicylic acid; CABG, coronary artery bypass graft; CCS, chronic coronary syndrome; DAPT, dual antiplatelet therapy; PCI, percutaneous coronary 
intervention.
Recommendation Table 13 — Recommendations for 
antithrombotic therapy in patients with diabetes and 
acute or chronic coronary syndrome without indications 
for long-term oral anticoagulation
Recommendations
Classa
Levelb
ASA at a dose of 75–100 mg o.d. is recommended in 
patients with diabetes and previous MI or 
revascularization (CABG or stenting).291,325,326
I
A
In patients with ACS and diabetes who undergo PCI, 
a P2Y12 receptor inhibitor (ticagrelor or prasugrel) is 
recommended in addition to ASA (75–100 mg o.d.), 
maintained over 12 months. 310–312,314
I
A
Clopidogrel 75 mg o.d. following appropriate loading 
(e.g. 600 mg or at least 5 days already on 
maintenance therapy) is recommended in addition to 
ASA for 6 months following coronary stenting in 
patients with CCS, irrespective of stent type, unless a 
shorter duration is indicated due to the risk or 
occurrence of life-threatening bleeding.327–332
I
A
Clopidogrel is recommended as an alternative in case 
of ASA intolerance.333
I
B
Continued
In patients with diabetes and ACS treated with 
DAPT who are undergoing CABG and do not 
require long-term OAC therapy, resuming a P2Y12 
receptor inhibitor as soon as deemed safe after 
surgery and continuing it up to 12 months is 
recommended.315,334,335
I
C
Prolonging DAPT beyond 12 months after ACS 
should be considered for up to 3 years in patients 
with diabetes who have tolerated DAPT without 
major bleeding complications.c,317,318,336
IIa
A
Adding very low-dose rivaroxaband to low-dose ASA 
for long-term prevention of serious vascular events 
should be considered in patients with diabetes and 
CCS or symptomatic PAD without high bleeding 
risk.304,305
IIa
B
© ESC 2023
ACS, acute coronary syndrome; ASA, acetylsalicylic acid; b.i.d., twice a day; CABG, 
coronary artery bypass graft; CCS, chronic coronary syndrome; DAPT, dual antiplatelet 
therapy; MI, myocardial infarction; OAC, oral anticoagulant; o.d., once daily; PAD, 
peripheral arterial disease; PCI, percutaneous coronary intervention. 
aClass of recommendation. 
bLevel of evidence. 
cIn case of ticagrelor, a reduced dose (60 mg b.i.d.) should be used.317
dRivaroxaban 2.5 mg b.i.d.


<!-- PAGE 39 -->

### Page 39

5.6.3. Patients with atherosclerotic cardiovascular 
disease and/or revascularization requiring long-term  
oral anticoagulation
In patients requiring long-term oral anticoagulants (OACs; e.g. those 
with AF) undergoing PCI for ACS or CCS, DAPT with clopidogrel is 
combined with full-dose OACs (triple antithrombotic therapy 
[TAT]). Combined antithrombotic drugs, while effective, increase 
major bleeding risk.337,338 RCTs have compared TAT with dual an­
tithrombotic therapy (DAT) combining an OAC mostly with clopi­
dogrel, in patients with AF and ACS or post-PCI (Supplementary 
data online, Table S14). These RCTs have some common features: 
a primary outcome of safety comprising moderate-to-major, often 
BARC-defined, bleeding (Supplementary data online, Figure S7); effi­
cacy (including CV death, MI, stroke, as well as revascularization, and/ 
or stent thrombosis) as a secondary endpoint, often with a non- 
inferiority comparison; relatively short follow-up (6–14 months); 
and limited sample size with few patients with diabetes (28–37% 
across RCTs; Supplementary data online, Table S14).339–342 Thus, 
these RCTs are underpowered to assess both the efficacy of DAT 
and the safety of major bleeding of TAT in patients with diabetes. 
Moreover, two meta-analyses suggest significantly higher MI and 
stent thrombosis rates with DAT vs. TAT (Supplementary data 
online, Table S14).343,344 The lack of high-quality evidence on efficacy, 
meta-analyses suggesting some harm, and the underlying high CV and 
stent thrombosis risk in patients with diabetes, indicate that TAT 
duration should be cautiously and systematically evaluated for 
both thrombotic and bleeding risks in the individual patient with 
diabetes.
5.6.4. Preventing gastrointestinal bleeding
Large observational studies or head-to-head RCTs show similar rates 
of gastrointestinal and non-gastrointestinal major bleeding for single 
antiplatelet therapy (SAPT) with low-dose ASA or a P2Y12 inhibitor 
(clopidogrel or ticagrelor).337,338,346–350 Thus, gastrointestinal mucosal 
bleeding appears to be due to pre-existing mucosal lesions associated 
with defective primary haemostasis secondary to platelet inhibition, 
rather than with a specific antiplatelet drug. A meta-analysis showed 
that gastroprotectant drugs significantly reduce the risk of gastro­
intestinal bleeding in patients on single or combined antithrombotic 
drugs.351 This benefit was also observed in the pre-specified sub- 
group of 6732 patients with diabetes in the COMPASS trial, consist­
ent with large population studies on proton pump inhibitors and 
OACs (either vitamin K antagonist [VKA] or non-vitamin K antagonist 
oral anticoagulant [NOACs]).352 Regarding CV safety, the composite 
of MI, stroke, CV death, CHD, and acute limb ischaemia was similar 
between pantoprazole and placebo, as was the rate of new-onset dia­
betes.337,351–355
Recommendation Table 14 — Recommendations for 
antithrombotic therapy in patients with diabetes and 
acute or chronic coronary syndrome and/or post- 
percutaneous coronary intervention requiring long- 
term oral anticoagulation
Recommendations
Classa
Levelb
In patients with AF and receiving antiplatelet therapy, 
eligible for anticoagulation, and without a 
contraindication,c NOACs are recommended in 
preference to a VKA.339,340,343
I
A
In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation, triple therapy with 
low-dose ASA, clopidogrel, and an OAC is 
recommended for at least 1 week, followed by dual 
therapy with an OAC and a single, oral, antiplatelet 
agent.339–342,344,345
I
A
In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation, prolonging triple 
therapy with low-dose ASA, clopidogrel, and an 
OAC should be considered up to 1 month if the 
thrombotic risk outweighs the bleeding risk in the 
individual patient.341–344
IIa
C
Continued
In patients with ACS or CCS and diabetes 
undergoing coronary stent implantation and having 
an indication for anticoagulation, prolonging triple 
therapy with low-dose ASA, clopidogrel, and an 
OAC up to 3 months may be considered if the 
thrombotic risk outweighs the bleeding risk in the 
individual patient.341–344
IIb
C
© ESC 2023
ACS, acute coronary syndrome; AF, atrial fibrillation; CCS, chronic coronary syndrome; 
NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant; PCI, 
percutaneous coronary intervention; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence. 
cContraindications to NOACs are prosthetic mechanical heart valve, mitral stenosis, and 
creatinine clearance below the approved threshold for the specific NOAC.
Recommendation Table 15 — Recommendations for 
gastric protection in patients with diabetes taking an­
tithrombotic drugs
Recommendations
Classa
Levelb
When antithrombotic drugs are used in combination, 
proton pump inhibitors are recommended to 
prevent gastrointestinal bleeding.337,347,348,351–353,355
I
A
When a single antiplatelet or anticoagulant drug is 
used, proton pump inhibitors should be considered 
to prevent gastrointestinal bleeding, considering the 
bleeding risk of the individual patient.338,347,348,351,352
IIa
A
When clopidogrel is used, omeprazole and 
esomeprazole are not recommended for gastric 
protection.356
III
B
© ESC 2023
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4081


<!-- PAGE 40 -->

### Page 40

5.7. Multifactorial approach to risk-factor 
management in diabetes
Optimal risk factor and lifestyle management, as well as early identification 
and treatment of comorbidities, is a cornerstone of treatment for 
T2DM.357–359 The Swedish National Diabetes Registry revealed a clear im­
provement of clinical outcomes by each risk factor within the target range 
(HbA1c, LDL-C, albuminuria, smoking, and SBP).360 In patients with ad­
vanced disease, e.g. T2DM and established microalbuminuria, an intensive, 
target-driven, multifactorial therapy (Steno-2 study; targets: HbA1c <6.5%, 
total cholesterol <4.5 mmol/L [175 mg/dL], and BP <130/80 mmHg) re­
sulted in 50% fewer microvascular and macrovascular events after 7.8 
years of follow-up.361 Long-term follow-up (21 years from baseline) 
showed significantly reduced end-stage renal disease combined with death 
(HR 0.53; 95% CI, 0.35–0.80), and risk of HF hospitalization reduced by 
70%.362 Overall, this resulted in a 7.9 year gain of life expectancy.363
These positive effects were not observed in the clinical intervention trials 
of intensified, multifactorial treatment for T2DM in primary care and early 
in the disease trajectory. The ADDITION (Anglo-Danish-Dutch Study of 
Intensive Treatment in People with Screen Detected Diabetes in 
Primary Care) trial showed that microvascular or macrovascular events 
were not significantly reduced after 5 or 10 years (17% and 13% reduction, 
respectively), while intervention only slightly improved HbA1c.364,365 In ac­
cordance, the J-DOIT3 (Japan Diabetes Optimal Integrated Treatment 
Study for 3 Major Risk Factors of Cardiovascular Diseases) trial in patients 
with T2DM aged 45–69 years revealed a non-significant trend towards a 
reduced primary composite outcome (non-fatal MI, stroke, revasculariza­
tion, or all-cause death; HR 0.81; 95% CI, 0.63–1.04; P = 0.094) with inten­
sive vs. conventional therapy.366 Post-hoc analyses showed that only 
cerebrovascular events were reduced (HR 0.42; 95% CI, 0.24–0.74; P =  
0.002), while no differences were seen for all-cause death and coronary 
events. In addition, the Look AHEAD trial, introducing lifestyle intervention 
in patients with obesity and T2DM with 10 years’ follow-up, did not dem­
onstrate a reduction in the composite CV outcome.56
Key problems in optimally treating patients with T2DM and CVD are 
the low rate of detection of T2DM in patients with CVD, the low re­
ferral rate to diabetes specialists, and the difficulty of prolonged adher­
ence to medication or lifestyle interventions in this patient group. The 
EUROASPIRE V survey reported that many patients with CVD (29.7%) 
had known diabetes, while 41.1% of those with unknown T2DM were 
dysglycaemic.367 Of patients with known diabetes, 31% had been ad­
vised to attend a diabetes clinic, though only 24% attended. Only 
58% of dysglycaemic patients were prescribed all cardio-protective 
drugs, and use of SGLT2 inhibitors or GLP-1 RAs was limited (3% 
and 1%, respectively).367 A BP target <140/90 mmHg was achieved in 
only 61% of patients with newly detected T2DM, and in 54% of patients 
with previously known T2DM.34 An LDL-C target <1.8 mmol/L was 
only achieved in 18% and 28% of patients, respectively. This was ex­
plained by low prescription rates of the combination of all cardio- 
protective drugs (antiplatelet therapy, beta-blockers, RAS inhibitors, 
and statins) in only 55% of patients with newly detected T2DM, and 
in 60% of patients with previously known T2DM.34 The concept of a 
polypill, e.g. containing aspirin, ramipril, and atorvastatin, may even im­
prove clinical events in secondary cardiovascular prevention.368
Furthermore, adherence to lifestyle intervention fades over time, with 
continuously increasing body weight after 1 year.56 To overcome adher­
ence failures, the 2021 ESC Guidelines on cardiovascular disease preven­
tion in clinical practice outlines a stepwise approach to treating risk factors 
and intensifying treatment to help physicians and patients pursue risk- 
factor targets, taking into account patient profiles and preferences, ensur­
ing targets are a part of a shared decision-making process involving 
healthcare professionals and patients.48 This stepwise approach starts 
with assessing CVD risk in all patients with diabetes, including glycaemic 
state and lifestyle risk-factor profile (Figure 13). CVD risk stratification 
should be individually adapted according to comorbidities, e.g. CAD, 
HF, AF, or PAD, as well as age, frailty, and sex. This includes discussing in­
dividual preferences with the patient, particularly regarding lifestyle strat­
egies and potential treatment benefits. Particularly in the field of T2DM, 
studies have shown benefits of a stepwise approach to intensify treat­
ment, and it appears that attaining treatment goals is similar, side effects 
are fewer, and patient satisfaction is significantly higher with such an ap­
proach.369,370 Supporting evidence comes from the Italian Diabetes and 
Exercise Study 2, which showed that a behavioural intervention strategy 
compared with standard care resulted in a sustained increase in physical 
activity and decrease in sedentary time among patients with T2DM.371
To achieve a high adherence and optimization of target goals, clinician– 
patient communication is crucial and should include a personalized ap­
proach explaining background and targets to improve understanding and 
encourage lifestyle changes and drug-therapy adherence. Aside from the 
disease entity, including symptoms, the patient’s ability to adopt a healthy 
lifestyle depends on individual cognitive and emotional factors, educational 
level, socioeconomic factors, and mental health. Perceived susceptibility to 
illness and the anticipated severity of the consequences are also prominent 
components of patients’ motivation.372 Patients can be motivated by mo­
tivational interviewing including the Open-ended questions, Affirmation, 
Reflective listening, and Summarizing (OARS) and Specific, Measurable, 
Achievable, Realistic, Timely (SMART) principles.372–374 Multidisciplinary 
behavioural approaches that combine the knowledge and skills of different 
caregivers are recommended.104 Adding exercise intervention combined 
with psychological support to diet recommendations is more effective 
than diet education alone.375 Assessing depression and depressive symp­
toms is important in patients with CVD and T2DM, as adequate treatment 
improves adherence.376,377
Mobile phone applications may improve adherence to both medica­
tion and behavioural changes, but more evidence, particularly in pa­
tients with CVD and T2DM, is needed.378 Regarding the education 
method, individual education is more effective than face-to-face or 
web and mobile phone education.375 Whether a tailored and auto­
mated text message (SMS) support programme may improve glycaemic 
control in adults with poorly controlled diabetes is equivocal.379
Recommendation Table 16 — Recommendations for a 
multifactorial approach in patients with type 2 diabetes 
with and without cardiovascular disease
Recommendations
Classa
Levelb
Identifying and treating risk factors and comorbidities 
early is recommended.357,358
I
A
A multifactorial approach to managing T2DM with 
treatment targets is recommended.361
I
B
Multidisciplinary behavioural approaches that 
combine the knowledge and skills of different 
caregivers are recommended.104,380
I
C
Principles of motivational interviewing should be 
considered to induce behavioural changes.372–374
IIa
C
Telehealth may be considered to improve risk 
profile.378,379
IIb
B
© ESC 2023
T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 41 -->

### Page 41

### 6 Management of coronary artery

disease and diabetes
6.1. Chronic coronary syndromes and 
diabetes
6.1.1. Clinical presentation
Diabetes is a well-established risk factor for ischaemic heart disease 
(IHD), and CAD accounts for 40−80% of deaths in patients with 
T2DM.148,359,381 In patients with CCS, T2DM is also associated 
with an increased risk of the combined outcome (CV death, MI, 
or stroke) with an adjusted HR of 1.28.39 Studies show that clinical 
symptoms of CAD in patients with diabetes are often less severe 
and atypical in presentation. In the BARI 2D (Bypass Angioplasty 
Revascularization Investigation 2 Diabetes) trial in patients with 
angiographically confirmed CAD and a mean diabetes duration of 
10.4 years, typical angina, anginal equivalent, or a combination of 
both were observed in 19%, 21%, and 42% of patients, respectively, 
whereas 18% remained asymptomatic.382,383 In 510 asymptomatic 
patients with diabetes without prior CVD, computed tomography 
(CT) revealed calcifications indicating the presence of coronary ath­
erosclerosis in 46% of patients.384 An even higher prevalence of 
CAD was found in an autopsy study of asymptomatic decedents 
with diabetes.385
6.1.2. Screening and diagnosis
For details about sensitivity, specificity, and pre-test probability of each 
procedure in the assessment of CHD, we refer to the 2019 ESC 
Guideline on chronic coronary syndromes.299
Screening for asymptomatic CAD in diabetes remains controversial. 
Various RCTs evaluating the impact of routine screening for CAD in 
asymptomatic patients with diabetes and no history of CAD showed 
Global CV risk and disease assessment
Obesity
Nutritiona
Inactivity
Smoking
Assessment of lifestyle risk factor components
Body weight
Body composition
Questionnaire
Questionnaire
Exercise testing
Questionnaire
General lifestyle recommendations
Adaption of lifestyle recommendations to 
comorbidities, age, frailty, sex, patient preference
Individualized multidisciplinary lifestyle intervention programme
Step 2
Step 1
HFpEF
HFrEF
AF
CAD
PAD
Figure 13 Assessment of lifestyle risk-factor components and stepwise lifestyle recommendations in patients with diabetes. AF, atrial fibrillation; CAD, 
coronary artery disease; CV, cardiovascular; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; 
PAD, peripheral arterial diseases. aNutrition includes components on quality and quantity of nutritional components, as well as alcohol consumption.
ESC Guidelines                                                                                                                                                                                          4083


<!-- PAGE 42 -->

### Page 42

no differences in CV outcomes at follow-up in those who underwent 
routine screening compared with standard recommendations.386–388
Data from a meta-analysis of five RCTs with 3299 asymptomatic pa­
tients with diabetes showed non-invasive CAD screening significantly 
reduced the rate of any cardiac event by 27% (RR 0.73; 95% CI, 
0.55–0.97; P = 0.028), driven by a non-significant reduction in non-fatal 
MI (RR 0.65; P = 0.062) and hospitalization for HF (RR 0.61; P = 0.1). 
Still, given the limitations of this analysis (e.g. different screening modal­
ities, heterogenous patient populations), non-invasive, routine screen­
ing for CAD in asymptomatic patients is not recommended.389
Moreover, in a recently published RCT involving men aged 65–74 years, 
routine CVD screening did not significantly reduce the incidence of 
death from any cause after a median follow-up of 5.6 years, also in a 
pre-specified diabetes sub-group.296
6.1.3. Management
The comprehensive management of patients with diabetes and estab­
lished CAD should start with a healthy lifestyle and reducing or elimin­
ating modifiable risk factors such as obesity, hypertension, or 
dyslipidaemia. The goal of pharmacotherapy should be to substantially 
reduce serious CV events. Targets and pharmacotherapy for glycaemia, 
BP, and LDL-C levels are addressed in the respective sections (Section 
5.2, 5.4, and 5.5).
6.1.3.1. Pharmacotherapy
6.1.3.1.1. Glucose-lowering medication. Based on the results of vari­
ous CVOTs, SGLT2 inhibitors and/or GLP-1 RAs are recommended in 
patients with T2DM and CAD to reduce CV events (Section 5.3).
6.1.3.1.2. Other medications. Due to the diffuse nature of CAD, 
some patients with diabetes are not amenable to revascularization. 
Symptom relief might then be achieved by increasing myocardial oxy­
gen supply with long-acting nitrates or CCBs, or by decreasing oxygen 
demand with the help of beta-blockers, non-dihydropyridine CCBs, ra­
nolazine, or ivabradine. Note that none of these medications improves 
mortality or the rate of ischaemic events. Beta-blockers with a simultan­
eous vasodilatory effect (e.g. carvedilol, nebivolol, labetalol) may be pre­
ferred due to their neutral or positive metabolic impact.390–392
Ranolazine, a drug that reduces myocardial ischaemia at the cellular le­
vel, also has the unique effect of reducing HbA1c, especially in patients 
with poor metabolic control.393,394 In normotensive patients with dia­
betes and CAD, ACE-Is or ARBs are also recommended to reduce the 
risk of CV events, especially in patients with HF or CKD.395–397
6.1.3.2. Revascularization
In patients with diabetes, the indications for myocardial revasculariza­
tion are the same as those in patients without diabetes, the essential as­
pects of which are reported in the 2018 ESC/EACTS Guidelines on 
myocardial revascularization and 2019 ESC Guideline on chronic cor­
onary syndromes.299,308 A detailed description of the evidence from 
outcome trials on revascularization in patients with diabetes can be 
found in Supplementary data online, Section 3.1.1. In brief, given the cur­
rent knowledge, in patients with diabetes and multivessel disease, 
CABG with arterial grafts is preferred over complex PCI, providing 
that patient characteristics (e.g. frailty, cerebrovascular disease) are 
considered.398 PCI with newer-generation drug-eluting stents (DES), 
whenever possible, is acceptable for patients with less-extensive dis­
ease (i.e. single-vessel disease or two-vessel disease not involving the 
left anterior descending, and those with SYNTAX Score ≤22). Thus, 
the extent of CAD, lesion complexity, and the risk of major surgery 
are key points in the decision-making process. Because most of the 
trials on revascularization contained patients with T2DM, current 
Guidelines cannot easily be applied to patients with T1DM. It has 
now been demonstrated that CABG is also superior to PCI in patients 
with T1DM and multivessel CAD.399
For recommendations for revascularization according to the extent 
of CAD, see the 2018 ESC/EACTS Guidelines on myocardial revascu­
larization and the 2019 ESC Guideline on chronic coronary 
syndromes.299,308
6.2. Acute coronary syndromes and 
diabetes
6.2.1. Clinical presentation and diagnosis
Diabetes is a frequent comorbidity in patients hospitalized for ACS, 
with an increasing prevalence over the last decade and a high mortality 
rate.409 Among patients presenting with ST-elevation myocardial in­
farction (STEMI), ∼25% have a history of diabetes and more than 
40% show a previously undiagnosed T2DM or pre-diabetes.410
Patients with diabetes more often present with non-typical symptoms 
compared with those without diabetes, and this impacts prompt diag­
nosis and treatment.411 Moreover, patients with diabetes frequently 
have multivessel disease and multiple coronary lesions, with a higher 
percentage of highly vulnerable atherosclerotic plaques associated 
with impaired microvasculature vasodilation.412,413
Recommendation Table 17 — Recommendations for 
revascularization in patients with diabetes
Recommendations
Classa
Levelb
It is recommended that similar revascularization 
techniques are implemented (e.g. the use of DES and 
the radial approach for PCI, and the use of the left 
internal mammary artery as the graft for CABG) in 
patients with and without diabetes.400
I
A
Myocardial revascularization in CCS is 
recommended when angina persists despite 
treatment with anti-anginal drugs or in patients with 
a documented large area of ischaemia (>10% 
LV).382,401,402,402a
I
A
Complete revascularization is recommended in 
patients with STEMI without cardiogenic shock and 
with multivessel CAD.403–405
I
A
Complete revascularization should be considered in 
patients with NSTE-ACS without cardiogenic shock 
and with multivessel CAD.406,407
IIa
C
Routine immediate revascularization of non-culprit 
lesions in patients with MI and multivessel disease 
presenting with cardiogenic shock is not 
recommended.408
III
B
© ESC 2023
CABG, coronary artery bypass graft; CAD, coronary artery disease; CCS, chronic coronary 
syndrome; DES, drug-eluting stents; LV, left ventricle; MI, myocardial infarction; NSTE-ACS, 
non-ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; 
STEMI, ST-elevation myocardial infarction. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 43 -->

### Page 43

6.2.2. Management
6.2.2.1. Pharmacotherapy
Patients with diabetes and ACS, despite the poor prognosis and high 
prevalence of comorbidities, are less likely to receive appropriate treat­
ment such as revascularization, reperfusion, or adequate DAPT.414,415
One of the reasons may be the lack of typical symptoms.416 While few 
studies have focused exclusively on patients with diabetes, analyses of 
studies indicate that guideline-directed pharmacotherapy provides pa­
tients with diabetes similar or improved absolute benefits compared 
with patients without diabetes, yet the incidence of events remains con­
stantly higher in those with vs. without diabetes.309,312,417
6.2.2.2. Glucose control in patients with acute coronary syndrome
Patients with ACS and hyperglycaemia on admission to hospital have a high­
er risk of death than patients with ACS without hyperglycaemia, irrespect­
ive of diabetes status.418 Mortality correlates more strongly to the blood 
glucose level than to the presence of diabetes.419,420Thus, early assessment 
of blood glucose level is strongly recommended in all subjects, although 
there is insufficient evidence that intensive glycaemic control improves 
prognosis. The DIGAMI 1 trial showed that early, tight glycaemic control 
with intravenous (i.v.) insulin–glucose infusion followed by subcutaneous in­
jections significantly reduced 1-year mortality compared with conventional 
glucose-lowering treatment.421 Conversely, the DIGAMI 2 study, and later 
pooled analyses of studies on insulin–glucose infusions did not confirm this 
observation.146,422Other studies have shown that adequate glycaemic con­
trol improves the prognosis of patients with ACS, while also demonstrating 
the importance of avoiding hypoglycaemia, which is strongly associated 
with worse outcomes.423,424 A criticism of previous studies is the inad­
equate characterization of glycaemia, with most studies analysing HbA1c 
as the glycaemic marker, when both hypoglycaemia and glycaemic variability 
potentially have a role in CV pathology.
Considering all evidence, it is best to attempt moderately tight gly­
caemic control while avoiding hypoglycaemia in the early hours of 
ACS. Continuous insulin infusion should be limited to cases where the 
optimal glycaemic control cannot be achieved otherwise; blood glucose 
level should be maintained <11.1 mmol/L (<200 mg/dL) or 
<10.0 mmol/L (<180 mg/dL) according to some recommenda­
tions.425–427 Frequent blood glucose testing, preferably hourly during 
the acute ACS phase, will help to avoid hypoglycaemia. CGM provides 
comprehensive glucose data while being more convenient than blood 
glucose testing, and the LIBERATES (Improving Glucose Control in 
Patients with Diabetes Following Myocardial Infarction: The Role of a 
Novel Glycaemia Monitoring Strategy) RCT in 141 insulin- or 
sulphonylurea-treated patients with T2DM and ACS showed that 
CGM over 3 months significantly reduced hypoglycaemic exposure 
compared with traditional capillary glucose testing, while being equally 
effective at reducing HbA1c.428 In the EMMY (Impact of EMpagliflozin 
on cardiac function and biomarkers of heart failure in patients with acute 
MYocardial infarction) trial, 467 patients were randomized to empagli­
flozin 10 mg or placebo within 72 h of PCI for acute MI.429 The study 
drug was associated with a significantly greater N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) reduction over 26 weeks (primary 
outcome) and a significant improvement in echocardiographic LV para­
meters, without demonstrating any difference in adverse events of spe­
cial interest including metabolic acidosis and diabetic ketoacidosis.429
It should be noted that hyperglycaemia in the acute phase of ACS 
might reflect stress hyperglycaemia and is not enough to diagnose dia­
betes. These patients should be further evaluated after discharge 
(Section 3).
Antithrombotic medication in patients with ACS is further described 
in Section 5.6.
6.2.2.3. Reperfusion strategies in ST-elevation myocardial infarction
The therapeutic strategy in patients with diabetes presenting with 
STEMI should not differ from that for patients without diabetes. As 
for the general population, prognosis is determined by early and effect­
ive reperfusion. Since patients with diabetes are more likely to present 
with atypical symptoms, reperfusion is often undertaken late.431
Although, patients with diabetes and STEMI, compared with those 
without diabetes, are older, more often have multivessel disease and 
concomitant conditions, and are less likely to receive reperfusion ther­
apy. Diabetes is regarded as an independent risk factor of early and late 
mortality.432–436 Primary angioplasty, performed in a timely fashion, 
also provides the best clinical outcomes in patients with diabetes.437
Several recent studies indicate the clinical benefit of early, single-stage, 
complete revascularization in patients with non-ST-elevation ACS 
(NSTE-ACS) and early complete revascularization in those with 
STEMI and multivessel disease.403–407,432–435 The exception is patients 
in cardiogenic shock, where it is recommended to limit the procedure 
to the infarct-related artery.408 Adding proton pump inhibitors, limiting 
use of glycoprotein IIb/IIIa inhibitors, and avoiding heparin in patients on 
OACs if the international normalized ratio (INR) >2.5 are 
recommended.308
6.2.2.4. Optimal timing of invasive strategy in non-ST-elevation acute 
coronary syndrome
In patients with diabetes and NSTE-ACS, the indications and timing of 
revascularization should not differ from those for patients without dia­
betes.438 Multiple studies have indicated that an early invasive strategy is 
beneficial in high-risk sub-groups.439–442 Since diabetes is one of the risk 
factors of poor prognosis, patients with diabetes may benefit signifi­
cantly more from the early invasive approach than those without dia­
betes.417,443 In a meta-analysis of eight RCTs in patients with 
NSTE-ACS, which compared an early vs. a delayed invasive strategy, 
diabetes, elevated troponin, and a Global Registry of Acute Coronary 
Events (GRACE) risk score >140 predicted lower mortality in the early 
invasive arm.444
Recommendation Table 18 — Recommendations for 
glycaemic control in patients with diabetes and acute 
coronary syndrome
Recommendations
Classa
Levelb
It is recommended to assess glycaemic status at initial 
evaluation in all patients with ACS.141,367,430
I
B
It is recommended to frequently monitor blood 
glucose levels in patients with known diabetes or 
hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).
I
C
Glucose-lowering therapy should be considered in 
patients with ACS with persistent hyperglycaemia, 
while episodes of hypoglycaemia should be 
avoided.423,424
IIa
C
© ESC 2023
ACS, acute coronary syndrome. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4085


<!-- PAGE 44 -->

### Page 44

According to current guidelines, an immediate invasive strategy 
(within 2 h from admission) should be applied to very high-risk patients, 
mostly with electrical or haemodynamic instability.426 These patients 
were excluded from all major randomized ACS trials. In addition, pa­
tients with severe symptoms, refractory to medical therapy, or those 
with electrocardiogram (ECG) signs suggesting the left main stem as 
a culprit vessel should be promptly referred for coronary angiography. 
An early invasive strategy (within 24 h) should be applied to high-risk 
patients, especially those with markedly elevated troponins, dynamic 
ST/T-segment changes, transient ST-segment elevation, or a GRACE 
risk score >140.
6.3. Ischaemia with no obstructive 
coronary artery disease in diabetes
Details on the role of ischaemia with no obstructive CAD are outlined 
in the Supplementary data online, Section 3.2.
7. Heart failure and diabetes
7.1. Definition and pathophysiology
Heart failure is not a single pathological disease but a clinical syndrome 
with current or prior symptoms and/or signs caused by a structural and/ 
or functional cardiac abnormality. It is corroborated by elevated natri­
uretic peptides and/or objective evidence of cardiogenic pulmonary or 
systemic congestion from diagnostic modalities, such as imaging or in­
vasive haemodynamic measurements.445
Heart failure is one of the most common initial manifestations of 
CVD in patients with T2DM, and may present as HFpEF, heart failure 
with mildly reduced ejection fraction (HFmrEF), or HFrEF (Table 9).446
Major causes of HF in diabetes are IHD (Section 6), hypertension 
(Section 5.3), direct or indirect effects of hyperglycaemia, and obesity 
and related factors on the myocardium.447,448 IHD is often accelerated, 
severe, diffuse, and silent, and increases the risk of MI and ischaemic 
myocardial dysfunction.449–452 Observational data have also identified 
that lower-extremity artery disease (LEAD), longer diabetes duration, 
ageing, increased BMI, and CKD (Section 9) are associated with HF in 
patients with diabetes (Table 10).449–452 Complex pathophysiological 
mechanisms may be responsible for the development of myocardial 
dysfunction, even in the absence of IHD or hypertension.453 For dec­
ades, the concept of diabetic cardiomyopathy has been discussed, 
with mostly experimental and smaller observational studies suggesting 
its presence; however, its existence has so far not been con­
firmed.447,454–458
7.2. Epidemiology and prognosis
Diabetes is an important risk factor for HF.459 Observational studies have 
consistently demonstrated a two- to four-fold increased risk of HF in in­
dividuals with diabetes compared with those without diabetes.460–463
The prevalence of chronic HF increases steadily with age for patients 
with and without diabetes. Patients with T2DM develop chronic HF 
more often and earlier in life than those without T2DM, with an incre­
mental risk inversely associated with age; for example, in one study, 
the incident rate ratio was 11.0 (95% CI, 5.6–21.8) for those <45 years, 
declining to 1.8 (95% CI, 1.6–2.2) for those aged 75–84 years, reflecting 
the higher absolute HF risk in elderly patients without diabetes.463
Unrecognized HF is frequent in T2DM: a cross-sectional study in patients 
aged ≥60 years with T2DM without known HF using a standardized diag­
nostic work-up, including medical history, physical examination, ECG, 
and echocardiography, indicated that HF was present in 28% of patients 
(∼25% HFrEF and ∼75% HFpEF).460–464
Vice versa, HF is associated with a diabetes incidence of 20–30 per 
1000 person-years in the first 5 years following HF hospitalization, 
which is substantially higher than for adults in the general population 
(10.1 per 1000 person-years).465,466 A large, pan-European registry 
found that ∼36% of all outpatients with stable HF had diabetes, while 
in patients hospitalized for acute HF for whom i.v. therapy (inotropes, 
vasodilators, or diuretics) was needed, diabetes was present in up to 
50%.467,468 In addition, available data from observational studies dem­
onstrate that diabetes prevalence in patients with HF is similar, irre­
spective of LVEF category.469,470
A significant association exists between diabetes and a higher risk of 
adverse outcomes in patients with HF, with the greatest incremental risk 
associated with diabetes observed in patients with HFrEF.467,471–475
However, CV mortality, including death caused by worsening HF, is 
also 50–90% higher in patients with HF and diabetes compared 
Table 9 Heart failure phenotypes according to ejection 
fraction distribution445
HF 
phenotype
HFpEF
HFmrEF
HFrEF
Criterion 1
Symptoms and/or 
signsa
Symptoms 
and/or signsa
Symptoms 
and/or signsa
Criterion 2
LVEF ≥50%
LVEF 41–49%
LVEF ≤40%
Criterion 3
Objective evidence of 
cardiac structural 
and/or functional 
abnormalities 
consistent with the 
presence of LV 
diastolic dysfunction 
or raised filling 
pressures, including 
raised natriuretic 
peptides
None
None
© ESC 2023
HF, heart failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart 
failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; 
LV, left ventricular; LVEF, left ventricular ejection fraction. 
aSymptoms include, for example, breathlessness, ankle swelling, and fatigue. Signs may not 
be present at an early stage or in patients receiving diuretics.
Table 10 Risk factors for developing heart failure in 
patients with diabetes
Cardiac risk factors
Ischaemic heart disease 
Myocardial infarction 
Hypertension 
Valvular heart disease 
Arrhythmias
Non-cardiac risk factors
Age 
Chronic kidney disease 
Increased body mass index 
Longer duration of diabetes 
Smoking 
Alcohol excess
© ESC 2023


<!-- PAGE 45 -->

### Page 45

with HF patients without diabetes, regardless of HF phenotype.471,475–477
In patients with acute HF, for whom i.v. therapy (inotropes, vasodi­
lators, or diuretics) was needed, diabetes was associated with higher 
risk of in-hospital death, 1 year all-cause death, and 1 year HF 
re-hospitalization.468,478
7.3. Screening and diagnosis
Patients with diabetes are at risk of HF but not all patients with diabetes 
will develop HF.479 Given that the prognosis of patients with both co­
morbidities is worse, it is of utmost importance to screen all patients 
with diabetes for HF to allow early implementation of life-saving therapies. 
To predict the HF risk among outpatients with T2DM, the WATCH-DM 
(Weight [BMI], Age, Hypertension, Creatinine, HDL-C, Diabetes control 
[fasting plasma glucose], QRS duration, MI, and CABG) risk score has 
been developed.480 Each increment of 1 unit in the risk score is associated 
with a 24% higher HF risk within 5 years. In addition, a biomarker-based 
risk score including high-sensitivity cardiac troponin T ≥6 ng/L, 
NT-proBNP ≥125 pg/mL, high-sensitivity C-reactive protein ≥3 mg/L, 
and LV hypertrophy by ECG (with one point for each abnormal param­
eter) demonstrated good discrimination and calibration for predicting 5- 
and 10-year HF risk among patients with diabetes. The highest 5-year risk 
of HF was noted among those with scores ≥3.481 The Heart Failure 
Association of the ESC reviewed the clinical evidence and value of further 
biomarker testing and currently recommends no further testing.482
To detect transition from being at risk of HF to developing HF, the 
following regular evaluation is recommended in patients with diabetes 
(Figure 14): 
• Regularly, a systematic survey for HF symptoms (breathlessness, dys­
pnoea on exertion, orthopnoea, paroxysmal nocturnal dyspnoea, 
nocturia, fatigue, tiredness, increased time to recover following exer­
cise) or signs (weight gain, peripheral oedema, elevated jugular ven­
ous pulse, rales, hepatojugular reflux, third heart sound, or laterally 
≤40%
 (HFrEF)
Repeat evaluation
 regularly
41%–49%
 (HFmrEF)
≥50% 
(HFpEF)
Symptoms and/or 
signs for HF and/or 
abnormal ECG
Patient with diabetes (at risk for HF)
Determine aetiology and commence treatment
Y
Suspected HF
NT-proBNP ≥125 pg/mL 
or BNP ≥35 pg/mL
Y
Echocardiography with 
structural and/or 
functional cardiac abnormality
Y
HF confirmed
Define HF phenotype based on LVEF measurement
N
N
N
Figure 14 Diagnostic algorithm for heart failure in patients with diabetes. BNP, B-type natriuretic peptide; ECG, electrocardiogram; HF, heart failure; 
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection 
fraction; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
ESC Guidelines                                                                                                                                                                                          4087


<!-- PAGE 46 -->

### Page 46

displaced apical impulse) is recommended. For more details, see the 
chronic heart failure.445
If one or more of the symptoms or signs above is present, HF can be 
suspected, and the following diagnostic tests are recommended: 
• Measurement of natriuretic peptides is recommended, if available. 
Values below the following cut-offs make the diagnosis of HF unlikely 
and other diagnoses should be considered:483–485
○B-type natriuretic peptide (BNP) <35 pg/mL (threshold in AF: 
<105 pg/mL).
○NT-proBNP <125 pg/mL (threshold in AF: <365 pg/mL).
However, natriuretic peptide concentrations may be disproportion­
ately low in patients with obesity or in women, and disproportionately 
high in patients with advanced CKD, advanced age, or AF.486,487 Still, 
elevated concentrations support the diagnosis of HF and may guide fur­
ther cardiac investigation.488
• ECG is recommended to detect abnormalities such as AF, signs of LV 
hypertrophy, Q waves, or widened QRS, each of which may be a sign 
of HF.489
• Echocardiography is recommended to assess cardiac function includ­
ing LV function, chamber size, LV hypertrophy, regional wall motion 
abnormalities (that may suggest CAD), right ventricular function, es­
timated pulmonary pressure, valvular function, and markers of diastol­
ic dysfunction. Transthoracic echocardiography may be considered to 
detect HF in patients with diabetes if other risk factors arise.
• Chest X-ray is recommended to investigate other causes of dys­
pnoea (e.g. pulmonary disease). It may provide supportive evidence 
of HF (e.g. cardiomegaly, pulmonary congestion, pleural effusion).
• Routine blood tests (including full blood count, urea, creatinine, and 
electrolytes, thyroid and liver function, lipids, and iron status (ferritin 
and transferrin saturation) are recommended to differentiate HF 
from other conditions, to obtain prognostic information, and to 
guide potential therapy. Additional diagnostic tests should be consid­
ered if other specific diagnoses are suspected (e.g. amyloidosis).
• If HF is confirmed, additional diagnostic tests are recommended as 
summarized in the 2021 ESC Guidelines for the diagnosis and treat­
ment of acute and chronic heart failure.445
7.4. Treatment of heart failure in patients 
with diabetes
7.4.1. Treatment of heart failure with reduced  
ejection fraction
Treatment of HFrEF encompasses therapeutic lifestyle modifications, as 
well as pharmacological and device therapies with benefits confirmed in 
RCTs, in which 30–40% of patients had diabetes. Treatment effects of 
medications and devices for HFrEF have been consistently demon­
strated to not differ in patients with vs. without diabetes. Importantly, 
while the RR reductions are consistently similar for those with and with­
out diabetes, given the higher absolute HFrEF clinical risk associated with 
diabetes, the ARR in patients with diabetes is typically higher, yielding a 
lower NNT for benefit among patients with diabetes.
The cornerstone of treatment for HFrEF is pharmacotherapy along­
side lifestyle interventions, which should be implemented before con­
sidering device therapy. The recent 2021 ESC Guidelines for the 
diagnosis and treatment of acute and chronic heart failure recommend 
starting quadruple therapy (angiotensin receptor–neprilysin inhibitor 
[ARNI]/ACE-I, MRA, beta-blocker, SGLT2 inhibitor).445 These four 
foundational treatments should be initiated early, as much of the ben­
efits are seen within 30 days of starting treatment, and adding new 
drugs yields greater benefits than up-titrating existing drug classes. In 
the STRONG-HF (Safety, Tolerability and Efficacy of Rapid 
Optimization, Helped by NT-proBNP testinG, of Heart Failure 
Therapies) trial, 1078 patients with acute HF, 29% of whom had dia­
betes at baseline, were assigned to either high-intensity care with up- 
titration of treatments to 100% of recommended doses within 2 weeks 
of discharge or to usual care.490 Safety and tolerability were assessed at 
weeks 1, 2, 3, and 6 by full physical examination and laboratory assess­
ments of NT-proBNP, sodium, potassium, glucose, kidney function, and 
haemoglobin measures. The study was stopped early due to a greater 
than expected between-group difference. The primary endpoint, con­
sisting of 180-day re-admission to hospital due to HF or all-cause death, 
was significantly reduced in the high-intensity group, with a RR reduc­
tion of 34% (HR 0.66; 95% CI, 0.50–0.86) with similar incidences of ser­
ious adverse events. Of note, no sub-group analysis exists on patients 
with diabetes. Based on these data, an intensive strategy of early initi­
ation of evidence-based treatment (SGLT2 inhibitors, ARNI/ACE-Is, 
beta-blockers, and MRAs), with rapid up-titration to trial-defined target 
doses and frequent follow-up visits in the first 6 weeks following dis­
charge from a HF hospitalization is recommended to reduce 
re-admissions or mortality. The sequence of therapy initiation should 
be based on the individual patient phenotype taking into account BP, 
heart rhythm, and heart rate, as well as kidney function and risk of hy­
perkalaemia. While the start dose of SGLT2 inhibitors is the same as the 
target dose, ARNI/ACE-Is, beta-blockers, and MRAs should be started 
at low dose and up-titrated to the maximum tolerated dose. For more 
details on HFrEF therapy, please refer to the 2021 ESC Guidelines for 
the diagnosis and treatment of acute and chronic heart failure.445 The 
Recommendation Table 19 — Recommendations for 
heart failure screening and diagnosis in patients with 
diabetes
Recommendations
Classa
Levelb
Evaluating for heart failure
If HF is suspected, it is recommended to measure 
BNP/NT-proBNP.485
I
B
Systematic survey for HF symptoms and/or signs of 
HF is recommended at each clinical encounter in all 
patients with diabetes.
I
C
Diagnostic tests in all patients with suspected heart failure
12-lead ECG is recommended.
I
C
Transthoracic echocardiography is recommended.
I
C
Chest radiography (X-ray) is recommended.
I
C
Continued
Routine blood tests for comorbidities are 
recommended, including full blood count, urea, 
creatinine and electrolytes, thyroid function, lipids, 
and iron status (ferritin and TSAT).
I
C
© ESC 2023
ECG, electrocardiogram; HF, heart failure; BNP, B-type natriuretic peptide; NT-proBNP, 
N-terminal pro-B-type natriuretic peptide; TSAT, transferrin saturation. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 47 -->

### Page 47

specific characteristics for patients with diabetes are presented in the 
following sections.
7.4.1.1. Sodium–glucose co-transporter-2 inhibitors
Two randomized placebo-controlled trials have investigated the effect of 
an SGLT2 inhibitor compared with placebo added to optimal medical 
therapy (OMT) in patients with HFrEF with and without diabetes. The 
DAPA-HF (Dapagliflozin and Prevention of Adverse Outcomes in 
Heart Failure) trial included patients if they were in New York Heart 
Association (NYHA) class II–IV, had an LVEF ≤40% despite OMT, and 
had elevated NT-proBNP (in sinus rhythm ≥600 pg/mL, in AF 
≥900 mg/mL, or ≥400 pg/mL if they had been hospitalized for HF within 
the previous 12 months). Patients with T1DM or an eGFR <30 mL/min/ 
1.73 m2 were excluded. Therapy with dapagliflozin 10 mg o.d. vs. placebo 
reduced the risk of the primary outcome, a composite of worsening 
HF (hospitalization or an urgent visit resulting in i.v. therapy for HF) or 
CV death, by 26% (HR 0.74; 95% CI, 0.65–0.85). In addition, dapagliflozin 
reduced all-cause mortality (HR 0.83; 95% CI, 0.71–0.97) and improved 
symptoms, physical function, and quality of life in patients with 
HFrEF.491,492 All of the clinical benefits observed were independent of 
baseline diabetes status and background glucose-lowering therapy, 
and consistent across the spectrum of HbA1c.491,493 The EMPEROR- 
Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart 
Failure with Reduced Ejection Fraction) trial evaluated empagliflozin vs. 
placebo and included patients with HFrEF with and without diabetes, 
with NYHA class II–IV, and LVEF ≤40% despite OMT, an eGFR 
≥20 mL/min/1.73 m2, and an elevated NT-proBNP (EF ≤30% or EF 
≤40% and HF hospitalization within 12 months: NT-proBNP ≥600 pg/ 
mL; EF 31–35%: NT-proBNP ≥1000 pg/mL; EF 36–40%: NT-proBNP 
≥2500 pg/mL). Empagliflozin 10 mg o.d. reduced the risk of the primary 
outcome, a composite of CV death or HF hospitalization, by 25% vs. pla­
cebo (HR 0.75; 95% CI, 0.65–0.86).494 This effect was consistent across 
patients with and without diabetes at baseline.495 Treatment with empa­
gliflozin improved quality of life.496 A meta-analysis of the DAPA-HF and 
EMPEROR-Reduced trials showed a consistent reduction in HF hospital­
ization or CV death, CV death, and all-cause mortality by SGLT2-inhibitor 
treatment without significant heterogeneity between trials.497
The combined SGLT1 and -2 inhibitor sotagliflozin was investigated 
in patients with T2DM who were recently hospitalized for worsening 
HF, irrespective of their LVEF (SOLOIST-WHF [Effect of Sotagliflozin 
on Cardiovascular Events in Patients with Type 2 Diabetes Post 
Worsening Heart Failure] trial). Patients with an eGFR <30 mL/min/ 
1.73 m2 were excluded. Sotagliflozin significantly reduced the RR of the 
composite primary outcome (CV death, HF hospitalization, or urgent visit 
for HF) by 33% compared with placebo (HR 0.67; 95% CI, 0.52–0.85). The 
treatment effect was consistent across the spectrum of LVEF.189
Thus, the SGLT inhibitors dapagliflozin, empagliflozin, and sotagliflo­
zin are recommended, in addition to OMT (with an ARNI/ACE-I, beta- 
blocker, and MRA), in patients with HFrEF and diabetes to reduce CV 
death and HF hospitalization.
Three studies have investigated whether SGLT2 inhibitors can be safely 
started in patients hospitalized for acute HF. The EMPA-RESPONSE-AHF 
(Effects of Empagliflozin on Clinical Outcomes in Patients With Acute 
Decompensated Heart Failure) trial randomized 80 patients with acute 
HF with (approximately one-third) and without diabetes to either empa­
gliflozin or placebo for 30 days.498 Treatment with empagliflozin did not 
affect visual analogue scale dyspnoea, diuretic response, NT-proBNP le­
vels, or duration of hospital stay, but was safe, increased urinary output, 
and reduced a combined endpoint of worsening HF, re-hospitalization 
for HF, or death at 60 days compared with placebo. In the 
SOLOIST-WHF trial mentioned above, 1222 patients with T2DM re­
ceived sotagliflozin or placebo, with a median follow-up of 9 months (trial 
stopped prematurely).189 Sotagliflozin therapy, initiated before or shortly 
after discharge, resulted in significantly fewer deaths from CV causes and 
hospitalizations and urgent visits for HF than placebo, with no increase in 
acute kidney injury. The EMPULSE (A Study to Test the Effect of 
Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure) trial 
randomized 530 hospitalized patients with and without diabetes with a pri­
mary diagnosis of acute de novo or decompensated HF, regardless of LVEF 
when clinically stable, to receive either empagliflozin or placebo. More pa­
tients treated with empagliflozin had clinical benefit (win ratio 1.36; 95% CI, 
1.09–1.68) compared with placebo. This effect was consistent for acute de 
novo and decompensated chronic HF and was observed regardless of LVEF 
or the presence of diabetes.499In these trials, very few cases of euglycaemic 
diabetic ketoacidosis were reported; still, physicians treating patients with 
diabetes with SGLT2 inhibitors in this setting should be aware of this rare 
but potentially serious complication. Of note, misinterpreting eGFR 
changes can lead to inappropriate discontinuation of disease-modifying 
agents and should be avoided.
7.4.1.2. Angiotensin receptor–neprilysin inhibitor and 
angiotensin-converting enzyme inhibitors
The ARNI sacubitril/valsartan has shown superior efficacy to enalapril in 
reducing CV death and HF hospitalization in patients with HFrEF, with 
or without diabetes.471 Patients were up-titrated to 200 mg b.i.d. sacu­
bitril/valsartan within 2–4 weeks.471 The beneficial effect of sacubitril/ 
valsartan over enalapril was consistent for patients with and without 
diabetes and across the spectrum of baseline HbA1c.
ACE-Is were the first class of drugs shown to reduce mortality and 
morbidity and improve symptoms in patients with HFrEF.500 There is 
no difference in efficacy in patients with and without diabetes.501–503
As RAS inhibitors increase the risk of hyperkalaemia and may acutely 
compromise kidney function, routine surveillance of serum creatinine 
and potassium levels is advised.504,505 However, misinterpreting eGFR 
changes often leads to inappropriate discontinuation of disease- 
modifying agents and should be avoided.504–506
7.4.1.3. Mineralocorticoid receptor antagonists
The steroidal MRAs spironolactone or eplerenone reduce death and 
HF hospitalization in patients with HFrEF, with consistent results in pa­
tients with or without diabetes.507,508 Eplerenone is more specific for 
blocking aldosterone and, therefore, causes less gynaecomastia. 
Caution should be exercised when using MRAs in patients with im­
paired renal function and in those with serum potassium concentration 
>5.0 mmol/L. The non-steroidal MRA finerenone has not been investi­
gated in patients with HFrEF (Section 9).
7.4.1.4. Beta-blockers
Beta-blockers are effective at reducing all-cause death and hospitaliza­
tion for HF in patients with HFrEF, with or without diabetes.509–512
Treatment benefits strongly support using beta-blockers in patients 
with HFrEF and diabetes.
7.4.1.5. Angiotensin-II receptor blockers
The place of ARBs in managing HFrEF has changed over the last few 
years. They are now recommended for patients who cannot tolerate 
ARNI or ACE-Is because of serious side effects. ARBs have similar treat­
ment effects in patients with HFrEF with or without diabetes.513–515
ESC Guidelines                                                                                                                                                                                          4089


<!-- PAGE 48 -->

### Page 48

7.4.1.6. Ivabradine
Ivabradine slows heart rate by inhibiting the If channel in the sinus node 
and is therefore only effective in patients in sinus rhythm. Ivabradine re­
duced the combined endpoint of CV death or HF hospitalization irre­
spective of diabetes status.516
7.4.1.7. Hydralazine and isosorbide dinitrate
There is no evidence to support the use of this fixed-dose combination ther­
apy in all patients with HFrEF, but rather limited to self-identified Black pa­
tients as per product labelling. An RCT in self-identified Black patients with 
HFrEF showed that adding the combination of hydralazine and isosorbide di­
nitrate to conventional therapy (ACE-I, beta-blocker, MRA) reduced mortal­
ity and HF hospitalization in patients in NYHA class III–IV.517 The beneficial 
effects were consistent in patients with or without diabetes.518
7.4.1.8. Digoxin
Digoxin may reduce the risk of HF hospitalization in patients with 
HFrEF treated with ACE-Is, irrespective of diabetes status.519
7.4.1.9. Diuretics
Despite a lack of evidence for the efficacy of either thiazide or loop 
diuretics in reducing CV outcomes in patients with HF, diuretics pre­
vent and treat symptoms and signs of fluid congestion in patients 
with HF.520 Importantly, a judicious use of diuretic therapy including al­
ternating dosing over time is warranted.521
7.4.1.10. Device therapy and surgery
Device therapies (implantable cardioverter defibrillator [ICD], cardiac 
resynchronization therapy [CRT], and CRT with an implantable defib­
rillator [CRT-D]) have similar efficacies and risks in patients with HFrEF 
with or without diabetes.522–525 These therapies should be considered 
according to treatment guidelines in the HFrEF population. Heart trans­
plantation could be considered in end-stage HF, but a large, prospective 
study of transplanted patients indicated a decreased likelihood of 
10-year survival in those with diabetes.526
7.4.2. Treatment of heart failure with mildly reduced 
ejection fraction
As in other forms of HF, diuretics should be used to control conges­
tion.520 Results from retrospective analyses of RCTs in patients with 
Recommendation Table 20 — Recommendations for 
heart failure treatments in patients with heart failure 
with reduced ejection fraction and diabetes
Recommendations
Classa
Levelb
Recommendations for the pharmacological treatment 
indicated in patients with HFrEF (NYHA class II–IV) and 
diabetes
SGLT2 inhibitors (dapagliflozin, empagliflozin, or 
sotagliflozinc) are recommended in all patients with 
HFrEF and T2DM to reduce the risk of HF 
hospitalization and CV death.189,491,494,497
I
A
Sacubitril/valsartan or an ACE-I is recommended in 
all patients with HFrEF and diabetes to reduce the 
risk of HF hospitalization and death.471,501,502,527
I
A
Beta-blockersd are recommended in patients with 
HFrEF and diabetes to reduce the risk of HF 
hospitalization and death.509–512,528
I
A
Continued
MRAse are recommended in patients with HFrEF and 
diabetes to reduce the risk of HF hospitalization and 
death.507,529
I
A
An intensive strategy of early initiation of 
evidence-based treatment (SGLT2 inhibitors, ARNI/ 
ACE-Is, beta-blockers, and MRAs), with rapid 
up-titration to trial-defined target doses starting before 
discharge and with frequent follow-up visits in the first 6 
weeks following a HF hospitalization is recommended 
to reduce re-admissions or mortality.490
I
B
Recommendations for other treatments indicated in selected 
patients with HFrEF (NYHA class II–IV) and diabetes
Device therapy with an ICD, CRT-P, or CRT-D is 
recommended in patients with diabetes, as in the 
general population with HFrEF.522–525
I
A
ARBs are recommended in symptomatic patients 
with HFrEF and diabetes who do not tolerate 
sacubitril/valsartan or ACE-Is, to reduce the risk of 
HF hospitalization and CV death.513–515
I
A
Diuretics are recommended in patients with HFrEF 
and diabetes with signs and/or symptoms of fluid 
congestion to improve symptoms, exercise capacity, 
and HF hospitalization.520
I
C
Ivabradine should be considered to reduce the risk of 
HF hospitalization and CV death in patients with 
HFrEF and diabetes in sinus rhythm, with a resting 
heart rate ≥70 b.p.m., who remain symptomatic 
despite treatment with beta-blockers (maximum 
tolerated dose), ACE-Is/ARBs, and MRAs.516
IIa
B
Hydralazine and isosorbide dinitrate should be 
considered in self-identified Black patients with 
diabetes and LVEF ≤ 35% or with LVEF <45% 
combined with a dilated left ventricle in NYHA class 
III–IV despite treatment with an ACE-I (or ARNI), a 
beta-blocker, and an MRA, to reduce the risk of HF 
hospitalization and death.517,518
IIa
B
Digoxin may be considered in patients with 
symptomatic HFrEF in sinus rhythm despite 
treatment with sacubitril/valsartan or an ACE-I, a 
beta-blocker, and an MRA, to reduce the risk of 
hospitalization.519
IIb
B
© ESC 2023
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; 
ARNI, angiotensin receptor–neprilysin inhibitor; CRT-D, cardiac resynchronization 
therapy with defibrillator; CRT-P, cardiac resynchronization therapy-pacemaker; CV, 
cardiovascular; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ICD, 
implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; MRA, 
mineralocorticoid receptor antagonist; NYHA, New York Heart Association; SGLT2, 
sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cSotagliflozin is a dual SGLT1/2 inhibitor. 
dSustained-released metoprolol succinate, carvedilol, bisoprolol, and nebivolol. 
eSpironolactone or eplerenone.


<!-- PAGE 49 -->

### Page 49

HFrEF or HFpEF indicate that patients with a LVEF between 40–50% 
benefitted from similar therapies to those with LVEF ≤40%.445
However, to date, no definitive RCT has evaluated therapies exclusively 
in patients with HFmrEF. The best evidence so far derives from 
SGLT2-inhibitor studies. The EMPEROR-Preserved (Empagliflozin 
Outcome Trial in Patients with Chronic Heart Failure With 
Preserved Ejection Fraction) trial included patients with NYHA class 
II–IV, an LVEF >40%, and an elevated NT-proBNP (>300 pg/mL in si­
nus rhythm; >900 pg/mL in AF).530 Patients with an eGFR <20 mL/ 
min/1.73 m2 were excluded. Compared with placebo, empagliflozin re­
duced the risk of the primary outcome, a composite of CV death or 
hospitalization for HF, by 21%, which was mainly related to a 29% lower 
risk of hospitalization for HF.530 This effect was independent of diabetes 
status, and baseline HbA1c did not modify the effects on the primary 
outcome.531 The DELIVER (Dapagliflozin Evaluation to Improve the 
Lives of Patients with Preserved Ejection Fraction Heart Failure) trial in­
cluded 6263 patients with NYHA class II–IV, an LVEF >40%, an elevated 
NT-proBNP (>300 pg/mL in sinus rhythm; >600 pg/mL in AF), and an 
eGFR ≥25 mL/min/1.73 m2. Compared with placebo, dapagliflozin re­
duced the primary outcome, a composite of worsening HF or CV 
death, by 18%, which was mainly driven by a reduction in hospitalization 
for HF. This effect was independent of diabetes status.532 A 
meta-analysis including 12 251 participants from DELIVER and 
EMPEROR-Preserved showed that SGLT2 inhibitors, compared with 
placebo, reduced a composite of CV death and first hospitalization 
for HF (HR 0.80; 95% CI, 0.73–0.87), with consistent reductions in 
both components: CV death (HR 0.88; 95% CI, 0.77–1.00) and first 
hospitalization for HF (HR 0.74; 95% CI, 0.67–0.83).533
There is no specific trial evaluating ARNI in patients with HFmrEF. 
The PARAGON-HF trial, which included patients with EF ≥45%, al­
though missing its primary endpoint overall, showed significant 
EF-by-treatment interaction. Sacubitril/valsartan, compared with valsar­
tan, reduced the likelihood of the primary composite outcome of CV 
death and total HF hospitalization by 22% in those with an LVEF below 
or equal to the median of 57%.534
7.4.3. Treatment of heart failure with preserved 
ejection fraction
Over the past decade, several large RCTs failed to achieve statistical sig­
nificance with regard to effects on the primary outcomes in patients 
with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (can­
desartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG 
Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsar­
tan).477,534–538 As presented above in section 7.4.2, the SGLT2 inhibi­
tors empagliflozin and dapagliflozin both reduced the RR of the 
primary composite outcome, CV death or hospitalization for HF, by 
21% and 18%, respectively.530,532 The treatment effect on the incidence 
of the primary outcome did not differ between LVEF sub-groups nor 
between patients with and without diabetes.531–533 The combined 
SGLT1 and -2 inhibitor sotagliflozin was investigated in patients with 
T2DM who were recently hospitalized for worsening HF, irrespective 
of their LVEF (SOLOIST-WHF trial); 20.9% of the patients had an 
LVEF ≥50%. Sotagliflozin reduced the risk of the primary composite 
outcome of CV death, HF hospitalization, and urgent visit for HF by 
33%, with a consistent effect across the spectrum of baseline LVEF. 
However, the number of events in the HFpEF group was too small 
to draw any firm conclusion.189
Diuretic therapy should be used to reduce symptoms of conges­
tion.520 Loop diuretics are preferred, but low-dose thiazide diuretics 
might be useful for managing hypertension. For treating comorbidities 
alongside HFpEF, refer to the 2021 ESC Guidelines for the diagnosis 
and treatment of acute and chronic heart failure.445
7.5. Safety profile of glucose-lowering 
agents in patients with heart failure and 
diabetes
For glycaemic targets in patients with diabetes, please refer to Section 
5.2.
7.5.1. Sodium–glucose co-transporter-2 inhibitors
Sodium–glucose co-transporter-2 inhibitors (see also Section 7.4.1.1) 
have been investigated in different populations with diabetes, ranging 
from patients with ASCVD or multiple ASCVD risk factors to patients 
recently hospitalized for worsening HF, with increasing ARR for 
HF-related outcomes according to higher patient risk (Figure 15; 
Supplementary data online, Table S15).
As outlined above, in dedicated HF trials, dapagliflozin and empagli­
flozin reduced CV death and HF hospitalization in patients with 
HFrEF with or without diabetes, and sotagliflozin reduced CV death 
and HF hospitalization in patients with T2DM and recent hospitalization 
for HF of any aetiology.189,491,494 Moreover, empagliflozin and dapagli­
flozin reduced the risk of CV death or HF hospitalization in patients 
with HFmrEF or HFpEF.530,532
While the EMPA-REG OUTCOME (empagliflozin) and VERTIS CV 
(ertugliflozin) trials investigated patients with T2DM and established 
ASCVD risk, the CANVAS Programme (canagliflozin) and 
DECLARE-TIMI 58 trial (dapagliflozin) included patients with 
established ASCVD or multiple ASCVD risk factors. In all of these 
placebo-controlled CVOTs of SGLT2 inhibitors, only a small proportion 
of patients had a baseline history of HF. Empagliflozin reduced the risk of 
HF hospitalization by 35% in patients with and without previous HF.71
Canagliflozin also significantly reduced the risk of HF hospitalization 
by 33%.151 Dapagliflozin significantly reduced the combined endpoint 
of CV death or HF hospitalization, a result driven mainly by lower rates 
of HF hospitalization.152 This effect was independent of pre-existing 
HF.540 Ertugliflozin did not reduce the combined endpoint of CV death 
or HF hospitalization, although there was a significant reduction in HF 
hospitalization and repeated hospitalizations.154,541
Recommendation Table 21 — Recommendations for 
heart failure treatments in patients with diabetes and 
left ventricular ejection fraction over 40%
Recommendations
Classa
Levelb
Empagliflozin or dapagliflozin are recommended in 
patients with T2DM and LVEF >40% (HFmrEF and 
HFpEF) to reduce the risk of HF hospitalization or 
CV death.530–533
I
A
Diuretics are recommended in patients with HFpEF 
or HFmrEF and diabetes with signs and/or symptoms 
of fluid congestion to improve symptoms, exercise 
capacity, and HF hospitalization.520
I
C
© ESC 2023
CV, cardiovascular disease; HF, heart failure; HFmrEF, heart failure with mildly reduced 
ejection fraction; HFpEF, heart failure with preserved ejection fraction; LVEF, left 
ventricular ejection fraction; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4091


<!-- PAGE 50 -->

### Page 50

In addition, four trials investigated the effect of SGLT2 inhibition in pa­
tients with CKD: CREDENCE (with canagliflozin) and SCORED (with so­
tagliflozin) in patients with T2DM; DAPA-CKD (with dapagliflozin) and 
EMPA-KIDNEY (with empagliflozin) in patients with and without diabetes. 
In these patients at high risk of HF, a consistent risk reduction of CV death 
or HF hospitalization was observed ranging from 23% to 31%.150,153,542,543
A meta-analysis of six outcome trials of four SGLT2 inhibitors in pa­
tients with T2DM (EMPA-REG OUTCOME, CANVAS Programme 
[two trials], DECLARE-TIMI-58, CREDENCE, VERTIS CV) demon­
strated a 32% reduction in HF hospitalization, with no heterogeneity 
between trials; the effect on HF hospitalization was independent of 
ASCVD.155 Thus, SGLT2 inhibitors are recommended for patients 
with T2DM and multiple ASCVD risk factors or established ASCVD 
to reduce HF hospitalization.
7.5.2. Glucagon-like peptide-1 receptor agonists
Eight CVOTs have been completed with GLP-1 RAs in patients with 
T2DM, and the prevalence of established HF in these trials ranged 
from 9% to 24%. Most GLP-1 RAs had a neutral effect on risk of HF 
hospitalization in the placebo-controlled RCTs assessing CV safety of 
glucose-lowering medications in patients with T2DM with or at high 
risk of ASCVD, despite increasing heart rate by 3–5 b.p.m.70,72,158– 
163,544 In addition, two meta-analyses including eight trials comprising 
60 080 patients found HF hospitalization to be reduced by 10–11% 
by GLP-1 RA compared with placebo.164,545
The AMPLITUDE-O trial, comparing efpeglenatide with placebo, 
showed a nominally significant benefit on hospitalization for HF. The 
trial included stratified randomization by baseline or anticipated use 
of SGLT2 inhibitors and had the highest prevalence (15.2%) of 
14
12
10
8
6
4
2
0
1
2
4
8
16
32
Absolute risk reduction with
SGLT2 inhibitors (per 100 pt-yrs)
DECLARE-TIMI-58
CANVAS
EMPA-KIDNEY
VERTIS-CV
EMPA-REG OUTCOME
CREDENCE
DELIVER
EMPEROR-Preserved
DAPA-CKD
Rate of first failure hospitalization or cardiovascular death in the placedo arm (per 100 pt-yrs)
DAPA-HF
EMPEROR-Reduced
SOLOIST-WHFa
NNT: 96–400
RRR: 12%–34%
NNT: 72–125
RRR: 29%–31%
NNT: 59
RRR: 21%
NNT: 21–36
RRR: 25%
NNT: 10
RRR: 129%
ARR: 0.25–1.04
per 100 pt-yrs
ARR: 0.80–1.39
per 100 pt-yrs
ARR: 1.8
per 100 pt-yrs
ARR: 3.9–5.2
per 100 pt-yrs
ARR: 10.4
per 100 pt-yrs
High risk T2DM
CKD
Chronic HFpEF
Chronic HFrEF
Worsening HF
Figure 15 Absolute risk reduction with sodium–glucose co-transporter-2 inhibitors in relation to patient risk based on rate of heart failure-related end­
points in the placebo arm of the respective trials. ARR, absolute risk reduction; CKD, chronic kidney disease; HF, heart failure; HFpEF, heart failure with 
preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; NNT, number needed to treat; pt-yrs, patient-years; RRR, relative risk re­
duction; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. Bubble plots demonstrate the consistent reductions in time to cardio­
vascular mortality or first HF hospitalization with SGLT2 inhibitors across all trials, with a greater ARR in patients at higher risk. The size of the bubble 
represents the sample size of the trial. NNT is estimated from the ARR. aEvent rates of first HF hospitalization or cardiovascular mortality were not reported 
in SOLOIST-WHF.189 Figure adapted from Butler et al. 2021.539


<!-- PAGE 51 -->

### Page 51

SGLT2 inhibitor use among GLP-1 RA trials. Data from an exploratory 
analysis of the AMPLITUDE-O trial suggest that the efficacy and safety 
of efpeglenatide was independent of concurrent SGLT2 inhibitor use, 
including HF hospitalization.546
Only three small RCTs of GLP-1 RAs have been conducted in pa­
tients with HFrEF.547 The LIVE trial randomly assigned 241 patients 
with chronic, stable HFrEF with or without DM to placebo or liraglu­
tide.548 While no changes in LVEF, quality of life, or functional class 
were noted after 24 weeks of treatment, more serious adverse cardiac 
events (sustained ventricular tachycardia, AF requiring intervention, and 
aggravation of IHD; 12 [10%] vs. 3 [3%] for liraglutide and placebo, re­
spectively; P = 0.04) occurred in the liraglutide group. The FIGHT trial 
(Functional Impact of GLP1 for HF Treatment) randomly assigned 300 
patients with and without DM with HFrEF and a recent hospitalization 
for HF to liraglutide or placebo. Following 180 days of treatment, the 
primary outcome (time to death, time to re-hospitalization for HF, 
and time-averaged proportional change in NT-proBNP level from base­
line to 180 days) was not different between groups. In addition, there 
was a non-significant between-group difference in the number of re- 
hospitalizations for HF (63 [41%] in the liraglutide group vs. 50 [34%] 
in the placebo group; HR 1.30, 95% CI, 0.89–1.88; P = 0.17).549 The 
third trial was a small (n = 82), randomized study evaluating 12 weeks 
of albiglutide vs. placebo in patients with HFrEF. No significant differ­
ences were seen in LVEF, 6 min walk test, myocardial glucose utilization, 
or oxygen use.550 The study was too small and too short to evaluate 
clinical outcomes.
7.5.3. Dipeptidyl peptidase-4 inhibitors
Four DPP-4 inhibitors (sitagliptin, saxagliptin, alogliptin, and linagliptin) 
have been examined in dedicated placebo-controlled CV safety trials 
in patients with T2DM with or at high risk of ASCVD. Saxagliptin signifi­
cantly increased the risk of HF hospitalization172 and is not recom­
mended in patients with DM with or at increased risk of HF. 
Alogliptin was associated with a non-significant trend towards an in­
crease in HF hospitalization.173 Sitagliptin and linagliptin had a neutral 
effect.174,178–180 Vildagliptin, not tested in a CVOT, had no significant 
effect on LVEF but led to an increase in LV volumes in a small trial.551
7.5.4. Insulin
In patients with T2DM and advanced HF, insulin use is independently 
associated with a significantly worse prognosis.552 Two basal insulins 
have been formally evaluated in dedicated CV outcomes trials. In the 
ORIGIN trial, 12 537 patients (mean age 63.5 years) at high CV risk, 
with IFG, IGT, or T2DM, were randomized to insulin glargine titrated 
to a fasting blood glucose level of ≤5.3 mmol/L (≤95 mg/dL) or stand­
ard care. After a median follow-up of 6.2 years, insulin glargine was 
neutral in its effect on HF hospitalizations.553 The DEVOTE rando­
mized trial, a double-blind comparison of the ultra-long-acting, once- 
daily insulin degludec vs. insulin glargine U100, enrolled 7637 patients 
with T2DM with ASCVD or at high CV risk.181 Treatment with insulin 
degludec vs. insulin glargine did not differ with respect to HF hospital­
ization; prior HF was independently associated with future HF 
hospitalization.554
7.5.5. Metformin
Metformin is suggested to be safe at all stages of HF with preserved or 
stable, moderately reduced kidney function (i.e. eGFR >30 mL/min/ 
1.73 m2). It is associated with a lower risk of death and HF hospitaliza­
tion compared with insulin and sulphonylureas in observational studies, 
though dedicated randomized, controlled, CVOTs evaluating safety and 
efficacy of metformin have not been conducted.555–557 Concerns re­
garding lactic acidosis have not been substantiated.558,559
7.5.6. Sulphonylureas
Data on the effects of sulphonylureas on HF are inconsistent. Data 
from two retrospective cohort studies, including 111 971 patients 
with diabetes, suggest an adverse safety profile showing ∼20–60% high­
er death rate and ∼20–30% higher risk of HF compared with metfor­
min.560,561 However, in the UKPDS, NAVIGATOR (Nateglinide And 
Valsartan in Impaired Glucose Tolerance Outcomes Research), and 
ADOPT trials, there were no increased HF signals.127,562–564 In add­
ition, data from the CAROLINA trial comparing linagliptin (shown to 
not increase the risk of HF hospitalization vs. placebo in the 
CARMELINA trial) vs. glimepiride did not show an elevated risk of 
HF hospitalization by this sulphonylurea.179
7.5.7. Thiazolidinediones
Thiazolidinediones increased the risk of HF hospitalization in several 
trials and are not recommended in patients with diabetes and symp­
tomatic HF.165,565–567
7.5.8. Special consideration: hypoglycaemia and risk 
of heart failure hospitalization
Although severe hypoglycaemic events were associated with higher HF 
hospitalization in some but not all studies, there is no clear evidence for 
causality.139,140,554,568Recent analyses have demonstrated bi-directional 
associations between hypoglycaemia and CV outcomes, including HF, 
suggesting that this is not causal, but rather reflects underlying frailty 
and risk of adverse outcomes.139,140
Figure 16 summarizes glucose-lowering treatment of patients with 
HF and T2DM.
ESC Guidelines                                                                                                                                                                                          4093


<!-- PAGE 52 -->

### Page 52

Recommendation Table 22 — Recommendations for glucose-lowering medications in patients with type 2 diabetes 
with and without heart failure
Recommendations
Classa
Levelb
Recommendations for glucose-lowering medications to reduce heart failure hospitalization in patients with type 2 diabetes with or 
without existing heart failure
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, or sotagliflozinc) are recommended in patients with T2DM with 
multiple ASCVD risk factors or established ASCVD to reduce the risk of HF hospitalization.71,150–153,541
I
A
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozinc) are recommended in patients with T2DM and HFrEF to reduce the risk of 
HF hospitalization and CV death.189,491,494,497
I
A
Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF 
hospitalization or CV death.530,532,533
I
A
Recommendations for additional glucose-lowering agents with safety demonstrated for heart failure hospitalization in patients with 
type 2 diabetes if additional glucose control is needed
GLP-1 RAs (lixisenatide, liraglutide, semaglutide, exenatide ER, dulaglutide, efpeglenatide) have a neutral effect on the risk of HF 
hospitalization, and should be considered for glucose-lowering treatment in patients with T2DM at risk of or with HF.70,158–164,545
IIa
A
DPP-4 inhibitors (sitagliptin and linagliptin) have a neutral effect on the risk of HF hospitalization, and should be considered for 
glucose-lowering treatment in patients with T2DM at risk of or with HF.174,179,180
IIa
A
Basal insulins (glargine and degludec) have a neutral effect on the risk of HF hospitalization and should be considered for glucose-lowering 
treatment in patients with T2DM at risk of or with HF.553,554
IIa
B
Metformin should be considered for glucose-lowering treatment in patients with T2DM and HF.d,555,556,558
IIa
B
Recommendations for glucose-lowering medications with an increased risk of heart failure hospitalization in patients with type 2 
diabetes
Pioglitazone is associated with an increased risk of incident HF in patients with diabetes and is not recommended for glucose-lowering 
treatment in patients at risk of HF (or with previous HF).165,566
III
A
The DPP-4 inhibitor saxagliptin is associated with an increased risk of HF hospitalization in patients with diabetes and is not recommended 
for glucose-lowering treatment in patients at risk of HF (or with previous HF).172
III
B
Recommendations for special consideration
It is recommended to switch glucose-lowering treatment from agents without proven CV benefit or proven safety to agents with proven 
CV benefit.e
I
C
© ESC 2023
ASCVD, atherosclerotic cardiovascular disease; CV, cardiovascular; DPP-4, dipeptidyl peptidase-4; ER, extended release; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HF, heart failure; 
HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular 
ejection fraction; MACE, major adverse cardiovascular events; s.c., subcutaneous; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence. 
cSotagliflozin is a dual SGLT1/2 inhibitor. 
dChronic and stable HF. 
eAgents with proven benefit: SGLT2 inhibitors: empagliflozin, canagliflozin, dapagliflozin, sotagliflozinc; GLP-1 RAs: liraglutide, semaglutide s.c., dulaglutide, efpeglenatide. In the VERTIS CV 
trial, ertugliflozin did not reduce the primary endpoint (three-point MACE) nor the key secondary endpoint (CV death or HF hospitalization), but reduced HF hospitalization as a secondary 
exploratory endpoint.


<!-- PAGE 53 -->

### Page 53

To reduce HF-related outcomesa in all patients with T2DM
and HF (HFpEF, HFmrEF, HFrEF)
SGLT2 inhibitorb
(Class I)
Independent of HbA1c
Independent of concomitant glucose-lowering medication
For additional glucose control
Metformin
(Class lla)
Insulin glargine
Insulin degludec
(Class lla)
Sitagliptin
Linagliptin
(Class lla)
GLP-1 RAc
(Class lla)
Other glucose-lowering agents with neutral effects on HF
in CVOTs should be considered
Pioglitazone
(Class III)
Saxagliptin
(Class Ill)
Other glucose-lowering agents with increased risk for HF
hospitalization in CVOTs are not recommended
Figure 16 Glucose-lowering treatment of patients with heart failure and type 2 diabetes. CVOT, cardiovascular outcomes trial; DPP-4, dipeptidyl 
peptidase-4; GLP-1 RA, glucagon-like peptide-1 receptor agonist; Hb1Ac, glycated haemoglobin; HF, heart failure; HFmrEF, heart failure with mildly reduced 
ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SGLT2, sodium–glucose 
co-transporter-2; T2DM, type 2 diabetes mellitus. aThis includes HF hospitalization or CV death. bEmpagliflozin, dapagliflozin, or sotagliflozin in patients 
with HFrEF, empagliflozin or dapagliflozin in patients with HFpEF and HFmrEF. cPreferred in patients with atherosclerotic cardiovascular disease and if weight 
reduction is needed; do not combine with DPP-4 inhibitors.
ESC Guidelines                                                                                                                                                                                          4095


<!-- PAGE 54 -->

### Page 54

### 8 Arrhythmias: atrial fibrillation,

ventricular arrhythmias, and 
sudden cardiac death and diabetes
Diabetes may increase the risk of cardiac arrhythmias via several fac­
tors including: associated CV risk factors (e.g. hypertension), CVD 
(i.e. CAD, prior MI, HF, or stroke), and diabetes-associated factors 
such as glucose control or diabetic neuropathy.157,569–572 The risk 
of cardiac arrhythmias or sudden cardiac death (SCD) in patients 
with diabetes is most often related to the presence and severity of 
underlying CVD, but diabetes-related factors may induce arrhyth­
mias independently of CV comorbidities.157,573–577 The risk of con­
duction disturbances and need for pacemaker therapy may also be 
higher in patients with T2DM than in controls, although the general 
management for these issues should not differ from that for other 
patients.578,579
8.1. Atrial fibrillation and diabetes
8.1.1. Epidemiology of atrial fibrillation and its 
association with diabetes
Patients with T1DM or T2DM may exhibit atrial electrical and 
structural remodelling associated with increased vulnerability for 
AF.580–583 Many epidemiological studies have reported an association 
of diabetes (mainly T2DM) with incident AF.584,585 Recent, large ana­
lyses confirmed that T1DM was also independently associated with a 
higher incidence of AF.586–588 Diabetes duration has also been asso­
ciated with AF; each year with diabetes conferred a 3% increase in 
the risk of AF.589 A meta-analysis of 11 studies with 108 703 AF cases 
in 1 686 097 patients showed a 40% greater risk of AF in the presence 
of diabetes. The effect was attenuated but still significant after adjusting 
for other risk factors (RR 1.24; 95% CI, 1.06–1.44).590 Although men 
have higher absolute rates for incidence of AF, the relative rates of in­
cident AF associated with diabetes are higher in women than in men for 
both T1DM and T2DM.586–588
Diabetes and AF frequently co-exist, and when this occurs, there is a 
substantially higher risk of all-cause death, CV death, stroke, kidney dis­
ease, and HF, regardless of diabetes type.541,577,591–596 Risk factors 
commonly associated with diabetes and AF (and not fully dissociable, 
e.g. hypertension and obesity) are also likely to worsen prognosis. In 
several observational studies, the age-adjusted association of diabetes 
with incident AF was no longer significant after multiple adjustments 
for hypertension, CV comorbidity, BMI, or obesity, thus suggesting 
that strategies for preventing AF in patients with diabetes should focus 
on controlling diabetes-associated comorbidities (especially weight, 
sleep apnoea, and BP).597–600
Intensive glucose lowering (target HbA1c <6.0%) has been asso­
ciated with similar incident AF rates than a less-stringent approach 
(HbA1c <8.0%).601 The rate of new-onset AF may, however, be af­
fected by diabetes therapy.577 The impact of anti-hyperglycaemic 
agents on the risk of AF is still debated. It has been suggested that met­
formin and pioglitazone may reduce the risk of AF.602 SGLT2 inhibitors, 
compared with placebo, were associated with more new-onset AF 
cases in EMPA-REG OUTCOME (empagliflozin vs. placebo), but fewer 
incident AF cases in CANVAS (canagliflozin vs. placebo) and 
DECLARE-TIMI 58 (dapagliflozin vs. placebo).71,151,153,603 In the 
EMPA-REG OUTCOME trial, empagliflozin, compared with placebo, 
reduced CV death or HF hospitalization consistently in patients with 
diabetes with or without AF (Pint = 0.56).604 It has recently been re­
ported that finerenone may reduce new-onset AF in patients with 
T2DM and CKD.605 This is consistent with results obtained with other 
MRAs in HF.508,606
In the ADVANCE study, patients with diabetes and AF (∼8%) had 
higher risks of all-cause death, CV death, major cerebrovascular events, 
and HF compared with patients with diabetes without AF. Lowering BP 
resulted in similar RR reduction in all-cause and CV death but, due to 
their higher risk of these events, the absolute benefits from BP control 
was much greater in patients with AF.607 In the VALUE (Valsartan 
Antihypertensive Long-term Use Evaluation) trial, hypertensive pa­
tients with new-onset diabetes had higher rates of new-onset AF com­
pared with patients without diabetes, and were at a higher risk of HF.608
Hence, AF in patients with diabetes should be viewed as a marker of 
adverse outcome, which should prompt aggressive management of all 
concomitant risk factors.609
8.1.2. Screening and managing atrial fibrillation in 
patients with diabetes
Detecting AF in patients with diabetes has clinical consequences be­
cause the risk of stroke is markedly higher in these patients. In the ab­
sence of other comorbidities, the annual risk of stroke can be 
estimated at 2.2% per year in isolated diabetes.610 Since asymptomatic 
(silent) AF is not uncommon, patients with diabetes should be oppor­
tunistically screened for AF by palpating pulse or by ECG.611 Patients 
with diabetes at high risk of AF would likely benefit from an active 
screening for AF, but more data are needed to define optimal AF 
screening strategies also including modern equipment, such as wear­
able digital devices in patients with diabetes (Supplementary data 
online, Table S16).612,613 Before starting treatment, clinical AF should


<!-- PAGE 55 -->

### Page 55

Screening results
ECG results
Systematic screening results
Consider repeated screening
No definite AF but symptoms or high risk
 of AF or high risk of ischaemic stroke
(CHA2DS2-VASc score >1 in men or >2 in women with diabetes)
Suspicion of AF
Atrial fibrillation confirmed
No atrial fibrillation
12-lead ECG
Symptomatic patient e.g. palpitations, dyspnoea
Asymptomatic patient
Opportunistic screening
 (e.g. pulse palpation, ECG)
(Class I)
Yearly opportunistic
 screening
Systematic screening:
repeated surface ECG, Holter ECG,
patient-activated or wearable device
Start treatment with OAC
(NOACs preferred over VKA)
According to CHA2DS2-VASc score
Screening and treatment of AF in patients with diabetes by healthcare professionals
Negative
Negative
Negative
Positive
Positive
Positive
Figure 17 Screening for atrial fibrillation in patients with diabetes. AF, atrial fibrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 
years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65–74 years, Sex category (female); ECG, electro­
cardiogram; OAC, oral anticoagulant; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
ESC Guidelines                                                                                                                                                                                          4097


<!-- PAGE 56 -->

### Page 56

be well documented using surface-lead ECG (≥30 s showing heart 
rhythm with no discernible repeating P waves and irregular R–R inter­
vals 
when 
atrioventricular 
conduction 
is 
not 
impaired; 
Figure 17).600,614
In patients with diabetes and established AF, controlling the ventricu­
lar rate is recommended to decrease symptoms and prevent AF-related 
complications, while asymptomatic patients mainly need thrombo- 
embolic prevention. In those with persistent symptoms despite ad­
equate rate control, or in those with LV dysfunction attributable to 
poorly controlled high ventricular rate, rhythm-control strategies 
should be attempted, including cardioversion, antiarrhythmic drug use, 
and catheter ablation, which is the general management in this setting 
whether diabetes is present or not.600,615–617 For details on managing 
AF, please refer to the 2020 ESC/EACTS Guidelines for the diagnosis 
and management of atrial fibrillation and recent European Heart 
Rhythm Association scientific documents.577,600,613
8.1.3. Preventing stroke in patients with atrial 
fibrillation and diabetes
Stratifying AF stroke risk with diabetes should use the established 
CHA2DS2-VASc (Congestive HF, Hypertension, Age ≥75 years [2 
points], Diabetes mellitus, Stroke/transient ischaemic attack [2 points], 
Vascular disease, Age [65–74 years], Sex category [female]) score; fol­
lowing stratification, stroke prevention (i.e. OAC) should be started in 
patients with >1 risk factor.600,618 The score is likely higher in patients 
with diabetes due to the common association with other risk factors 
for stroke, such as arterial hypertension, age over 65 or 75 years, asso­
ciated vascular disease, or HF. Several studies found that diabetes inde­
pendently predicted stroke in patients with AF.619 However, diabetes 
may not be a significant risk factor for stroke in the elderly.620 The 
Stroke in AF Working Group attributed a RR of 1.7 (95% CI, 1.4– 
2.0) for stroke in patients with AF and diabetes, as well as an absolute 
stroke risk of 2–3.5% per year for non-anticoagulated patients in the 
same population.621 Diabetes is probably not the most potent inde­
pendent risk factor for stroke in AF compared with the other items 
in the CHA2DS2-VASc score, but it is included in this risk-stratification 
tool, giving a point alongside most other items.600,618,622–624 The in­
creased risk of stroke associated with AF and diabetes is similar in 
T1DM and T2DM except perhaps a slightly increased risk in T2DM 
compared with T1DM in patients <65 years of age. The risk of stroke 
in patients with diabetes and AF may increase with longer diabetes dur­
ation, increasing levels of HbA1c, and more diabetes-related comorbid­
ities, such as nephropathy and retinopathy.625,626
As an OAC is being initiated, a clinical bleeding risk score, such as the 
HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, 
Bleeding history or predisposition, Labile international normalized ra­
tio, Elderly [>65 years], Drugs/alcohol concomitantly) score, should 
be used to identify patients at risk of bleeding, and importantly, to ad­
dress the potentially reversible bleeding risk factors (that should be 
considered in all patients, irrespective of HAS-BLED score).600 Due 
to the increased risk of several CV adverse events in patients with dia­
betes, a similar RR reduction with OACs generally translates into great­
er ARR in the diabetes population.577 The beneficial efficacy and safety 
of NOACs compared with warfarin seem conserved in patients with 
AF and diabetes, irrespective of their baseline stroke risk or the pres­
ence of other CV risk factors.577,627–629
8.2. Ventricular arrhythmias and risk of 
sudden cardiac death and diabetes
Compared with the general population, patients with diabetes have an 
increased risk of both SCD and non-SCD.575,615,644–646 In a 
meta-analysis of 14 studies involving 346 356 participants and 5647 
SCD cases, the risk of SCD was two-fold higher in patients with dia­
betes compared with patients without diabetes (adjusted HR 2.25; 
95% CI, 1.70–2.97).647 However, patients with diabetes also exhibited 
a nearly three-fold greater risk of non-SCD than patients without 
Recommendation Table 23 — Recommendations for 
atrial fibrillation in patients with diabetes
Recommendations
Classa
Levelb
Screening
Opportunistic screening for AF by pulse taking or 
ECG is recommended in patients ≥65 years of 
age.577,611,630,631
I
B
Opportunistic screening for AF by pulse taking or 
ECG is recommended in patients with diabetes <65 
years of age (particularly when other risk factors are 
present) because patients with diabetes exhibit a 
higher AF frequency at a younger age.577,611,631,632
I
C
Systematic ECG screening should be considered to 
detect AF in patients aged ≥75 years, or those at high 
risk of stroke.577,633–635
IIa
B
Anticoagulation
Oral anticoagulation is recommended for preventing 
stroke in patients with AF and diabetes and with at 
least one additional (CHA2DS2-VASc) risk factor for 
stroke.636
I
A
For preventing stroke in AF, NOACs are 
recommended in preference to VKAs, with the 
exception of patients with mechanical valve 
prostheses or moderate to severe mitral stenosis.637
I
A
Oral anticoagulation should be considered for 
preventing stroke in patients with AF and diabetes 
but no other CHA2DS2-VASc risk factor for stroke. 
This includes patients with T1DM or T2DM <65 
years old.638–640
IIa
B
Use of a formal, structured, bleeding risk score 
(HAS-BLED score) should be considered to identify 
modifiable and non-modifiable risk factors for 
bleeding in patients with diabetes and AF, and to 
identify patients in need of closer follow-up.641–643
IIa
B
© ESC 2023
AF, atrial fibrillation; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥ 75 
years (2 points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), 
Vascular disease, Age 65–74 years, Sex category (female); ECG, electrocardiogram; 
HAS-BLED, Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or 
predisposition, Labile international normalized ratio, Elderly (>65 years), Drugs/alcohol 
concomitantly; NOAC, non-vitamin K antagonist oral anticoagulant; T1DM, type 1 
diabetes mellitus; T2DM, type 2 diabetes mellitus; VKA, vitamin K antagonist. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 57 -->

### Page 57

diabetes (adjusted HR 2.90; 95% CI, 1.89–4.46).646 Men at all ages have 
a higher risk of SCD than women, but in the presence of diabetes, the 
risk of SCD is higher in both men and women.575,615,644–646,648
Both hyperglycaemia and hypoglycaemia are independently asso­
ciated 
with 
increased 
risk 
of 
ventricular 
arrhythmias.649
Insulin-induced hypoglycaemia has been associated with nocturnal 
death (also called ‘dead-in-bed syndrome’) in T1DM, and arrhythmic 
deaths were reported in several T2DM trials.187,576,650–654 Diabetic kid­
ney disease might also play a role in the arrhythmia-associated mechan­
ism of sudden death in this setting.655
Hypoglycaemia-associated arrhythmias are difficult to document, but 
observational studies using CGM and Holter monitoring in small T2DM 
cohorts showed that hypoglycaemic episodes were common, often 
asymptomatic, and associated with various arrhythmias.656,657
Compared with daytime hypoglycaemia, nocturnal episodes were 
more common and associated with a greater risk of bradycardia or at­
rial ectopy, while ventricular arrhythmias were equally common.656,657
The use of antiarrhythmic drugs should follow the general principles 
and precautions related to pharmacological treatment of cardiac ar­
rhythmias.600,658 In patients with diabetes and an ICD, there is an in­
creased risk of death in those who have appropriate therapy 
compared to those who do not.659 In contrast, patients with diabetes 
may have a lower risk of inappropriate therapy or ICD shock, since 
they may be more sedentary with consequently less frequent 
exercise-induced sinus tachycardia and also lower incidence of lead 
fracture.600,658,659
Observational studies have reported significant corrected QT (QTc) 
interval prolongation possibly associated with microvascular complica­
tions, atypical patterns of microvolt T-wave alternans, altered heart 
rate variability, or heart rate turbulence in patients with diabetes, but 
none of these tests should routinely be used to stratify the risk of ven­
tricular arrhythmias or SCD in clinical practice.658,660–668 There may 
also be a direct effect of both hyper- and hypoglycaemia on QTc inter­
val.669–671 The mechanisms by which hyperglycaemia may produce ven­
tricular instability may be increased sympathetic activity, increased 
cytosolic calcium content in myocytes, or both.672 The risk of cardiac 
events is usually related to the underlying heart disease rather than ven­
tricular premature beats.669–671
There is no diabetes-specific protocol for SCD screening, but all pa­
tients diagnosed with diabetes should undergo regular evaluation for 
CV risk factors or structural heart disease.48,576,658 Patients with dia­
betes and symptoms suggestive of cardiac arrhythmias (e.g. palpitations, 
pre-syncope, or syncope) should undergo further detailed diagnostic 
assessment.576 Patients with diabetes and frequent premature ventricu­
lar beats, episodes of non-sustained ventricular tachycardia, or symp­
toms suggestive of HF should be examined for the presence of an 
underlying structural heart disease and their eligibility for an ICD should 
be assessed; this is a general principle in managing patients with HF, ir­
respective of diabetes status.658 In case of sustained ventricular arrhyth­
mias, diagnosing underlying structural heart disease with imaging 
techniques and coronary angiography is usually needed if no obvious 
trigger factors, such as electrolyte imbalance, can be identified.48,576,658
Although cardiac arrhythmias were not specifically investigated in ei­
ther the LEADER or the EMPA-REG OUTCOME trials, an antiarrhyth­
mic effect of these drugs (perhaps mediated by glucagon-release 
stimulation or increased blood ketone bodies, which may have 
sympathico-suppressive effects) has been hypothesized to contribute 
to the reduced risk of CV death.71,72 In the DAPA-HF trial, dapagliflozin 
reduced the risk of the composite outcome of serious ventricular ar­
rhythmia, resuscitated cardiac arrest, or sudden death by 21% in 
patients with HFrEF, compared with placebo.673 The benefit was mainly 
observed >9 months post-randomization, suggesting that the beneficial 
effects of dapagliflozin require time to develop and may involve cellular 
mechanisms that slow the progression of HFrEF.674 However, a recent 
meta-analysis indicated that SGLT2 inhibition was not associated with 
an overall lower risk of SCD or ventricular arrhythmias in patients 
with T2DM and/or HF and/or CKD, although the point estimates sug­
gested potential benefits.675
9. Chronic kidney disease and 
diabetes
9.1. Chronic kidney disease definitions, 
staging, and screening
Chronic kidney disease has a major effect on global morbidity and mor­
tality.676 CKD is defined as abnormalities of kidney structure or func­
tion, present for >3 months, with implications for health. It is staged 
primarily by categories of glomerular filtration rate (GFR) and albumin­
uria.677 The CKD Epidemiology Collaboration (CKD-EPI) has devel­
oped accurate eGFR equations based on creatinine ± cystatin C 
measurements.678 An eGFR ≥60 mL/min/1.73 m2 does not constitute 
CKD unless there is albuminuria or other evidence of kidney disease 
(Table 11).677 A persistent decrease in eGFR <60 mL/min/1.73 m2 
(i.e. stages G3–5), however, is sufficient to confirm CKD. This level 
of eGFR is associated with increased risk of CKD progression and 
CVD.43,679,680 The most advanced stage of CKD is characterized by 
an eGFR <15 mL/min/1.73 m2, and recently implemented nomencla­
ture refers to this as ‘kidney failure’.681 Such low levels of eGFR may 
Table 11 KDIGO staging by glomerular filtration rate 
and urinary albumin-to-creatinine ratio categories with 
colour chart for risk of initiation of maintenance kidney 
replacement therapy
Albuminuria stage eGFR stage 
(mL/min/ 
1.73 m2)
A1 <3 mg/ 
mmol 
(<30 mg/g)
A2 3–30 
mg/mmol 
(30– 
300 mg/g)
A3 
>30 mg/ 
mmol 
(>300 mg/g)
G1 (≥90)
G2 (60–89)
G3a (45–59)
G3b (30–44)
G4 (15–29)
G5 (<15)
© ESC 2023
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; KDIGO, Kidney 
Disease: Improving Global Outcomes. 
Note that this staging uses a ratio 1:10 to convert the urinary albumin-to-creatinine ratio 
from mg/mmol to mg/g, but the precise ratio is 1:8.84. 
Green is low risk (and represents no CKD if there is no structural or histological evidence 
of kidney disease). Relative to low risk (estimated at 0.04/1000 patient-years), yellow is 
moderately increased risk (at least ∼5×), orange is high risk (at least ∼20×), and red is 
very high risk (at least ∼150×). Risk of cardiovascular death approximately mirrors the 
same pattern. 
Table adapted from the KDIGO 2012 Clinical Practice Guideline for the Evaluation and 
Management of Chronic Kidney Disease. Reprinted with permission from Elsevier.677
ESC Guidelines                                                                                                                                                                                          4099


<!-- PAGE 58 -->

### Page 58

necessitate the need to start maintenance kidney replacement therapy 
(KRT).677
Albuminuria is an early marker of nephropathy and predicts both risk 
of kidney failure and CVD independently of eGFR.43,682 Nephropathy 
caused by diabetes is a leading cause of CKD globally, and screening pa­
tients with diabetes for CKD is recommended at least annually.676,677 A 
spot urine sample measuring UACR is an efficient method to identify 
and quantify albuminuria.677,683 Changes in UACR or GFR slope are 
used as surrogate trial endpoints for nephroprotection, but more de­
finitive evidence for reducing risk of kidney failure in patients with dia­
betes generally requires categorical endpoints based on a ≥40% 
sustained decline in GFR.684,685
9.2. Management of cardiovascular disease 
risk and kidney failure in patients with 
chronic kidney disease and diabetes
Risk of CVD increases progressively with lower levels of eGFR and, in 
those with advanced CKD, structural abnormalities of the heart, HF, 
and sudden death are particular features.679,680,686–688 Increased risk 
of CAD also accompanies CKD, often with calcification of atheroscler­
otic plaques.679,689 Accelerated vascular media calcification with in­
creased vascular stiffness is also a feature of CKD and attributed to 
disordered 
calcium–phosphate 
metabolism, 
referred 
to 
as 
CKD-mineral bone disorder (CKD-MBD).690,691 Managing CVD risk 
in patients with CKD and diabetes may, therefore, need to consider mul­
tiple interventions and both traditional and CKD-specific risk fac­
tors.361,692–694
All patients with diabetes and CKD should be offered standard ad­
vice on smoking, nutrition, and exercise.45 A raised BMI is independent­
ly associated with risk of CKD, and behavioural interventions to 
promote weight loss in people with T2DM reduce the risk of develop­
ing very high-risk CKD over the long-term.57,695,696 Management of 
people with diabetes and CKD is then based on sequentially initiating 
and titrating doses of pharmacological interventions with proven effi­
cacy (Figure 18).
Statin-based therapy reduces the risk of major atherosclerotic events 
(i.e. coronary death, non-fatal MI, ischaemic stroke, and coronary revascu­
larization) in patients with CKD, but does not meaningfully slow progres­
sion of CKD.248,697–699 Trials of statin-based therapy, combined in 
collaborative meta-analyses, show a trend towards smaller relative reduc­
tions per mmol/L reduction in LDL-C on major atherosclerotic events as 
eGFR declines, with uncertainty about benefits among patients on dialy­
sis.697 This diminution in RR reduction at decreased eGFR implies that 
more intensive LDL-C-lowering regimens are required to maximize ben­
efits.697 The goal in patients with CKD and diabetes should be to achieve 
the largest possible absolute reduction in LDL-C safely.697,700
Four large trials recruiting different types of patients with CKD have 
confirmed the safety of intensive LDL-C lowering with statins alone 
(atorvastatin, rosuvastatin, fluvastatin), or combining a moderate dose 
of simvastatin with ezetimibe.698,701–704 Although there is no dedicated, 
large-scale trial of a PCSK9 inhibitor in patients with CKD, sub-group 
analyses by CKD stage from the FOURIER trial of the PCSK9 inhibitor 
evolocumab found its LDL-C-lowering effect was preserved in patients 
with stage G3 CKD, and CV benefits on atherosclerotic events ap­
peared unmodified by baseline eGFR.699
Several drugs developed to manage CVD risk or hyperglycaemia 
have been shown to reduce the risk of CKD progression in large trials 
that recruited patients with T2DM and CKD (Figure 18). These in­
clude RAS inhibitors, SGLT2 inhibitors, and finerenone. There is 
increasing evidence that these interventions should be started early 
to prevent end-organ damage in at-risk patients.
Blocking RAS with an ACE-I (captopril) or ARBs (irbesartan/losar­
tan) prevented kidney failure in patients with diabetes and overt ne­
phropathy in dedicated clinical outcomes trials.705–707
ARBs 
(irbesartan/telmisartan) also slowed progression from microalbumi­
nuria (albuminuria stage A2) to overt nephropathy.708,709 These 
RAS inhibitors are therefore recommended in patients with diabetes 
as soon as CKD is clinically diagnosed. Combining an ARB with an 
ACE-I, however, is not recommended, as large trials have identified 
an increased risk of hyperkalaemia and acute kidney injury, without 
demonstrable additional benefits of such ‘dual-blockade’ on risk of 
kidney failure or CVD.710
In contrast, combining an SGLT2 inhibitor with an ACE-I or ARB has 
clear beneficial effects on risk of kidney failure and hospitalization for HF 
in patients with CKD and T2DM.153,542 The CREDENCE, DAPA-CKD, 
and EMPA-KIDNEY placebo-controlled trials were all stopped early for 
efficacy while testing canagliflozin, dapagliflozin, and empagliflozin, re­
spectively.153,543,711 All three trials found the RR reductions for kidney 
disease progression were unmodified by baseline eGFR, with 
EMPA-KIDNEY reporting clear benefits in patients with eGFR 20– 
30 mL/min/1.73 m2.153,542,543,712,713 EMPA-KIDNEY included 254 pa­
tients with an eGFR <20 mL/min/1.73 m2 at randomization, and once in­
itiated, SGLT2 inhibitors could be continued until the need of KRT. As 
patients with decreased eGFR are at the highest absolute risk of kidney 
disease progression, these trials’ results should encourage the initiation 
of SGLT2 inhibitors in patients with CKD down to at least an eGFR of 
20 mL/min/1.73 m2 with continued use until the need for KRT (despite 
low eGFR substantially attenuating their HbA1c-lowering effect). 
Meta-analysis of all the large SGLT2 inhibitor trials shows benefits of 
SGLT2 inhibitors on the risk of HF hospitalization or CV death are 
also unmodified by eGFR (at a trial level; Figure 19).714 The combined 
SGLT1/2 inhibitor sotagliflozin was analysed vs. placebo in the 
SCORED trial in patients with T2DM and CKD (eGFR 25–60 mL/min/ 
1.73 m2); sotagliflozin reduced the primary composite of the total num­
ber of CV deaths, hospitalizations for HF, and urgent visits for HF by 26% 
vs. placebo (HR 0.74; 95% CI, 0.63–0.88; P < 0.001).150 Initiating an 
SGLT2 inhibitor alongside an ACE-I or ARB is therefore recommended 
in patients with T2DM following the first clinical evidence of CKD. In pa­
tients with T1DM and CKD, the absence of large trials with sufficient 
follow-up means it is unclear whether the absolute benefits of SGLT2 
inhibitors on kidney failure and CVD outcomes are outweighed by the 
high absolute risk of ketoacidosis with SGLT2 inhibitors.715,716
MRAs reduce BP and albuminuria in patients with CKD.717 The 
placebo-controlled FIDELIO-DKD (Efficacy and Safety of Finerenone 
in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney 
Disease) and FIGARO-DKD (Efficacy and Safety of Finerenone in 
Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of 
Diabetic Kidney Disease) trials demonstrated for the non-steroidal 
MRA finerenone that these effects translate into reduced risk of kidney 
failure and a reduction of the combined CV outcome of CV death, non- 
fatal MI, non-fatal stroke, or hospitalization for HF in patients with CKD 
and T2DM who are already on maximum ACE-I or ARB.718–720
FIDELIO-DKD demonstrated reduced risk of a categorical kidney out­
come, a primary composite outcome combining kidney failure, a sus­
tained decline in eGFR of at least 40%, or death from renal causes, in 
patients with eGFR 25–60 mL/min/1.73 m2 and UACR of 34– 
567 mg/mmol (30–5000 mg/g), or eGFR 60–75 mL/min/1.73 m2 with 
UACR of 34–567 mg/mmol (300–5000 mg/g; mean eGFR 43 ±  
13 mL/min/1.73 m2; median UACR 96 mg/mmol [852 mg/g]).719


<!-- PAGE 59 -->

### Page 59

Information on the safety and efficacy of combining MRAs with 
SGLT2 inhibitors in CKD is limited as only ∼4% of FIDELIO-DKD, 
∼8% of FIGARO-DKD, ∼5% of DAPA-CKD, and no CREDENCE par­
ticipants were prescribed such a combination.153,718,719,721 Sub-group 
analyses considering those co-prescribed MRA and SGLT2 inhibitors 
suggest their combined use does not modify safety findings from the 
key trials.150,189,722–726
FIDELIO-DKD and FIGARO-DKD excluded patients with a potas­
sium of >4.8 mmol/L, as MRAs cause hyperkalaemia.718,719
Combining RAS and SGLT2 inhibitors does not appear to cause hyper­
kalaemia, and a hypothesis has been raised that SGLT2 inhibitors re­
duce the risk of severe hyperkalaemia among MRA users with 
HF.153,542,710,723,724,727,728 Finerenone is therefore recommended in 
addition to an RAS inhibitor in patients with T2DM and eGFR 
To reduce cardiovascular risk
To reduce kidney failure risk
Statin-based regimen
(Class I)
SGLT2 inhibitorb
(Class I)
BP control
(Class I)
Finerenone
(Class I)
ACE-I or ARB
(Class I)
For additional glucose control
Glucose-lowering medications with suggested cardiovascular benefit
GLP-1 RA
DPP-4 inhibitor
Insulin
Metformin (if eGFR >30 mL/min/1.73 m2)
Glucose-lowering medications with neutral or no proven cardiovascular benefit
Treatment of patients with T2DM and CKDa
To reduce cardiovascular and kidney failure risk
Figure 18 Pharmacological management to reduce cardiovascular or kidney failure risk in patients with type 2 diabetes and chronic kidney disease. ACE-I, 
angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; BP, blood pressure; CKD, chronic kidney disease; CV, cardiovascular; CVD, 
cardiovascular disease; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; RAS, 
renin–angiotensin system; SGLT2, sodium–glucose co-transporter-2; T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine ratio. aA statin- 
based regimen reduces CV risk in CKD while ACE-I or ARBs reduce kidney failure risk; SGLT2 inhibitors, BP control, and finerenone reduce both CV risk and 
kidney failure risk. SGLT2 inhibitors, RAS inhibitors, and finerenone are particularly effective at reducing risk of kidney failure when albuminuria is present [e.g. 
UACR ≥3 mg/mmol (30 mg/g); stage A2 and A3]. bCanagliflozin, empagliflozin, or dapagliflozin.
ESC Guidelines                                                                                                                                                                                          4101


<!-- PAGE 60 -->

### Page 60

No diabetes
High atherosclerotic cardiovascular riska
Mean eGFR: 80 mL/min/1.73m2
Kidney disease progression
Acute kidney injury
Cardiovascular death or hospitalization for heart failure
Ketoacidosis
Lower limb amputationb
-2
-1
-5
0.3
0.6
-45
4
4
4
21
0.2
-15
-10
5
-5
0
-20
-25
-30
-35
-40
Events avoided or caused per 1000
patient-years in
SGLT2i groups
Placebo population mean event rate
Events avoided or caused per 1000
patient-years in
SGLT2i groups
Placebo population mean event rate
-6
-4
0.5
1.0
-45
16
23
6
148
0.5
-15
-10
5
-5
0
-20
-25
-30
-35
-40
-34
Stable heart failure
Mean eGFR: 61 mL/min/1.73m2
7
17
1.0
104
-2
-5
c
0.0
-23
Mean eGFR: 64 mL/min/1.73m2
Events avoided or caused per 1000
patient-years in
SGLT2i groups
Placebo population mean event rate
-11
-4
1.3
1.1
-45
29
19
7
47
1.2
-15
-10
5
-5
0
-20
-25
-30
-35
-40
-11
Chronic kidney disease
Mean eGFR: 45 mL/min/1.73m2
48
16
0.6
11
-15
-5
c
0.0
-2
Mean eGFR: 40 mL/min/1.73m2
Diabetes
Figure 19 Absolute benefits and harms of sodium–glucose co-transporter-2 inhibitors in patients with and without diabetes. eGFR, estimated glomerular 
filtration rate; RR, relative risk; SE, standard error; SGLT2i, sodium–glucose co-transporter-2 inhibitor. Patient group-specific absolute effects estimated by 
applying the diabetes sub-group-specific RR to the average event rate in the placebo arms (first event only). Negative numbers indicate events avoided by 
SGLT2 inhibition per 1000 patient-years. Error bars represent SE in the numbers of events avoided or caused, estimated from uncertainty in the RRs. Mean 
eGFR values are given for combined trial populations by patient group and diabetes status. Placebo population mean event rates are the absolute numbers of 
events per 1000 patient-years in the placebo groups of all trials in the relevant subpopulation. aAdditionally, two (SE 0.5) fewer myocardial infarctions per 
1000 patient-years of SGLT2i treatment were observed in the diabetes and high atherosclerotic cardiovascular risk group. bRRs to determine absolute effects 
for lower-limb amputation included the CANVAS trial. cToo few ketoacidosis events to estimate absolute effects. Figure adapted from the Nuffield 
Department of Population Health Renal Studies Group and SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. This is an open access article 
distributed under the terms of the Creative Commons CC-BY License. https://creativecommons.org/licenses/by/4.0/714


<!-- PAGE 61 -->

### Page 61

>60 mL/min/1.73 m2 with UACR ≥34 mg/mmol (≥300 mg/g), or 
eGFR 25–60 mL/min/1.73 m2 and UACR ≥3 mg/mmol (≥30 mg/g), 
with appropriate potassium monitoring.718,719
9.3. Blood pressure and glycaemic control 
in patients with diabetes and chronic 
kidney disease
In patients with T2DM, BP lowering reduces CV risk, with relative ben­
efits similar in people with and without CKD.196,693,729 RR reductions 
for CVD per 10 mmHg of lower SBP are greater in patients with a start­
ing SBP of ≥140 mmHg, but a reduced risk of stroke and albuminuria is 
evident with a further reduction in SBP in those with an SBP 
<140 mmHg.196 Whether intensively lowering moderately elevated 
SBP prevents kidney failure, however, is uncertain.
The effect of tight glycaemic control, as compared with standard con­
trol, on risk of kidney failure is also uncertain, but such an approach reduces 
risk of developing or worsening of diabetic nephropathy based on mea­
sures of albuminuria.132,133,730 Personalized HbA1c targets of 6.5−8.0% 
(48−64 mmol/mol) are suggested for people with diabetes and CKD, 
with a target <7.0% (<53 mmol/mol) still recommended to reduce micro­
vascular complications, wherever possible.132,133 Above eGFR 30 mL/min/ 
1.73 m2, metformin with appropriate dose adjustment can be used, but 
below eGFR 30 mL/min/1.73 m2, metformin should generally be stopped 
to avoid risk of lactic acidosis due to its accumulation.731,732
In CKD, HbA1c monitoring may be less reliable when eGFR is 
<30 mL/min/1.73 m2, and self-monitoring or CGM may help safely 
achieve tight glycaemic control in such patients.45
Another potential strategy to help achieve glycaemic targets in pa­
tients with CKD is use of GLP-1 RAs. Extrapolating evidence from 
trials in patients with T2DM suggest GLP-1 RAs safely improve gly­
caemic control and may reduce weight and CV risk in patients with 
CKD.164 Meta-analysis of the GLP-1 RAs trials (lixisenatide, liraglutide, 
semaglutide, exenatide, albiglutide, dulaglutide, efpeglenatide) showed 
they favourably lower levels of albuminuria in T2DM, with some 
GLP-1 RAs reducing MACE in those with prior CVD or at high CV 
risk.164 The size of RR reductions on MACE appears similar in people 
with or without reduced eGFR.164 Dulaglutide has been tested in pa­
tients with T2DM and CKD stages G3–4. It was as effective at lower­
ing HbA1c as insulin glargine, but it reduced weight, had lower rates of 
symptomatic hypoglycaemia, and slowed eGFR decline compared 
with insulin glargine.733 The benefits of GLP-1 RAs on risk of kidney 
failure have yet to be confirmed, and a definitive assessment of sema­
glutide in the FLOW (Effect of Semaglutide Versus Placebo on the 
Progression of Renal Impairment in Subjects With Type 2 Diabetes 
and Chronic Kidney Disease) trial of 3535 patients with T2DM and 
albuminuric CKD is ongoing.734
An alternative to GLP-1 RAs in CKD is a DPP-4 inhibitor. Linagliptin 
safely lowers HbA1c in patients with T2DM and CKD but does not re­
duce risk of CVD or kidney failure.180
9.4. Roles for antithrombotic therapy and 
invasive strategies in managing 
atherosclerotic cardiovascular disease in 
patients with diabetes and chronic kidney 
disease
Low-dose ASA (75–100 mg o.d.) is indicated in patients with diabetes and/ 
or CKD and ASCVD.325 In primary ASCVD prevention in T2DM and 
CKD, the benefits and risks of low-dose ASA may be finely 
counterbalanced.291,292,325,735 CKD is associated with both increased 
ASCVD and bleeding risk, and so the net effects of low-dose ASA 
(75 mg o.d.) in CKD (stages G3–G4 or G1–2 with albuminuria) without 
ASCVD is being tested in the large, open-label, ATTACK (Aspirin to 
Target Arterial Events in Chronic Kidney Disease) trial.679,736,737 The net 
benefit of low-dose rivaroxaban (2.5 mg b.i.d.) on atherothrombotic vs. 
bleeding risk is also being tested in the large, placebo-controlled, 
TRACK (Treatment of Cardiovascular Disease with Low Dose 
Rivaroxaban in Advanced Chronic Kidney Disease) trial in people with 
CKD stage G4–5 who are at high CVD risk due to diabetes, age >65 years, 
or prior ASCVD.738
Invasive vs. medical management strategies for stable moderate or se­
vere CAD in CKD have been assessed in the ISCHEMIA-CKD 
(International Study of Comparative Health Effectiveness with Medical 
and Invasive Approaches–Chronic Kidney Disease) trial, in which 57% 
(444/777) of participants had diabetes.739 The trial was conducted in 
parallel with the large ISCHEMIA trial.740 When results from both these 
trials are considered alongside one another, ISCHEMIA-CKD suggests 
that an initial conservative approach using intensive medical therapies 
to manage stable CAD is appropriate for patients with diabetes and 
an eGFR <30 mL/min/1.73 m2.739 ISCHEMIA-CKD did not replicate 
the anti-anginal benefits of an invasive strategy observed in 
ISCHEMIA, but such benefits should not be ruled out due to lower 
power.739,740 It should also be noted that patients with acute MI, un­
stable CAD, or unacceptable levels of angina were excluded from 
both trials, meaning optimal management of such conditions in patients 
with CKD may still include an intensive strategy (Section 6).
Serum phosphate may increase in advanced CKD (e.g. eGFR <30 mL/ 
min/1.73 m2) and is associated with an increased risk of CVD.694 Lowering 
phosphate, controlling parathyroid hormone, and maintaining normal cal­
cium levels is common practice in nephrology despite a lack of definitive 
evidence that it modifies risk of CVD.691,741 Some evidence suggests the 
dose of calcium-based phosphate binders should be restricted.742,743In pa­
tients with T2DM and CKD, correcting renal anaemia improves quality of 
life, but does not reduce the risk of CVD and may increase the risk of 
stroke.744 Renal specialist advice should be sought for managing a raised 
serum phosphate (>1.5 mmol/L) or other evidence of CKD-MBD, and re­
nal anaemia (e.g. haemoglobin <10 g/dL).
Recommendation Table 24 — Recommendations for 
patients with chronic kidney disease and diabetes
Recommendations
Classa
Levelb
Intensive LDL-C lowering with statins or a statin/ 
ezetimibe combination is recommended.c,697,698
I
A
A BP target of ≤130/80 mmHg is recommended to 
reduce risk of CVD and albuminuria.196
I
A
Personalized HbA1c targets 6.5–8.0% (48–64 mmol/ 
mol) are recommended, with a target <7.0% 
(<53 mmol/mol) to reduce microvascular 
complications, wherever possible.132,133
I
A
The maximum tolerated dose of an ACE-I or ARB is 
recommended.705–709
I
A
A SGLT2 inhibitor (canagliflozin, empagliflozin, or 
dapagliflozin)d is recommended in patients with 
T2DM and CKD with an eGFR ≥20 mL/min/1.73 m2 
to reduce the risk of CVD and kidney 
failure.150,153,542,543,711,714,715
I
A
Continued
ESC Guidelines                                                                                                                                                                                          4103


<!-- PAGE 62 -->

### Page 62

### 10 Aortic and peripheral arterial

diseases and diabetes
10.1. The impact of diabetes on peripheral 
atherosclerosis
Diabetes is one of the most important risk factors for the develop­
ment and progression of atherosclerosis.747–751 The number of pa­
tients with atherosclerosis associated with diabetes is steadily 
increasing alongside the increasing number of patients with diabetes 
worldwide. Peripheral atherosclerosis summarizes LEAD and carotid 
atherosclerosis.
10.1.1. Diabetes and lower-extremity artery disease
The impact of diabetes differs between vascular territories.747 The strong 
correlation between LEAD and diabetes is well established.747–749 Up to 
30% of all patients with intermittent claudication and ∼50–70% of 
patients with chronic limb-threatening ischaemia (CLTI) have dia­
betes.750,752 Patients with diabetes and LEAD show specific anatomic 
and morphologic characteristics, which are important for further man­
agement.753 In addition, patients with diabetes have occlusions of arteries 
below the knee more often than do patients without diabetes. Moreover, 
severe calcification, such as media sclerosis and development of collateral 
circulation, is typical for these patients.753
Compared with patients without diabetes, those with diabetes de­
velop LEAD at a younger age and have faster LEAD progression, 
with more patients having CLTI. Prolonged diabetes duration, sub- 
optimal glycaemic control, co-existing CV risk factors, and other 
end-organ damage (e.g. proteinuria) increase the prevalence of 
LEAD.751 Moreover, patients with microangiopathy are at increased 
risk of CLTI and major amputation.754,755 In a cohort study with 125  
674 participants, the presence of microvascular disease such as retinop­
athy, nephropathy, or neuropathy independently increased the risk of 
amputation.754
For patients with a diabetic foot ulcer (diabetic foot disease), the 
risk of death at 5 years is 2.5 times higher than for patients with dia­
betes but no foot ulcer.752,756 In patients with diabetes, pain is often 
masked because of peripheral neuropathy with decreased pain sensi­
tivity. Therefore, atherosclerosis is often advanced when diagnosed. 
CLTI is the clinical presentation of advanced disease, characterized 
by ischaemic rest pain; however, pain may be absent in patients 
with diabetes. The 2017 ESC Guidelines on the diagnosis and treat­
ment of peripheral arterial diseases and the 2019 Global Vascular 
Guidelines on the management of chronic limb-threatening ischaemia 
proposed the Wound, Ischaemia, and foot Infection (WIfI) classifica­
tion to stratify amputation risk and the potential benefits of revascu­
larization (Supplementary data online, Table S17).747,757,758 Patients 
with diabetes and critical limb ischaemia are at very high risk of lower- 
limb amputation and recurrent wounds. All of these factors increase 
the risk of limb infection.
Although 20–30% of patients with diabetes have LEAD, more than 
half of these have no clinical symptoms.760 Therefore, screening and 
early diagnosis is important to allow early treatment and prevent major 
amputation. Clinical evaluation includes medical history, assessing 
symptoms, palpating peripheral pulses, and evaluating skin colour and 
temperature. In addition, examination for neuropathy is important; 
however, the sensitivity of clinical examination is limited.761
Therefore, screening for LEAD is indicated in patients with diabetes 
and foot ulceration.747,761 There is a lack of evidence concerning the 
frequency of screening for LEAD in patients with diabetes, but it seems 
plausible to assess leg perfusion regularly.
An ankle–brachial index (ABI) ≤0.90 is diagnostic for LEAD, with 
80% sensitivity and 95% specificity in all populations.760,762 However, 
the accuracy of ABI is lower in patients with diabetes.762,763 Beyond 
LEAD, an ABI ≤0.90 (or >1.40) is associated with an increased risk 
of death and CV events.762,763 Measuring ABI can be difficult due to 
medial calcinosis (ABI >1.40), in which case, other tests are useful for 
diagnosing LEAD, including Doppler waveform analysis of the ankle ar­
teries, or the toe–brachial index (TBI), which may be helpful because 
medial calcinosis barely affects digital arteries. A TBI <0.70 is diagnostic 
for LEAD.747,763
In patients with intermittent claudication, a treadmill test is useful for 
assessing walking distance.747 Duplex scan is the first-line imaging for 
confirming LEAD and should be performed at least when revasculariza­
tion is indicated. Magnetic resonance angiography or CT angiography 
can also help to plan further treatment (Figure 20).
Finerenone is recommended in addition to an ACE-I 
or ARB in patients with T2DM and eGFR >60 mL/ 
min/1.73 m2 with a UACR ≥30 mg/mmol (≥300 mg/ 
g), or eGFR 25–60 mL/min/1.73 m2 and UACR 
≥3 mg/mmol (≥30 mg/g) to reduce CV events and 
kidney failure.718–720
I
A
A GLP-1 RA is recommended at eGFR >15 mL/min/ 
1.73 m2 to achieve adequate glycaemic control, due 
to low risk of hypoglycaemia and beneficial effects on 
weight, CV risk, and albuminuria.164
I
A
Low-dose ASA (75–100 mg o.d.) is recommended in 
patients with CKD and ASCVD.325,735
I
A
It is recommended that patients with diabetes are 
routinely screened for kidney disease by assessing 
eGFR defined by CKD-EPI and UACR.43,678,745
I
B
Treatment with intensive medical or an initial invasive 
strategy is recommended in people with CKD, 
diabetes, and stable moderate or severe CAD, due to 
similar outcomes.e,740,746
I
B
Kidney specialist advice may be considered for 
managing a raised serum phosphate, other evidence 
of CKD-MBD, and renal anaemia.
IIb
C
Combined use of an ARB with an ACE-I is not 
recommended.710
III
B
© ESC 2023
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin-II receptor blocker; ASA, 
acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; 
CAD, coronary artery disease; CKD, chronic kidney disease; CKD-EPI, chronic kidney 
disease epidemiology; CKD-MBD, chronic kidney-mineral bone disorder; CV, 
cardiovascular; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; 
GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; 
LDL-C, low-density lipoprotein-cholesterol; o.d., once daily; SGLT2, sodium–glucose 
co-transporter-2; T2DM, type 2 diabetes mellitus; UACR, urinary albumin-to-creatinine 
ratio. 
aClass of recommendation. 
bLevel of evidence. 
cLittle evidence of benefit in patients on dialysis. 
dSotagliflozin reduces CV risk but has not demonstrated a reduction in the risk of kidney 
failure. 
eISCHEMIA-CKD trial primary and key secondary outcomes were a composite of ‘death or 
non-fatal myocardial infarction’ and ‘death, non-fatal myocardial infarction, or 
hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest’, respectively.


<!-- PAGE 63 -->

### Page 63

Ulcer or wound
Wound healing without
 revascularization likely
LEAD
LEAD
Intermittent claudication
Regular screening
Clinical examination ABI
(Additional MRA or CTAc)
Revascularization
Regular screening
Exercise trainingb
Limited daily practice despite exercise training
Regular screening / follow-up
Clinical symptoms for LEAD
Aetiology for LEAD
≤0.9 or >1.4
Wound managementb
Search for other causes
 for limited walking distance
Wound healing
Clinical examination
ABI (TBIa), TcPO2
Duplex sonography
WIfI score
Clinical examination
ABI (TBIa)
Duplex sonography
Treadmill test
TBIa 
Duplex sonography
Treadmill test
Patients with diabetes
Y
Y
Y
Y
Y
N
N
N
N
N
N
N
Y
Y
Figure 20 Screening for and managing lower-extremity artery disease in patients with diabetes. ABI, ankle–brachial index; CTA, computed tomography 
angiography; LEAD, lower-extremity artery disease; MRA, magnet resonance angiography; TBI, toe–brachial index; TcPO2, transcutaneous oxygen pressure; 
WlfI, Wound, Ischaemia, foot Infection. aTBI when ABI >1.4. bFurther information regarding wound management and exercise training can be found in the 
revascularization.
ESC Guidelines                                                                                                                                                                                          4105


<!-- PAGE 64 -->

### Page 64

Due to the high burden of comorbidities in patients with diabetes, 
interdisciplinary co-operation is crucial. The medical management of 
LEAD in patients with diabetes does not differ from that recommended 
for patients with ASCVD in general including SGLT2 inhibitors and 
GLP-1 RAs.747,757,764,765 Still, it should be noted that for the SGLT2 in­
hibitor canagliflozin, the risk of amputation was increased in the 
CANVAS study, a finding that has not been repeated in the 
CREDENCE trial comparing canagliflozin with placebo in patients 
with T2DM and CKD, nor in CVOTs with other SGLT2 inhibitors.151
Still, according to US Food and Drug Administration requirements, 
the amputation risk with canagliflozin is described in the Warnings 
and Precautions section of the prescribing information. There are 
some discussions as to whether the use of GLP-1 RAs could be prefer­
able in patients with LEAD. Ongoing studies may help to clarify this 
question in the future.
Recent data showed that the combination of low-dose ASA and riv­
aroxaban 2.5 mg b.i.d. reduces MACE and major adverse limb events 
including amputation (MALE) compared with ASA and placebo, par­
ticularly in patients with PAD.766 A sub-group analysis of patients 
with LEAD showed a significantly higher MACE and MALE rate com­
pared with patients with CAD and a higher benefit of the combination 
therapy.767 Improvement of prognosis was similar in patients with 
(44%) and without diabetes. The total number of major bleeding events 
was increased but fatal or critical organ bleeding did not.
Patients with intermittent claudication should take part in exercise 
training programmes (30–45 min, at least three times per week), as 
regular intensive exercise improves walking distance.747
In patients with CLTI, revascularization must be attempted when pos­
sible, and amputation should only be considered when revascularization 
options fail.768 With respect to the revascularization modality of choice, 
we refer to dedicated guidelines. There has not been a specific trial on 
revascularization strategies in patients with diabetes; however, a review 
of 56 studies including patients with diabetes suggested higher limb- 
salvage rates after revascularization (78–85% at 1 year) compared with 
conservative management.768 Due to disease progression, long-term 
follow-up is very important in patients with diabetes and LEAD.769
10.1.2. Diabetes and carotid artery disease
According to the results of a recent community-based study, the preva­
lence of diabetes linearly correlated with carotid plaques, and patients 
with diabetes had more advanced carotid atherosclerosis than indivi­
duals without diabetes.770 Based on a prospective cohort study with 
300 patients, which showed a high prevalence of carotid atherosclerosis 
especially in men, screening of male patients with diabetes and a history 
of CAD or ABI <0.85 has been suggested.771 Nevertheless, in patients 
with diabetes without a history of cerebrovascular disease, there is only 
limited evidence that carotid screening improves outcomes, and regular 
screening is not recommended.747,772 Asymptomatic carotid artery dis­
ease is frequently treated conservatively, and the patient is followed up 
with duplex ultrasound.
Carotid revascularization should be considered in asymptomatic pa­
tients with one or more indicators of increased stroke risk (previous 
transient ischaemic attack/stroke, ipsilateral silent infarction, stenosis 
progression, or high-risk plaques), and if the estimated peri-operative 
stroke or death rate is <3% and the patient’s life expectancy is >5 years. 
In symptomatic patients, carotid revascularization is indicated if the 
stenosis is >70%, and should be considered if the stenosis is >50%, as­
suming that the estimated peri-operative stroke or death rate is 
<6%.747
With respect to the impact of diabetes on carotid revascularization, a 
meta-analysis of 14 observational studies involving 16 264 patients 
showed that patients with diabetes had a higher risk of peri-operative 
stroke and death versus those without diabetes.773 The CREST 
(Carotid Revascularization Endarterectomy versus Stenting) trial was 
the only trial comparing carotid endarterectomy and carotid artery 
stenting to enrol enough patients with diabetes (n = 759) for sub-group 
analysis.774 Although re-stenosis rates were low at 2 years after carotid 
stenting (6.0%) and carotid endarterectomy (6.3%), diabetes predicted 
re-stenosis with both techniques.
Details on revascularization strategies can be found in the 2017 ESC 
Guidelines on the diagnosis and treatment of peripheral arterial diseases.747
10.2. Diabetes and aortic aneurysm
Current evidence shows a lower risk of developing aortic aneurysm in 
patients with diabetes compared with persons without dia­
betes.759,775,776There are different mechanisms under discussion includ­
ing effects on extracellular matrix volume, extracellular matrix glycation, 
the formation of advanced glycation end-products, inflammation, oxida­
tive stress, and intraluminal thrombus biology.777 Moreover, some med­
ications, such as metformin used to treat diabetes, seem to have 
protective effects on the development of abdominal aortic aneurysms.
Nevertheless, aortic aneurysm is associated with atherosclerosis and 
general secondary prevention is recommended based on expert 
consensus.
Recommendation Table 25 — Recommendations for 
peripheral arterial and aortic diseases in patients with 
diabetes
Recommendation
Classa
Levelb
Lower-extremity arterial disease
In patients with diabetes and symptomatic LEAD, 
antiplatelet therapy is recommended.325
I
A
In patients with diabetes and CLTI, it is 
recommended to assess the risk of amputation; the 
WIfI score is useful for this purpose.747,758
I
B
As patients with diabetes and LEAD are at very high 
CV risk, a LDL-C target of <1.4 mmol/L (<55 mg/dL) 
and a LDL-C reduction of at least 50% is 
recommended.778,779
I
B
Screening for LEAD is recommended on a regular 
basis, with clinical assessment and/or ABI 
measurement.
I
C
Patient education about foot care is recommended in 
patients with diabetes, and especially those with 
LEAD, even if asymptomatic. Early recognition of 
tissue loss and/or infection, and referral to a 
multidisciplinary team, is mandatory to improve limb 
salvage.
I
C
An ABI ≤0.90 is diagnostic of LEAD, irrespective of 
symptoms. In symptomatic cases, further assessment 
including duplex ultrasound is recommended.
I
C
When ABI is elevated (>1.40), other non-invasive 
tests, including TBI or duplex ultrasound, are 
recommended.
I
C
Continued


<!-- PAGE 65 -->

### Page 65

### 11 Type 1 diabetes and

cardiovascular disease
This section summarizes evidence-based recommendations to effect­
ively manage CV risk factors in patients with T1DM; the section does 
not address the control of glucose levels, which must follow the prin­
ciples of patient self-management under the guidance of the diabetes 
healthcare multidisciplinary team according to clinical recommenda­
tions by EASD/ADA.1
People with T1DM face a three-fold increase in mortality compared 
with the general population, which translates into an 11-year reduction 
in life expectancy; CVD mortality accounts for 30–44% of all deaths in 
patients with T1DM.780–784
The DCCT prospectively investigated not only the impact of an in­
tensified glucose-lowering treatment strategy on microvascular compli­
cations in patients with T1DM, but also the rate of macrovascular 
events at long-term follow-up. This study showed that intensified insu­
lin therapy lasting over a mean of 6.5 years halved the incidence and 
progression of microvascular sequelae, which was associated with a sig­
nificant decrease in HbA1c, compared with conventional therapy.126
After a mean follow-up of 17 years in >90% of the initially enrolled pa­
tients, CV risk was also significantly reduced by 42% in the intensified- 
treatment group, and the reduction in HbA1c over the first 6.5 years 
was significantly associated with a reduction in CV risk.785 In the 
EDIC (Epidemiology of Diabetes Interventions and Complications) 
study, patients were followed up for over 30 years and the following 
was concluded: (i) hyperglycaemia is the primary modifiable mediator 
of late complications in T1DM; (ii) near-normal glucose control reduces 
the incidence and progression of microvascular complications, such as 
retinopathy, nephropathy, and neuropathy; and (iii) intensive diabetes 
therapy reduces CV complications in T1DM.786
Recently, a mediation analysis and multi-variable models of the EDIC 
trial showed that the quality of adjustment of traditional risk factors ac­
counts for only ∼50% of the cardio-protective effect of improved 
metabolic control.787 About 40% of the cardio-protective effect re­
mains for HbA1c or elevated glucose concentrations per se. 
Accordingly, recent analyses from the Swedish National Diabetes 
Register evaluated the prognostic significance of 17 risk factors for 
death, acute MI, or stroke. Of the 32 611 patients with T1DM in this 
Swedish registry cohort, 5.5% died over the course of 10.4 years. 
The strongest predictors of death and CV endpoints were HbA1c, al­
buminuria, diabetes duration, systolic BP, and LDL-C concentration.788
Thus, reducing CV risk in patients with T1DM relates to both low­
ering HbA1c and controlling other classical CV risk factors, including 
BP and LDL-C. Therefore, glucose control target values are recom­
mended for most adults with T1DM by the joint consensus report of 
the ADA and EASD: HbA1c <53 mmol/mol or <7.0%; pre-prandial glu­
cose 4.4–7.2 mmol/L or 80–130 mg/dL; and 1–2 h post-prandial glu­
cose <10.0 mmol/L or <180 mg/dL.13 Hypoglycaemia should be 
avoided, especially in patients with CV complications.
Advances in diabetes technologies have started a new era in clinical 
practice, and the use of CGM has now become widespread. CGM can 
significantly improve glycaemic control in T1DM, providing more de­
tailed information and introducing new outcome variables including 
time-in-range and glycaemic variability.138
Management strategies should adapt new therapies and technologies 
as they become available, according to the wishes and desires of the 
person with diabetes.
11.1. Cardiovascular risk assessment in 
type 1 diabetes
With respect to treatment targets and thresholds for other CV risk fac­
tors, a critical question is predicting CV risk in patients with T1DM 
without CVD. Determining ASCVD risk in patients with T1DM is 
less well studied than in patients with T2DM.
In 2011, an observational study using the data from 3661 patients in the 
Swedish National Diabetes Register proposed a 5-year CVD risk model for 
use in patients with T1DM.789 More recently, the Steno Type 1 Risk Engine 
was externally validated at 5 years but lacks validation at 10 years.790 Age at 
the onset and duration of diabetes are two risk factors that lead the estima­
tion of CV risk. Thus, patients diagnosed with T1DM at an early age show an 
increased incidence of CVD. In addition, excess mortality in patients diag­
nosed with T1DM under the age of 10 years, compared with those aged 
26–30 years at diagnosis, has been highlighted by a Swedish study.791
This concept has been underlined by the Pittsburgh Epidemiology of 
Diabetes Complications (EDC) study, which showed duration of diabetes 
to be an independent risk factor for MACE.791,792 Several other risk factors 
related to diabetes management, including glycaemic control, insulin re­
quirements, smoking, cardiac autonomic neuropathy, dysfunctional im­
mune response, and insulin resistance, are to be taken into account.788
A recent risk tool, developed based on the Scottish/Swedish 
Diabetes Registry and validated in the Swedish National Diabetes 
Register can provide individualized risk predictions.793 This 10-year 
ASCVD risk prediction tool https://diabepi.shinyapps.io/cvdrisk/ could 
facilitate risk estimation and discussions with patients with T1DM.
11.2. Managing cardiovascular risk
Analogies of recommendations for risk-factor modifications in patients 
with T1DM derive from the fact that there is no direct evidence that 
CV risk reduction by lowering causal CV risk factors, like LDL-C or 
Duplex ultrasound is recommended as the first-line 
imaging method to assess the anatomy and 
haemodynamic status of lower-extremity arteries.
I
C
In case of CLTI, revascularization is recommended 
whenever feasible for limb salvage.747,758
I
C
In patients with chronic, symptomatic LEAD without 
high bleeding risk, a combination of low-dose 
rivaroxaban (2.5 mg b.i.d.) and ASA (100 mg o.d.) 
should be considered.766
IIa
B
Carotid artery disease
In patients with diabetes and carotid artery disease, it 
is recommended to implement the same diagnostic 
work-up and therapeutic strategies (medical, surgical, 
or endovascular) as in patients without diabetes.
I
C
Aortic aneurysm
In patients with diabetes and aortic aneurysm, it is 
recommended to implement the same diagnostic 
work-up and therapeutic strategies (medical, surgical, 
or endovascular) as in patients without diabetes.
I
C
© ESC 2023
ABI, ankle–brachial index; ASA, acetylsalicylic acid; b.i.d., twice a day; CLTI, chronic 
limb-threatening ischaemia; CV, cardiovascular; LDL-C, low-density lipoprotein-cholesterol; 
LEAD, lower-extremity artery disease; o.d., once a day; TBI, toe–brachial index; WIfI, 
Wound, Ischaemia, foot Infection. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4107


<!-- PAGE 66 -->

### Page 66

BP, differs in patients with T1DM or T2DM. However, the recommen­
dations are given in the awareness that, in most CVOTs for lipids, BP, 
antiplatelet agents, and anticoagulation, patients with T1DM were ex­
cluded or recruited in small groups. In the following, we summarize re­
commendations of the respective sections with focus on specific 
aspects or caveats that should be considered in patients with T1DM.794
11.2.1. Exercise and lifestyle
Data on the effects of exercise on T1DM are inconclusive. Aerobic fit­
ness improved HbA1c in patients with T1DM, but did not affect BMI, 
BP, and lipids.795
11.2.2. Lipid lowering
Statins remain the cornerstone of lipid-lowering treatment. In patients 
with T1DM at a younger age, starting statins early might be justified 
with long duration of disease, two additional risk factors, or microalbu­
minuria. In the Cholesterol Treatment Trialists’ Collaboration 
meta-analysis, 1466 patients with T1DM were also included.248
Increased cholesterol absorption in T1DM compared with T2DM 
may explain why ezetimibe, a drug that directly decreases cholesterol 
absorption, may reduce LDL-C more in T1DM than in T2DM.796,797
11.2.3. Blood pressure
People with T1DM may benefit from stringent BP-lowering strategies. 
A recent analysis of the EDC study in patients without known CAD 
showed that the optimal BP threshold associated with reduced CVD 
risk was 120/80 mmHg in young adults with childhood-onset 
T1DM.798 Routine ambulatory BP monitoring is recommended to iden­
tify subjects with masked hypertension, as demonstrated in a Finnish 
study in which one-quarter of patients with T1DM had underlying 
hypertension and increased arterial stiffness.799
11.2.4. Antiplatelet therapy
Antiplatelet agents may be beneficial in individuals with T1DM without 
symptomatic ASCVD who have at least one additional major CV risk 
factor.800
11.3. Glucose-lowering agents beyond 
insulin
Glucagon-like peptide-1 receptor agonists or SGLT2 inhibitors are cur­
rently not indicated for T1DM.
Although GLP-1 RAs and SGLT2 inhibitors reduce CV risk in patients 
with T2DM in large CVOTs, no such data are available for patients with 
T1DM. For GLP-1 RAs, despite showing potential in reducing HbA1c 
and weight in patients with T1DM in the ADJUNCT ONE (The Efficacy 
and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment 
of Type 1 Diabetes) Treat-To-Target trial, concerns have been raised 
about increased rates of symptomatic hypoglycaemia and hyperglycaemia 
with ketosis.801 Another RCT in patients with T1DM also showed no sig­
nificant overall reduction in HbA1c by liraglutide compared with pla­
cebo.802 Adding SGLT2 inhibitors at a lower than usual dose to insulin 
therapy in T1DM may reduce glucose variability and facilitate glucose con­
trol, thereby reducing insulin doses and hypoglycaemia.803 However, ke­
toacidosis at lower glucose levels, so called ‘euglycaemic ketoacidosis’, 
has been reported in 2–3% of patients with T1DM taking SGLT2 inhibi­
tors.804 This is a potentially lethal complication.
11.4. Renal protection in type 1 diabetes
As in patients with T2DM, patients with T1DM should be regularly 
screened for kidney disease by assessing eGFR defined by CKD-EPI 
and UACR.677 RAS blockade with an ACE-I prevents kidney failure in 
patients with T1DM and overt nephropathy (Section 9).705,805 RAS in­
hibitors are therefore recommended in patients with T1DM as soon as 
kidney damage is first clinically evident.
12. Person-centred care
A person-centred approach that encourages and empowers patients to 
actively take part in finding solutions to their problems is suggested.806
Person-centred care, including shared decision-making, goes beyond 
maintaining active person consent to decisions and the person’s partici­
pation to the development of the therapeutic plan. It shapes disease 
management to advance the life and health-related quality of life of 
the person.806,807 It helps people make better healthcare decisions 
based on their informed preferences in collaboration with their health­
care professionals (HCPs). 806 Person-centred care requires: 
• Identifying and integrating patient needs, background, and culture 
into decisions regarding health practices.808–812
• Active person participation as a key factor for successful self- 
management.808 This encompasses all kinds of preferences, as well 
as physical, psychosocial, behavioural, and financial needs in the devel­
opment of the therapeutic plan.808,813 It also refers to meal planning, 
planned physical activity, managing symptoms, blood glucose moni­
toring, medical treatments, and managing episodes of illness and of 
low and high blood glucose, as well as psychosocial, cultural, and spir­
itual consequences of health conditions.814–816
Recommendation Table 26 — Recommendations for 
patients with type 1 diabetes
Recommendation
Classa
Levelb
In patients with T1DM, it is recommended that 
adjustment of glucose-lowering medication follows 
principles of patient self-management under the 
guidance of the diabetes healthcare multidisciplinary 
team.
I
C
Avoiding hypoglycaemic episodes is recommended, 
particularly in those with established CVD.780–782
I
C
Statins should be considered for LDL-C lowering in 
adults older than 40 years with T1DM without a 
history of CVD to reduce CV risk.787
IIa
B
Statins should be considered for use in adults 
younger than 40 years with T1DM and other risk 
factors of CVD or microvascular end-organ damage 
or 10-year CVD risk ≥10% to reduce CVD 
risk.787,788
IIa
B
The use of the Scottish/Swedish risk prediction 
model may be considered to estimate 10-year CVD 
risk in patients with T1DM.793
IIb
B
© ESC 2023
CV, cardiovascular; CVD, cardiovascular disease; LDL-C, low-density lipoprotein-cholesterol; 
T1DM, type 1 diabetes mellitus. 
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 67 -->

### Page 67

• Motivation and support of people with diabetes, such as: support to 
stop smoking; adopt a healthy diet; increase PA and exercise; man­
age other comorbidities, such as arthritis, renal failure, frailty, and 
cognitive impairment, which increase risk of drug interactions; 
and manage body weight, taking psychosocial factors into ac­
count.817–826
• Interdisciplinary teams comprising the person (including caregivers/ 
family), physicians, nurses, social workers, physiotherapists, occupa­
tional therapists, dieticians, pharmacists, physical activity specialists, 
and psychologists are effective for enhancing effective communica­
tion, collaboration, and preventing CVD.827,828 The most effective 
models of preventive care are those that adopt a total risk- 
management approach (i.e. those that address all of the risk factors 
that impact CV health) using behavioural counselling with action 
plans, education, comprehensive, goal-setting, and problem-solving 
approaches, and proven therapeutics supported by frequent follow- 
up, either face to face or by telephone and/or digital health 
interventions.820,829,830
Figure 21 summarizes the model of person-centred care approach 
for patients with diabetes with or without CVD, considering sex and 
cultural and socioeconomic factors.
Person-centred care
Family/caregivers
Cultural, gender, physical,
psychological, socioeconomic, spiritual perspectives
Physicians, nurses,
dietologists, psychologists,
physiotherapists, etc
Face-to-face meetings
Telemedicine
Persons with diabetes
Interdisciplinary team
Frequent follow-up
Communication,
relationship development,
education, empowerment,
support, holistic, comprehensive
& problem-solving care,
self-management
Figure 21 Person-centred care approach for patients with diabetes with or without cardiovascular disease.
ESC Guidelines                                                                                                                                                                                          4109


<!-- PAGE 68 -->

### Page 68

### 13 Practical guidance

New guidelines and clinical recommendations for treating T2DM are pa­
tient centred and evidence based; the clinical picture and risk of 
cardio-renal complications, rather than HbA1c alone, are the forefront 
of personalized treatment decisions. The primary therapeutic goals in pa­
tients with diabetes and ASCVD or increased risk of CV complications is 
protecting organs and improving prognosis (Figure 1). Accordingly, these 
ESC Guidelines on CVD and diabetes are based on the extensive data 
from large CVOTs of recent years. For patients with T2DM and 
ASCVD, a wealth of data exists but CV risk reduction in those without 
ASCVD is less clear. Thus, to provide recommendations for treatment 
strategies to lower CV risk in patients with T2DM but without 
ASCVD or severe TOD, an appropriate tool for stratifying risk in these 
patients is of major importance. Therefore, an extension of SCORE2 for 
T2DM, named SCORE2-Diabetes, is provided to predict 10-year risk of 
fatal and non-fatal CVD events (MI, stroke) across four European risk re­
gions in patients without ASCVD or severe TOD.63
Implementation of the current Guidelines should be fostered not only 
by using respective educational tools developed by the ESC including the 
ESC Clinical Practice Guideline, but also by integrating it into national elec­
tronic health-record systems and digital-based healthcare solutions.
The evidence-based concept of the current Guidelines, its key messages, 
and gaps of evidence as medical needs for future research must be distrib­
uted to all healthcare stakeholders, policymakers, politicians, and the gen­
eral public. Awareness should be raised, respectively, on national and 
European levels, including in European Union (EU) parliament and respon­
sible commissions.
From our point of view, the current Guidelines might provide a blue­
print for approaching multimorbid patients with common, chronic, 
non-communicable diseases such as ASCVD, HF, diabetes, and CKD. 
Non-communicable diseases are one of the greatest burdens on health­
care systems and societies in Europe and many other areas of the 
world. Therefore, we hope that the current Guidelines will contribute 
to the ultimate goal of managing CVD and CV risk in patients with dia­
betes: to improve patients’ prognosis and health-related quality of life.
14. Key messages
Diagnosis of diabetes 
• Raised fasting or random glucose, elevated HbA1c, or an abnormal 
OGTT is diagnostic of diabetes; a single abnormal test is sufficient 
with symptoms, while two abnormal tests are usually required with­
out symptoms.
• Undiagnosed diabetes is common, particularly in individuals with 
CVD. Therefore, screening for diabetes in all individuals with CVD, 
including HF, is recommended using HbA1c and/or fasting glucose.
Cardiovascular risk assessment 
• All patients with diabetes should be evaluated for the presence of 
ASCVD and severe TOD.
• In patients with T2DM without symptomatic ASCVD or severe 
TOD, 10-year CVD risk via SCORE2-Diabetes should be calculated.
Lifestyle 
• For smokers, smoking cessation is a primary target of lifestyle inter­
vention in patients with CVD and diabetes.
• Exercise should be introduced in all patients with CVD and T2DM, 
following the paradigm ‘every step counts’.
• In patients with obesity and T2DM with or without CVD, reducing 
weight combined with increasing daily PA through structured exer­
cise sessions are key lifestyle components to improve metabolic con­
trol, improve exercise capacity, and reduce clinical outcomes.
• A Mediterranean diet supplemented with olive oil and/or nuts re­
duces the incidence of major CV events in patients with CVD.
Glycaemic targets 
• Tight glycaemic control reduces short- and long-term microvascular 
disease.
• Tight glycaemic control reduces long-term macrovascular complica­
tions (over 20 years).
• Hypoglycaemia is associated with adverse CV outcomes and is best 
avoided.
Glucose-lowering therapy 
• ASCVD complications are common in patients with T2DM.
• Glycaemic status should be systematically evaluated in all patients 
with or at high risk of CVD, as diabetes status informs many clinical 
decisions in cardiology.
• Independent of baseline HbA1c or additional glucose-lowering 
agents, selected SGLT2 inhibitors and GLP-1 RAs reduce CV events 
in patients with T2DM with ASCVD and/or severe TOD.
Blood pressure 
• BP targets should be individualized for hypertensive patients.
• Optimal BP control reduces the risk of micro- and macrovascular 
complications.
• Controlling BP often requires multiple drug therapies with an RAS in­
hibitor, and a CCB or diuretic. Dual therapy is recommended as first- 
line treatment.
• All hypertensive patients with diabetes, irrespective of their anti- 
hypertensive treatments, should monitor their BP at home.
Lipids 
• Statins remain the first-line and state-of-the-art therapy to decrease 
LDL-C levels.
• Ezetimibe and PCSK9 inhibitors in addition to statins (if treatment 
targets have not been achieved)—or alone (in case of documented 
Recommendation Table 27 — Recommendations for 
person-centred care in diabetes
Recommendations
Classa
Levelb
Structured education programmes are 
recommended in patients with diabetes to improve 
diabetes knowledge, glycaemic control, disease 
management, and patient empowerment.811,812,821
I
A
Person-centred care is recommended to facilitate 
shared control and decision-making within the 
context of person priorities and goals.822–824
I
C
Providing individual empowerment strategies should 
be considered to enhance self-efficacy, self-care, and 
motivation in patients with diabetes.825,826,831–834
IIa
B
© ESC 2023
aClass of recommendation. 
bLevel of evidence.


<!-- PAGE 69 -->

### Page 69

intolerance to statins)—significantly reduce LDL-C levels, thus im­
proving CV outcomes.
Antithrombotic therapy 
• Based on the presence of ASCVD and individual CV risk, antiplatelet 
agents are a cornerstone of preventing CV events in patients with 
diabetes.
• Shortening or scaling down DAPT to clopidogrel should be 
avoided in patients with diabetes post-ACS, given their high back­
ground CV risk, the lack of efficacy data, and the poor bio-activation 
of clopidogrel.
• Platelet-function testing guided de-escalation should be avoided 
based on lack of evidence and poor bio-activation of clopidogrel.
Multifactorial approach 
• Continuous, multidisciplinary counselling is necessary to achieve 
long-term lifestyle changes.
Management of coronary artery disease 
• In patients with CAD, SGLT2 inhibitors and/or GLP-1 RAs reduce 
the risk of CV events.
• In patients with diabetes and multivessel CAD, suitable coronary 
anatomy for revascularization, and low predicted surgical mortality, 
CABG is superior to PCI.
Heart failure 
• The prognosis of patients with diabetes and HF is worse compared 
with patients with HF without diabetes.
• Beta-blockers, ARNI/ACE-Is, MRAs, and SGLT2 inhibitors are recom­
mended as cornerstone therapies for patients with HFrEF and diabetes.
• Empagliflozin and dapagliflozin reduce the combined endpoint of CV 
death or HF hospitalization in patients with HF and a LVEF >40%.
• Glucose-lowering treatment with SGLT2 inhibitors in patients with 
diabetes and HF reduces HF-related endpoints.
• Saxagliptin and pioglitazone increase the risk of HF hospitalization in 
patients with diabetes and HF.
Arrhythmias 
• AF is common in patients with diabetes, and increases mortality, risk 
of stroke, and risk of HF.
• Opportunistic screening for AF is recommended for patients with 
diabetes aged ≥65 years by palpating pulse (or using wearable de­
vices) and systematic ECG screening when age is ≥75 years. AF 
should always be confirmed by ECG.
• Opportunistic screening for AF by pulse taking or ECG is recom­
mended in patients with diabetes aged <65 years in view of their 
risk of AF and the possibly associated risk of ischaemic stroke.
Chronic kidney disease 
• CKD in patients with diabetes is associated with high risk of develop­
ing kidney failure and CVD.
• Patients with diabetes should be regularly screened for CKD, or have 
their CKD staged, by assessing eGFR and UACR.
• Certain ACE-I/ARBs, SGLT2 inhibitors, and finerenone reduce the risk 
of kidney failure and the risk of CVD in patients with T2DM and CKD.
Aortic and peripheral arterial diseases 
• LEAD is a common complication in patients with diabetes and asso­
ciated with poorer prognosis.
• Patients with diabetes are at higher risk of CLTI as the first clinical 
manifestation of LEAD, supporting regular screening with ABI meas­
urement for early diagnosis.
• The management of patients with LEAD and indications for different 
treatment strategies are similar in patients with or without diabetes, 
although the options for revascularization may be poorer in patients 
with diabetes because of diffuse and distal lesions.
Type 1 diabetes 
• Glucose-lowering therapy in T1DM should follow principles of pa­
tient self-management under the guidance of the diabetes healthcare 
multidisciplinary team.
Person-centred care 
• A person-centred approach is a key factor in successful self- 
management, resulting in greater patient satisfaction, adherence to 
therapeutic plans, and improved health outcomes.
• Important factors for self-management of diabetes and comorbidities 
are education, motivation, empowerment, and continuing supportive 
care of individuals.
15. Gaps in evidence
Diagnosis of diabetes 
• Global screening programmes for diabetes, adjusted for regional 
demographics and ethnic groups, are required to establish the 
most accurate and cost-effective screening test.
Lifestyle 
• RCTs of long-term exercise intervention to reduce CV outcomes are 
needed in different patient groups with diabetes and CVD, e.g. CAD, 
HFpEF, HFrEF, AF, or PAD.
• Large RCTs assessing the benefit of a multidisciplinary team to in­
crease adherence to lifestyle interventions and optimal medication 
are needed in patients with T2DM and CVD.
• The applicability and best practice of telehealth needs to be evaluated 
in elderly and frail patients with T2DM and CVD.
Glycaemic targets 
• The independent role of hypoglycaemia, glycaemic variability, 
time-in-range, and post-prandial hyperglycaemia in CV pathology re­
quires further research.
• Large-scale studies are required to understand the role of modern 
glucose-monitoring strategies (CGM) in improving macrovascular 
and HF outcomes.
Glucose-lowering therapy 
• It remains unclear if the combination therapy of GLP-1 RAs and 
SGLT2 inhibitors is complementary in cardio-renal outcomes in pa­
tients with T2DM.
• It needs to be examined if more intensive glycaemic control, achieved 
with novel medications, might prove to have incremental CV efficacy.
ESC Guidelines                                                                                                                                                                                          4111


<!-- PAGE 70 -->

### Page 70

Blood pressure 
• High-quality data on managing BP in T1DM are lacking.
• Optimal targets for (isolated) DBP in patients with diabetes and 
hypertension remain inconclusive.
• More information on optimizing CV protection in diabetes by man­
aging BP based on out-of-office BP levels should be provided by ran­
domized intervention trials.
Lipids 
• Optimal LDL-C target levels for patients with diabetes need to 
be established; good scientific evidence is especially missing in 
T1DM.
• Novel lipid-lowering drugs, such as inclisiran need efficacy data on CV 
endpoints both in the general population and in patients with 
diabetes.
Antithrombotic therapy 
• More data on primary CV prevention are needed for patients with 
T1DM.
• Future phase 3 RCTs testing antithrombotic drugs in CV prevention 
should share homogeneous classifications of bleeding to make the 
benefit-risk profile of mono- or combined therapy comparable 
across different studies.
• The benefit-risk profile of ASA in CV prevention in patients with dia­
betes, documented significant atherosclerotic lesions (peripheral or 
coronary), or high CAC score but without history of stroke or MI 
should be further investigated in RCTs.
• Since documented kidney and/or eye microvascular disease inde­
pendently predict future CV events, it needs to be assessed whether 
patients with diabetes with microvascular disease and no history of 
MACE would benefit from early primary prophylaxis.
• It needs to be demonstrated in adequately powered, superiority, 
efficacy-based RCTs whether 12-month DAPT post-ACS can be re­
duced to a shorter period in patients with diabetes using SAPT with 
ASA or with a P2Y12 inhibitor.
• The optimal duration of TAT post-ACS in patients with diabetes and 
AF needs to be established.
Multifactorial approach 
• An optimal intervention protocol to improve adherence remains to 
be established, particularly addressing patients with diabetes and co­
morbidities, and the elderly population.
• Sex and ethnicity differences regarding efficacy of multifactorial inter­
ventions need to be evaluated.
• Evaluation of E-health applications to improve adherence to lifestyle 
intervention and medication also assessing clinical outcomes is 
needed in patients with CVD and diabetes.
Management of coronary artery disease 
• Optimal glycaemic control and in-hospital anti-glycaemic strategies 
for the outcomes of ACS and stable CAD, as well as after coronary 
revascularization, remain to be established.
• Although newer-generation DES have improved outcomes in pa­
tients with diabetes, RCTs are needed to determine whether they 
can reduce the gap in outcomes between CABG and PCI.
• No direct comparison RCT has focused on revascularization in pa­
tients with diabetes and left main disease.
• Robust data on patients with CAD and T1DM are missing.
• The effect of anti-inflammatory strategies in patients with diabetes 
should be assessed in dedicated trials.
Heart failure 
• The effect of finerenone on cardio-renal endpoints in patients with 
diabetes and HFrEF or HFpEF needs to be examined.
• More mechanistic studies are warranted to better understand how 
SGLT2 inhibitors improve HF outcomes.
• Research is needed to guide OMT in patients with HF and T1DM.
• The prognostic benefit of HF screening with BNP/NT-proBNP in 
asymptomatic patients with diabetes needs to be determined.
Arrhythmias 
• Better evidence is needed regarding the risks of atrial and ventricular 
arrhythmias associated with T1DM and how they should be optimally 
managed.
• Optimal screening methods and treatment for patients with diabetes 
still need to be defined in RCTs.
• The role of AF in diabetes needs to be evaluated in CVOTs.
• Whether SGLT2 inhibitors reduce the risk of CV death by reducing the 
risk of ventricular tachyarrhythmias should be more precisely evaluated.
Chronic kidney disease 
• CV and renal effects of using non-steroidal MRAs in patients with CKD on 
a combined ACE-I/ARB + SGLT2-inhibitor regimen need to be explored.
• Net benefits of antiplatelet therapy in patients with diabetes and 
CKD with and without ASCVD need to be examined.
Aortic and peripheral arterial diseases 
• The frequency and mode of vascular screening in patients with dia­
betes needs to be assessed.
• Specific trials are needed to help clinicians choose different pharma­
cological strategies according to the presence of PAD.
Type 1 diabetes 
• Comprehensive cardio-protection management in patients with 
early-onset T1DM needs to be evaluated.
• The role of ameliorating insulin resistance and using adjunctive ther­
apies to reduce CV risk remains to be elucidated.
• Lifestyle intervention trials in patients with T1DM and CVD are lacking.
Person-centred care 
• Better CVD management of women with diabetes is needed.
• Effective interdisciplinary approaches to better manage glycaemic 
control and minimize the risk of complications are required.
• Data are lacking on personalization of mobile Health (mHealth) by 
assessing how individual factors, such as health literacy, culture, socio­
economic status, ageing, behaviours, and treatment plan, impact pa­
tient engagement with mHealth tools and clinical outcomes.
16. Sex differences
Epidemiological studies suggest that diabetes is a stronger risk factor for 
CVD in women compared with men. Data from large CVOTs do not sug­
gest sex differences with respect to the benefit of CV risk-reducing


<!-- PAGE 71 -->

### Page 71

strategies in T2DM, i.e. treatment with SGLT2 inhibitors or GLP-1 RAs. 
Although women are under-represented in clinical trials, there is no evi­
dence for sex-specific recommendations for managing CVD in patients 
with diabetes. However, epidemiological and real-world data suggest that 
guideline-directed therapy in women is less likely to be applied compared 
with men.835–837 This should be explored in future studies. Therefore, 
we recommend implementing sex-balanced recruitment strategies for fu­
ture CVOTs. In addition, pre-specified analyses addressing sex differences 
are needed. Most importantly, every effort should be made to ensure wo­
men receive equal healthcare opportunities in managing CVD in diabetes.
17. ‘What to do’ and ‘What not to do’ messages from the Guidelines
Table 12 ‘What to do’ and ‘What not to do’
Recommendations
Classa
Levelb
Recommendations for diagnosis of diabetes
Screening for diabetes is recommended in all individuals with CVD, using fasting glucose and/or HbA1c.
I
A
It is recommended that the diagnosis of diabetes is based on HbA1c and/or fasting plasma glucose, or on an OGTT if still in doubt.
I
B
Recommendations for assessing cardiovascular risk in patients with diabetes
It is recommended to screen patients with diabetes for the presence of severe TOD.
I
A
It is recommended to assess medical history and the presence of symptoms suggestive of ASCVD in patients with diabetes.
I
B
In patients with T2DM without symptomatic ASCVD or severe TOD, it is recommended to estimate 10-year CVD risk via 
SCORE2-Diabetes.
I
B
Recommendations for weight reduction in patients with diabetes
It is recommended that individuals living with overweight or obesity aim to reduce weight and increase physical exercise to improve 
metabolic control and overall CVD risk profile.
I
A
Recommendations for nutrition in patients with diabetes
It is recommended to adopt a Mediterranean or plant-based diet with high unsaturated fat content to lower cardiovascular risk.
I
A
Recommendation for physical activity/exercise in patients with diabetes
It is recommended to increase any physical activity (e.g. 10 min daily walking) in all patients with T2DM with and without CVD. Optimal is a 
weekly activity of 150 min of moderate intensity or 75 min of vigorous endurance intensity.
I
A
It is recommended to adapt exercise interventions to T2DM-associated comorbidities, e.g. frailty, neuropathy, or retinopathy.
I
B
It is recommended to introduce structured exercise training in patients with T2DM and established CVD, e.g. CAD, HFpEF, HFmrEF, 
HFrEF, or AF to improve metabolic control, exercise capacity and quality of life, and to reduce CV events.
I
B
It is recommended to perform resistance exercise in addition to endurance exercise at least twice a week.
I
B
Recommendation for smoking cessation in patients with diabetes
It is recommended to stop smoking to reduce cardiovascular risk.
I
A
Recommendations for glycaemic targets
It is recommended to apply tight glycaemic control (HbA1c <7%) to reduce microvascular complications.
I
A
It is recommended to avoid hypoglycaemia, particularly in patients with CVD.
I
B
It is recommended to individualize HbA1c targets according to comorbidities, diabetes duration, and life expectancy.
I
C
Recommendations for glucose-lowering treatment for patients with type 2 diabetes and atherosclerotic cardiovascular disease to 
reduce cardiovascular risk
It is recommended to prioritize the use of glucose-lowering agents with proven CV benefits followed by agents with proven CV safety over 
agents without proven CV benefit or proven CV safety.
I
C
Sodium–glucose co-transporter-2 inhibitors
SGLT2 inhibitors with proven CV benefit are recommended in patients with T2DM and ASCVD to reduce CV events, independent of 
baseline or target HbA1c and independent of concomitant glucose-lowering medication.
I
A
Glucagon-like peptide-1 receptor agonists
GLP-1 RAs with proven CV benefit are recommended in patients with T2DM and ASCVD to reduce CV events, independent of baseline or 
target HbA1c and independent of concomitant glucose-lowering medication.
I
A
Continued
ESC Guidelines                                                                                                                                                                                          4113


<!-- PAGE 72 -->

### Page 72

Recommendations for blood pressure in patients with diabetes
Screening for hypertension
Regular BP measurements are recommended in all patients with diabetes to detect and treat hypertension to reduce CV risk.
I
A
Treatment targets
Anti-hypertensive drug treatment is recommended for people with diabetes when office BP is ≥140/90 mmHg.
I
A
It is recommended to treat hypertension in patients with diabetes in an individualized manner. The BP goal is to target SBP to 130 mmHg 
and <130 mmHg if tolerated, but not <120 mmHg. In older people (age >65 years), it is recommended to target SBP to 130–139 mmHg.
I
A
Treatment and evaluation
Lifestyle changes (weight loss if overweight, physical activity, alcohol restriction, sodium restriction, increased consumption of vegetables, 
using low-fat dairy products) are recommended in patients with diabetes and hypertension.
I
A
It is recommended to initiate treatment with a combination of an RAS inhibitor and a CCB or thiazide/thiazide-like diuretic.
I
A
Recommendations for lipids and diabetes
Lipid targets in patients with diabetes
In patients with T2DM at moderate CV risk, an LDL-C target of <2.6 mmol/L (<100 mg/dL) is recommended.
I
A
In patients with T2DM at high CV risk, an LDL-C target of <1.8 mmol/L (<70 mg/dL) and LDL-C reduction of at least 50% is recommended.
I
A
In patients with T2DM at very high CV risk, an LDL-C target of <1.4 mmol/L (<55 mg/dL) and LDL-C reduction of at least 50% is 
recommended.
I
B
In patients with T2DM, a secondary goal of a non-HDL-C target of <2.2 mmol/L (<85 mg/dL) in very high CV risk patients, and <2.6 mmol/ 
L (<100 mg/dL) in high CV risk patients, is recommended.
I
B
Lipid-lowering treatment in patients with diabetes
Statins are recommended as the first-choice LDL-C-lowering treatment in patients with diabetes and above-target LDL-C levels. 
Administration of statins is defined based on the CV risk profile of the patients and the recommended LDL-C (or non-HDL-C) target levels.
I
A
A PCSK9 inhibitor is recommended in patients at very high CV risk, with persistently high LDL-C levels above target despite treatment with 
a maximum tolerated statin dose, in combination with ezetimibe, or in patients with statin intolerance.
I
A
If the target LDL-C is not reached with statins, combination therapy with ezetimibe is recommended.
I
B
Recommendations for antithrombotic therapy in patients with diabetes and acute or chronic coronary syndrome without indications 
for long-term oral anticoagulation
ASA at a dose of 75–100 mg o.d. is recommended in patients with diabetes and previous MI or revascularization (CABG or stenting).
I
A
In patients with ACS and diabetes who undergo PCI, a P2Y12 receptor inhibitor (ticagrelor or prasugrel) is recommended in addition to ASA 
(75–100 mg o.d.), maintained over 12 months.
I
A
Clopidogrel 75 mg o.d. following appropriate loading (e.g. 600 mg or at least 5 days already on maintenance therapy) is recommended in 
addition to ASA for 6 months following coronary stenting in patients with CCS, irrespective of stent type, unless a shorter duration is 
indicated due to the risk or occurrence of life-threatening bleeding.
I
A
Clopidogrel is recommended as an alternative in case of ASA intolerance.
I
B
In patients with diabetes and ACS treated with DAPT who are undergoing CABG and do not require long-term OAC therapy, resuming a 
P2Y12 receptor inhibitor as soon as deemed safe after surgery and continuing it up to 12 months is recommended.
I
C
Recommendations for antithrombotic therapy in patients with diabetes and acute or chronic coronary syndrome and/or 
post-percutaneous coronary intervention requiring long-term oral anticoagulation
In patients with AF and receiving antiplatelet therapy, eligible for anticoagulation, and without a contraindication, NOACs are 
recommended in preference to a VKA.
I
A
In patients with ACS or CCS and diabetes undergoing coronary stent implantation and having an indication for anticoagulation, triple 
therapy with low-dose ASA, clopidogrel, and an OAC is recommended for at least 1 week, followed by dual therapy with an OAC and a 
single, oral, antiplatelet agent.
I
A
Recommendations for gastric protection
When antithrombotic drugs are used in combination, proton pump inhibitors are recommended to prevent gastrointestinal bleeding.
I
A
When clopidogrel is used, omeprazole and esomeprazole are not recommended for gastric protection.
III
B
Recommendations for a multifactorial approach in patients with diabetes
Identifying and treating risk factors and comorbidities early is recommended.
I
A
A multifactorial approach to managing T2DM with treatment targets is recommended.
I
B
Multidisciplinary behavioural approaches that combine the knowledge and skills of different caregivers are recommended.
I
C
Continued


<!-- PAGE 73 -->

### Page 73

Recommendations for revascularization in patients with diabetes
It is recommended that similar revascularization techniques are implemented (e.g. the use of DES and the radial approach for PCI, and the 
use of the left internal mammary artery as the graft for CABG) in patients with and without diabetes.
I
A
Myocardial revascularization in CCS is recommended when angina persists despite treatment with anti-anginal drugs or in patients with a 
documented large area of ischaemia (>10% LV).
I
A
Complete revascularization is recommended in patients with STEMI without cardiogenic shock and with multivessel CAD.
I
A
Routine immediate revascularization of non-culprit lesions in patients with MI with multivessel disease presenting with cardiogenic shock is 
not recommended.
III
B
Recommendations for glycaemic control in patients with diabetes and acute coronary syndrome
It is recommended to assess glycaemic status at initial evaluation in all patients with ACS.
I
B
It is recommended to frequently monitor blood glucose levels in patients with known diabetes or hyperglycaemia (defined as glucose levels 
≥11.1 mmol/L or ≥200 mg/dL).
I
C
Recommendations for heart failure screening and diagnosis in patients with diabetes
Evaluation for heart failure
If HF is suspected, it is recommended to measure BNP/NT-proBNP.
I
B
Systematic survey for HF symptoms and/or signs of HF is recommended at each clinical encounter in all patients with diabetes.
I
C
Diagnostic tests in all patients with suspected heart failure
12-lead ECG is recommended.
I
C
Transthoracic echocardiography is recommended.
I
C
Chest radiography (X-ray) is recommended.
I
C
Routine blood tests for comorbidities are recommended, including full blood count, urea, creatinine and electrolytes, thyroid function, 
lipids, and iron status (ferritin and TSAT).
I
C
Recommendations for heart failure treatments in patients with heart failure with reduced ejection fraction and diabetes
Recommendations for pharmacological treatment indicated in patients with HFrEF (NYHA class II–IV) and diabetes
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozin) are recommended in all patients with HFrEF and T2DM to reduce the risk of 
HF hospitalization and death.
I
A
Sacubitril/valsartan or an ACE-I is recommended in all patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death.
I
A
Beta-blockers are recommended in patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death.
I
A
MRAs are recommended in patients with HFrEF and diabetes to reduce the risk of HF hospitalization and death.
I
A
An intensive strategy of early initiation of evidence-based treatment (SGLT2 inhibitors, ARNI/ACE-Is, beta-blockers, and MRAs), with rapid 
up-titration to trial-defined target doses starting before discharge and with frequent follow-up visits in the first 6 weeks following a HF 
hospitalization is recommended to reduce re-admissions or mortality.
I
B
Recommendations for other treatments indicated in selected patients with HFrEF (NYHA class II–IV) and diabetes
Device therapy with an ICD, CRT-P, or CRT-D is recommended in patients with diabetes, as in the general population with HFrEF.
I
A
ARBs are recommended in symptomatic patients with HFrEF and diabetes who do not tolerate sacubitril/valsartan or ACE-Is, to reduce the 
risk of HF hospitalization and  death.
I
A
Diuretics are recommended in patients with HFrEF and diabetes with signs and/or symptoms of fluid congestion to improve symptoms, 
exercise capacity, and HF hospitalization.
I
C
Recommendations for the treatment of heart failure patients with left ventricular ejection fraction >40% and diabetes
Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF 
hospitalization or CV death.
I
A
Diuretics are recommended in patients with HFpEF or HFmrEF and diabetes with signs and/or symptoms of fluid congestion to improve 
symptoms, exercise capacity, and HF hospitalization.
I
C
Recommendations for glucose-lowering medications in patients with type 2 diabetes with and without heart failure
Recommendations for glucose-lowering medications to reduce heart failure hospitalization in patients with type 2 diabetes with or 
without existing heart failure
SGLT2 inhibitors (empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, or sotagliflozin) are recommended in patients with T2DM with 
multiple ASCVD risk factors or established ASCVD to reduce the risk of HF hospitalization.
I
A
SGLT2 inhibitors (dapagliflozin, empagliflozin, or sotagliflozin) are recommended in patients with T2DM and HFrEF to reduce the risk of HF 
hospitalization and death.
I
A
Continued
ESC Guidelines                                                                                                                                                                                          4115


<!-- PAGE 74 -->

### Page 74

Empagliflozin or dapagliflozin are recommended in patients with T2DM and LVEF >40% (HFmrEF and HFpEF) to reduce the risk of HF 
hospitalization or CV death.
I
A
Recommendations for glucose-lowering medications with an increased risk of heart failure hospitalization in patients with type 2 
diabetes
Pioglitazone is associated with an increased risk of incident HF in patients with diabetes and is not recommended for glucose-lowering 
treatment in patients at risk of HF (or with previous HF).
III
A
The DPP-4 inhibitor saxagliptin is associated with an increased risk of HF hospitalization in patients with diabetes and is not recommended 
for glucose-lowering treatment in patients at risk of HF (or with previous HF).
III
B
Recommendations for special consideration in patients with heart failure and diabetes
It is recommended to switch glucose-lowering treatment from agents without proven CV benefit or proven safety to agents with proven 
CV benefit.
I
C
Recommendations for atrial fibrillation in patients with diabetes
Screening for atrial fibrillation in diabetes
Opportunistic screening for AF by pulse taking or ECG is recommended in patients ≥65 years of age.
I
B
Opportunistic screening for AF by pulse taking or ECG is recommended in patients with diabetes <65 years of age (particularly when other 
risk factors are present) because patients with diabetes exhibit a higher AF frequency at a younger age.
I
C
Anticoagulation for atrial fibrillation in patients with diabetes
Oral anticoagulation is recommended for preventing stroke in patients with AF and diabetes and with at least one additional 
(CHA2DS2-VASc) risk factor for stroke.
I
A
For preventing stroke in AF, NOACs are recommended in preference to VKAs, with the exception of patients with mechanical valve 
prostheses or moderate to severe mitral stenosis.
I
A
Recommendations for patients with chronic kidney disease and diabetes
Intensive LDL-C lowering with statins or a statin/ezetimibe combination is recommended.
I
A
A BP target of ≤130/80 mmHg is recommended to reduce risk of CVD and albuminuria.
I
A
Personalized HbA1c targets 6.5–8.0% (48–64 mmol/mol) are recommended, with a target <7.0% (<53 mmol/mol) to reduce 
microvascular complications, wherever possible.
I
A
The maximum tolerated dose of an ACE-I or ARB is recommended.
I
A
A SGLT2 inhibitor (canagliflozin, empagliflozin, or dapagliflozin) is recommended in patients with T2DM and CKD with an eGFR ≥20 mL/ 
min/1.73 m2 to reduce the risk of CVD and kidney failure.
I
A
Finerenone is recommended in addition to an ACE-I or ARB in patients with T2DM and eGFR >60 mL/min/1.73 m2 with a UACR ≥30 mg/ 
mmol (≥300 mg/g), or eGFR 25–60 mL/min/1.73 m2 and UACR ≥3 mg/mmol (≥30 mg/g) to reduce CV events and kidney failure.
I
A
A GLP-1 RA is recommended at eGFR >15 mL/min/1.73 m2 to achieve adequate glycaemic control, due to low risk of hypoglycaemia and 
beneficial effects on weight, CV risk, and albuminuria.
I
A
Low-dose ASA (75–100 mg o.d.) is recommended in patients with CKD and ASCVD.
I
A
It is recommended that patients with diabetes are routinely screened for kidney disease by assessing eGFR defined by CKD-EPI and UACR.
I
B
Treatment with intensive medical or an initial invasive strategy is recommended in people with CKD, diabetes, and stable moderate or 
severe CAD, due to similar outcomes.
I
B
Combined use of an ARB with an ACE-I is not recommended.
III
B
Recommendations for aortic and peripheral arterial diseases and diabetes
Lower-extremity artery disease in patients with diabetes
In patients with diabetes and symptomatic LEAD, antiplatelet therapy is recommended.
I
A
In patients with diabetes and CLTI, it is recommended to assess the risk of amputation; the WIfI score is useful for this purpose.
I
B
As patients with diabetes and LEAD are at very high CV risk, an LDL-C target of <1.4 mmol/L (<55 mg/dL) and an LDL-C reduction of at 
least 50% is recommended.
I
B
Screening for LEAD is recommended on a regular basis, with clinical assessment and/or ABI measurement.
I
C
Patient education about foot care is recommended in patients with diabetes, and especially those with LEAD, even if asymptomatic. Early 
recognition of tissue loss and/or infection, and referral to a multidisciplinary team, is mandatory to improve limb salvage.
I
C
An ABI ≤0.90 is diagnostic of LEAD, irrespective of symptoms. In symptomatic cases, further assessment including duplex ultrasound is 
recommended.
I
C
When ABI is elevated (>1.40), other non-invasive tests, including TBI or duplex ultrasound, are recommended.
I
C
Duplex ultrasound is recommended as the first-line imaging method to assess the anatomy and haemodynamic status of lower-extremity 
arteries.
I
C
Continued


<!-- PAGE 75 -->

### Page 75

### 18 Quality indicators

Quality indicators (QIs) are tools that may be used to evaluate care qual­
ity, including structural, process, and outcomes of care.838 They may also 
serve as a mechanism for enhancing adherence to Guideline recommen­
dations, through associated quality-improvement initiatives and bench­
marking of care clinicians.839,840 As such, the role of QIs in improving 
care and outcomes for CVD is increasingly recognized by healthcare au­
thorities, professional organizations, payers, and the public.838
The ESC understands the need for measuring and reporting quality 
and outcomes of CV care and has established methods for developing 
the ESC QIs for quantifying care and outcomes for CVDs.838 To date, 
the ESC has developed QI suites for a number of CVDs in parallel with 
writing the ESC Clinical Practice Guidelines.841–844
The ESC aims to harmonize its QIs for various CV conditions and in­
tegrate them with ESC registries, providing real-world data about the 
patterns and outcomes of care for CVD across Europe.845
19. Supplementary data
Supplementary data is available at European Heart Journal online.
20. Data availability statement
No new data were generated or analysed in support of this research.
21. Author information
Author/Task Force Member Affiliations: Katharina Schütt, 
Department of Internal Medicine I Cardiology, RWTH Aachen 
University, Aachen, Germany; Dirk Müller-Wieland, Department of 
Internal Medicine I Cardiology, RWTH Aachen University, Aachen, 
Germany; Ramzi A. Ajjan, Clinical Population and Sciences 
Department, Leeds Institute of Cardiovascular and Metabolic Medicine, 
University of Leeds, Leeds, United Kingdom, Department of Diabetes 
and Endocrinology, Leeds Teaching Hospitals Trust, Leeds, United 
Kingdom; Manuel J. Antunes, Faculty of Medicine, University of 
Coimbra, Coimbra, Portugal; Ruxandra M. Christodorescu, 
Department V Internal Medicine, University of Medicine and Pharmacy 
V. Babeș, Timișoara, Romania, Research Center Institute of 
Cardiovascular Diseases, Timișoara, Romania; Carolyn Crawford 
(United Kingdom), ESC Patient Forum, Sophia Antipolis, France; 
Emanuele Di Angelantonio, Department of Public Health and 
Primary Care University of Cambridge, Cambridge, United Kingdom, 
Health Data Science Centre, Human Technopole, Milan, Italy; Björn 
Eliasson, Institute of Medicine, Sahlgrenska University Hospital, 
Gothenburg, Sweden; Christine Espinola-Klein, Department of 
Angiology, Center of Cardiology, University Medical Center of the 
Johannes Gutenberg University Mainz, Mainz, Germany; Laurent 
Fauchier, Cardiology Department Centre Hospitalier Universitaire 
Trousseau, Université de Tours, Tours, France; Martin Halle, 
Preventive Sports Medicine and Sports Cardiology, Technical University 
In case of CLTI, revascularization is recommended whenever feasible for limb salvage.
I
C
Carotid artery disease in patients with diabetes
In patients with diabetes and carotid artery disease, it is recommended to implement the same diagnostic work-up and therapeutic 
strategies (medical, surgical, or endovascular) as in patients without diabetes.
I
C
Aortic aneurysm in patients with diabetes
In patients with diabetes and aortic aneurysm, it is recommended to implement the same diagnostic work-up and therapeutic strategies 
(medical, surgical, or endovascular) as in patients without diabetes.
I
C
Recommendations for type 1 diabetes and cardiovascular disease
In patients with T1DM, it is recommended that adjustment of glucose-lowering medication follows principles of patient self-management 
under the guidance of the diabetes healthcare multidisciplinary team.
I
C
Avoiding hypoglycaemic episodes is recommended, particularly in those with established CVD.
I
C
Recommendations for person-centred care in diabetes
Structured education programmes are recommended in patients with diabetes to improve diabetes knowledge, glycaemic control, disease 
management, and patient empowerment.
I
A
Person-centred care is recommended to facilitate shared control and decision-making within the context of person priorities and goals.
I
C
© ESC 2023
ABI, ankle–brachial index; ACE-I, angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; AF, atrial fibrillation; ARB, angiotensin-II receptor blocker; ARNI, angiotensin 
receptor–neprilysin inhibitor; ASA, acetylsalicylic acid; ASCVD, atherosclerotic cardiovascular disease; BNP, B-type natriuretic peptide; BP, blood pressure; CABG, coronary artery 
bypass graft; CAD, coronary artery disease; CCB, calcium channel blocker; CCS, chronic coronary syndrome; CHA2DS2-VASc, Congestive heart failure, Hypertension, Age ≥75 years (2 
points), Diabetes mellitus, Stroke or transient ischaemic attack (2 points), Vascular disease, Age 65–74 years, Sex category (female); CKD, chronic kidney disease; CKD-EPI, chronic 
kidney disease epidemiology; CLTI, chronic limb-threatening ischaemia; CRT-D, cardiac resynchronization therapy with an implantable defibrillator; CRT-P, cardiac resynchronization 
therapy-pacemaker; CV, cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DES, drug-eluting stents; DPP-4, dipeptidyl peptidase-4; ECG, electrocardiogram; 
eGFR, estimated glomerular filtration rate; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA1c, glycated haemoglobin; HDL-C, high-density lipoprotein-cholesterol; HF, heart 
failure; HFmrEF, heart failure with mildly reduced ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; ICD, 
implantable cardioverter defibrillator; LEAD, lower-extremity artery disease; LDL-C, low-density lipoprotein-cholesterol; LV, left ventricle; LVEF, left ventricular ejection fraction; MI, 
myocardial infarction; MRA, mineralocorticoid receptor antagonist; NOAC, non-vitamin K antagonist oral anticoagulant; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, 
New York Heart Association; OAC, oral anticoagulant; o.d., once daily; OGTT, oral glucose tolerance test; PCI, percutaneous coronary intervention; PCSK9, proprotein convertase 
subtilisin/kexin type 9; RAS, renin–angiotensin system; SBP, systolic blood pressure; SCORE2-Diabetes, type 2 diabetes-specific 10-year CVD risk score; SGLT2, sodium–glucose 
co-transporter-2; STEMI, ST-elevation myocardial infarction; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TBI, toe–brachial index; TOD, target-organ damage; TSAT, 
transferrin saturation; UACR, urinary albumin-to-creatinine ratio; VKA, vitamin K antagonist; WIfI, Wound, Ischaemia, foot Infection. 
aClass of recommendation. 
bLevel of evidence.
ESC Guidelines                                                                                                                                                                                          4117


<!-- PAGE 76 -->

### Page 76

of Munich, Muenchen, Germany; William G. Herrington, Nuffield 
Department of Population Health, University of Oxford, Oxford, 
United Kingdom; Alexandra Kautzky-Willer, Department of 
Medicine III, Medical University of Vienna, Vienna, Austria, Institute for 
Gender Medicine, La pura women’s health resort Kamptal, Gars am 
Kamp, Austria; Ekaterini Lambrinou, Department of Nursing, 
Cyprus University of Technology, Limassol, Cyprus; Maciej Lesiak, 
1st Department of Cardiology, Poznan University of Medical Sciences, 
Poznan, Poland; Maddalena Lettino, Cardiothoracic and Vascular 
Department, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy; 
Darren K. McGuire, Department of Internal Medicine, Division of 
Cardiology, University of Texas Southwestern Medical Center, Dallas, 
United States of America, Parkland Health and Hospital System, Dallas, 
United States of America; Wilfried Mullens, Cardiology, Ziekenhuis 
Oost Limburg, Genk, Belgium, Faculty of Medicine and Life Sciences, 
University Hasselt, Hasselt, Belgium; Bianca Rocca, Section of 
Pharmacology, Catholic University School of Medicine, Rome, Italy; and 
Naveed Sattar, School of Cardiovascular and Metabolic Health, 
University of Glasgow, Glasgow, United Kingdom.
22. Appendix
ESC Scientific Document Group
Includes Document Reviewers and ESC National Cardiac Societies.
Document Reviewers: Eva Prescott (CPG Review Co-ordinator) 
(Denmark), Francesco Cosentino (CPG Review Co-ordinator) 
(Sweden), Magdy Abdelhamid (Egypt), Victor Aboyans (France), Sotiris 
Antoniou (United Kingdom), Riccardo Asteggiano (Italy), Iris 
Baumgartner (Switzerland), Sergio Buccheri (Sweden), Hector Bueno 
(Spain), Jelena Čelutkienė (Lithuania), Alaide Chieffo (Italy), Christina 
Christersson (Sweden), Andrew Coats (United Kingdom), Bernard 
Cosyns (Belgium), Martin Czerny (Germany), Christi Deaton (United 
Kingdom), 
Volkmar 
Falk 
(Germany), 
Brian 
A. 
Ference 
(United Kingdom), Gerasimos Filippatos (Greece), Miles Fisher (United 
Kingdom), Heikki Huikuri (Finland), Borja Ibanez (Spain), Tiny Jaarsma 
(Sweden), Stefan James (Sweden), Kamlesh Khunti (United Kingdom), 
Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Basil 
S. Lewis (Israel), Maja-Lisa Løchen (Norway), John William McEvoy 
(Ireland), Borislava Mihaylova (United Kingdom), Richard Mindham 
(United Kingdom), Lis Neubeck (United Kingdom), Jens Cosedis 
Nielsen (Denmark), Gianfranco Parati (Italy), Agnes A. Pasquet 
(Belgium), Carlo Patrono (Italy), Steffen E. Petersen (United Kingdom), 
Massimo F. Piepoli (Italy), Amina Rakisheva (Kazakhstan), Xavier 
Rossello (Spain), Peter Rossing (Denmark), Lars Ryden (Sweden), 
Eberard Standl (Germany), Lale Tokgozoglu (Türkiye), Rhian M. Touyz 
(Canada/United Kingdom), Frank Visseren (Netherlands), Massimo 
Volpe (Italy), Christiaan Vrints (Belgium), and Adam Witkowski (Poland).
ESC National Cardiac Societies actively involved in the review 
process of the 2023 ESC Guidelines for the management of cardiovas­
cular disease in patients with diabetes: Armenia: Armenian 
Cardiologists Association, Lusine Hazarapetyan; Austria: Austrian 
Society of Cardiology, Andreas Zirlik; Azerbaijan: Azerbaijan 
Society of Cardiology, Yasmin Rustamova; Belgium: Belgian Society 
of Cardiology, Philippe van de Borne; Bosnia and Herzegovina: 
Association of Cardiologists of Bosnia and Herzegovina, Šekib 
Sokolović; Bulgaria: Bulgarian Society of Cardiology, Nina 
Gotcheva; Croatia: Croatian Cardiac Society, Davor Milicic; 
Cyprus: Cyprus Society of Cardiology, Petros Agathangelou; 
Czechia: Czech Society of Cardiology, Michal Vrablík; Denmark: 
Danish Society of Cardiology, Morten Schou; Egypt: Egyptian 
Society of Cardiology, Hosam Hasan-Ali; Estonia: Estonian Society 
of Cardiology, Margus Viigimaa; Finland: Finnish Cardiac Society, 
Riikka Lautamäki; France: French Society of Cardiology, Victor 
Aboyans; Georgia: Georgian Society of Cardiology, Zurab 
Klimiashvili; Germany: German Cardiac Society, Malte Kelm; 
Greece: Hellenic Society of Cardiology, Gerasimos Siasos; 
Hungary: Hungarian Society of Cardiology, Róbert Gábor Kiss; 
Iceland: Icelandic Society of Cardiology, Berglind Libungan; Ireland: 
Irish Cardiac Society, Maeve Durkan; Israel: Israel Heart Society, 
Barak Zafrir; Italy: Italian Federation of Cardiology, Furio Colivicchi; 
Kazakhstan: Association of Cardiologists of Kazakhstan, Meiramgul 
Tundybayeva; Kosovo (Republic of): Kosovo Society of 
Cardiology, Ibadete Bytyçi; Kyrgyzstan: Kyrgyz Society of 
Cardiology, 
Erkin 
Mirrakhimov; 
Latvia: 
Latvian 
Society 
of Cardiology, Karlis Trusinskis; Lebanon: Lebanese Society of 
Cardiology, Georges Saadé; Lithuania: Lithuanian Society of 
Cardiology, Jolita Badarienė; Luxembourg: Luxembourg Society 
of Cardiology, Cristiana-Astra Banu; Malta: Maltese Cardiac Society, 
Caroline Jane Magri; Montenegro: Montenegro Society of 
Cardiology, Aneta Boskovic; Morocco: Moroccan Society of 
Cardiology, Mustapha El Hattaoui; Netherlands: Netherlands 
Society of Cardiology, Fabrice Martens; North Macedonia: The 
National Society of Cardiology of North Macedonia, Marijan 
Bosevski; Norway: Norwegian Society of Cardiology, Eva Cecilie 
Knudsen; Poland: Polish Cardiac Society, Paweł Burchardt; 
Portugal: 
Portuguese 
Society 
of 
Cardiology, 
Ricardo 
Fontes-Carvalho; Romania: Romanian Society of Cardiology, 
Dragos Vinereanu; San Marino: San Marino Society of Cardiology, 
Tatiana Mancini; Serbia: Cardiology Society of Serbia, Branko 
Beleslin; Slovakia: Slovak Society of Cardiology, Emil Martinka; 
Slovenia: Slovenian Society of Cardiology, Zlatko Fras; Spain: 
Spanish Society of Cardiology, Almudena Castro Conde; Sweden: 
Swedish Society of Cardiology, Linda Mellbin; Switzerland: Swiss 
Society of Cardiology, David Carballo; Syrian Arab Republic: 
Syrian Cardiovascular Association, Walid Bsata; Tunisia: Tunisian 
Society of Cardiology and Cardiovascular Surgery, Fathia Mghaieth; 
Türkiye: Turkish Society of Cardiology, Baris Gungor; Ukraine: 
Ukrainian Association of Cardiology, Olena Mitchenko; United 
Kingdom of Great Britain and Northern Ireland: British 
Cardiovascular Society, Stephen Wheatcroft; and Uzbekistan: 
Association of Cardiologists of Uzbekistan, Raisa Trigulova.
ESC Clinical Practice Guidelines (CPG) Committee: Eva 
Prescott (Chairperson) (Denmark), Stefan James (Co-Chairperson) 
(Sweden), Elena Arbelo (Spain), Colin Baigent (United Kingdom), 
Michael A. Borger (Germany), Sergio Buccheri (Sweden), Borja 
Ibanez (Spain), Lars Køber (Denmark), Konstantinos C. Koskinas 
(Switzerland), John William McEvoy (Ireland), Borislava Mihaylova 
(United Kingdom), Richard Mindham (United Kingdom), Lis Neubeck 
(United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes 
A. Pasquet (Belgium), Amina Rakisheva (Kazakhstan), Bianca Rocca 
(Italy), Xavier Rosselló (Spain), Ilonca Vaartjes (Netherlands), 
Christiaan Vrints (Belgium), Adam Witkowski (Poland), and Katja 
Zeppenfeld (Netherlands).
23. Acknowledgements
The Task Force Chairs thank Marlo Verket for her support in the 
co-ordination of this document.


<!-- PAGE 77 -->

### Page 77
